Patent abridgements Part 2 [2.7 MB PDF] - Intellectual Property ...

INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND 

(21) 583562 (22) 8 Feb 2005 

(54) Site-specific serine recombinases from Streptococcus pyogenes 

phage SF370.1 and Bacillus subtilis pahge recombinase SPbetac2and 

methods of their use 

(51) IPC2012.01:C07H21/04; C12N15/85 

(71) Intrexon Corporation 

(72) Padidam, Malla 

(31) 11/049552 (32) 2 Feb 2005 (33) US 

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, 

Melbourne, Victoria 3000, Australia 

(57) A method for obtaining site-specific recombination in an isolated 

eukaryotic cell comprising: - Providing an isolated eukaryotic cell that 

comprises a first recombination site and a second recombination 

site; - Contacting the first and second recombination site with 

a prokaryotic recombinase polypeptide resulting in recombination 

between the two sites; -The first recombination site is either a phage 

genomic recombination attachment site (attP) or a bacterial genomic 

recombination attachment site (attB) and the second recombination is 

either attP or attB, provided that when the first recombination site is attP 

the second recombination site is attB or vice versa; - The recombinase 

is a Streptococcus pyogenes phage recombinase or a Bacillus subtilis 

phage recombinase, in particular, the recombinases are SF370.1 or 

SPbetac2 recombinase. The method also encompasses the use of 

pseudo attP and attB recombination sites as well as a third and fourth, 

and a fifth and sixth recombination site. 

(62) Divided out of 556716 

(21) 583662 (22) 15 Aug 2008 

(54) COMPOSITIONS COMPRISING PHOSPHOLIPIDS 

(86) PCT/AU2008/001191 (87) WO2009/023903 

(51) IPC2012.01:A61P35/00; A61P25/28; A61K31/683, 685, 688; 

A61P29/00; A23L1/29; A61K38/01; A23C9/00, 14 

(71) MURRAY GOULBURN CO-OPERATIVE CO LIMITED 

(72) BROWN, Andrew; ROWNEY, Michelle 

(31) 2007904444 (32) 17 Aug 2007 (33) AU 

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins 

Centre, 342 Lambton Quay, Wellington 6011, New Zealand 

(57) Disclosed herein is a method for preparation of a phospholipid 

enriched dairy extract comprising at least 30% phospholipid, said 

method comprising: (a) contacting a dairy product with a protease under 

appropriate conditions to allow hydrolysis of milk proteins to occur to 

produce a hydrolysate; and (b) subjecting the hydrolysate to a filtration 

step to separate it into a retentate fraction and a permeate fraction, 

whereby at least some protein is present in the permeate fraction, and 

the retentate fraction provides a dairy derived extract comprising at 

least 30% phospholipid w/w, wherein the dairy product is selected from 

the group consisting of cream, colostrum, milk fat globule membrane 

(MFGM), AMF serum, buttermilk and whole milk or processed products 

thereof and wherein the dairy derived extract comprises at least 80% 

phospholipid as a percentage of total fat in the extract. 


(21) 583664 (22) 22 Aug 2008 

(54) CO-CRYSTALS OF PYRIMETHANIL AND DITHIANON 

(86) PCT/EP2008/061000 (87) WO2009/047043 

(51) IPC2012.01:A01N43/32, 54; C07D239/42; C07D339/08 

(71) BASF SE 

(72) VOGEL, Ralf; SAXELL, Heidi Emilia; SOWA, Christian 

(31) 07115950.3 (32) 7 Sep 2007 (33) EP 



(57) Disclosed are co-crystals of pyrimethanil and dithianon, which, in a 

X-ray powder diffractogram at 25 degrees C, show at least three of the 

following reflexes: 2 theta = 7.46 ± 0.20 2 theta = 9.98 ± 0.20 2 theta 

= 13.28 ± 0.20 2 theta = 23.09 ± 0.20 2 theta = 24.38 ± 0.20 2 theta = 

27.01 ± 0.20. Also disclosed are processes for preparing the co-crystals 

and their use for controlling phytopathogenic fungi. 

(21) 583665 (22) 10 Sep 2008 

(54) FUNGICIDAL MIXTURES OF TRITICONAZOLE AND 

DIFENOCONAZOLE 

(86) PCT/EP2008/061994 (87) WO2009/037162 

(51) IPC2012.01:A01N43/653; A01P3/00 

(71) BASF SE 

(72) LINDHOLM, Don Craig; YPEMA, Hendrik Leonard; FROESE, Nathan 

Todd 

(31) 60/973223 (32) 18 Sep 2007 (33) US 

(31) PCT/EP2008/051375 (32) 5 Feb 2008 (33) EP 



(57) Disclosed is a fungicidal mixture comprising triticonazole 

(formula I) and difenoconazole (formula II). Also disclosed 

is the fungicidal composition, either solid or liquid 

containing the two compounds and the method for 

controlling harmful fungi (especially Phakopsara). Triticonazole 

is also known as (RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1- 

(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol and difenoconazole is 

also known as 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 

4-chlorophenyl ether. 

(21) 583670 (22) 1 Aug 2008 

(54) PRODUCTION OF 2S CANOLA PROTEIN INVOLVING CATION 

EXCHANGE 

(86) PCT/CA2008/001425 (87) WO2009/018660 

(51) IPC2012.01:C07K14/415; C07K1/14, 18; C11D1/00 

(71) BURCON NUTRASCIENCE (MB) CORP. 

(72) SEGALL, Kevin, I; SCHWEIZER, Martin 

(31) 60/935,281 (32) 3 Aug 2007 (33) US 

(74) A J PARK, State Insurance Tower, Level 22, 1 Willis Street, Wellington 

6011, New Zealand 

(57) Disclosed is a method of producing substantially pure 2S canola 

protein, which includes: solubilizing canola proteins from canola oil seed 

meal using an aqueous saline solution having a salt concentration of 

0.25 to 0.35 M and a pH of 5 to 6 to form a canola protein solution, 

separating the canola protein solution from residual canola oil seed 

meal, contacting the canola protein solution with a cation-exchange 

medium at a pH of 5 to 6 to bind the 2S canola protein to the cationexchange 

medium in preference to other canola proteins, separating the 

bound 2S canola protein from unbound canola proteins and impurities, 

and separating the bound 2S canola protein from the cation-exchange 

medium. 

(21) 583689 (22) 11 Sep 2008 

(54) F1F0-ATPASE INHIBITORS AND RELATED METHODS 

(86) PCT/US2008/076021 (87) WO2009/036175 

(51) IPC2012.01:C07C233/02; C07C279/04 

(71) THE REGENTS OF THE UNIVERSITY OF MICHIGAN 

(72) NEY, Gina; GLICK, Gary D 

(31) 60/972,553 (32) 14 Sep 2007 (33) US 

PATENT OFFICE JOURNAL 1594 27 April 2012 Page 95


(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand 

(57) Disclosed is a compound represented by Formula I including salts 

thereof, wherein: R1 is imidazolidonyl or a heteroaryl containing at least 

1 ring nitrogen atom; R2 and R3 represent independently for each 

occurrence hydrogen or (C1-C4)alkyl; R5 represents independently for 

each occurrence hydrogen, halogen, alkyl, haloalkyl, aryl, heteroaryl, 

-NO2, -CN, -C(O)aryl, -C(O)heteroaryl, -C(O)N(R2)aryl, or -C( O)N 

(R2)heteroaryl; N is 0, 1, 2, 3 or 4 m represents independently for 

each occurrence 1 or 2; and the stereochemical configuration at a 

stereocenter in a compound represented by Formula I is R, S, or a 

mixture thereof. 

(21) 583697 (22) 26 Aug 2008 

(54) SUBSTITUTED 6-PHENYLNICOTINIC ACIDS AND THE USE 

THEREOF 

(86) PCT/EP2008/006969 (87) WO2009/033561 

(51) IPC2012.01:C07D213/80; A61K31/455; A61P3/06; A61P9/00 

(71) BAYER ANIMAL HEALTH GMBH 

(72) Meier, Heinrich; BARFACKER, Lars; ALBRECHT-KUPPER, Barbara; 

KOLKHOF, Peter; CANCHO GRANDE, Yolanda; NITSCHE, Adam; 

SCHMECK, Carsten; SCHAMBERGER, Jens; LUSTIG, Klemens 

(31) 10 2007 042 754.0 (32) 7 Sep 2007 (33) DE 


(57) The disclosure relates to substituted 6-phenylnicotinic acid derivatives 

of formula (I) wherein the variables are as defined in the specification, 

to processes for their preparation, to their use for the treatment and/ 

or prophylaxis of diseases and to their use for preparing medicaments 

for the treatment and/or prophylaxis of diseases, preferably for the 

treatment and/or prophylaxis of cardiovascular diseases, in particular 

dyslipidaemias, arteriosclerosis and heart failure. 

(21) 583699 (22) 29 Aug 2008 

(54) CO-CRYSTALS OF VX-950 (TELAPREVIR) OTHER 

COMPONENTS AND PHARMACEUTICAL COMPOSITIONS 

COMPRISING THE SAME 

(86) PCT/US2008/010254 (87) WO2009/032198 

(51) IPC2012.01:C07D403/12; A61K31/454; A61P1/16 

(71) VERTEX PHARMACEUTICALS, INC. 

(72) ZHANG, Yuegang; CONNELLY, Patrick R; JOHNSTON, Steve 

(31) 60/969,023 (32) 30 Aug 2007 (33) US 



(57) Disclosed is a co-crystal comprising a compound of formula I 

(commonly known as telaprevir or VX-950) and a co-crystal former 

selected from the group consisting of 3-methoxy-4-hydroxybenzoic acid, 

2,4-dihydroxybenzoic acid, and 2,5-dihydroxybenzoic acid. 

(21) 583712 (22) 23 Sep 2008 

(54) Compositions for sealing wounds in woody plants 

(86) PCT/EP2008/062685 (87) WO2009/040339 

(51) IPC2012.01:A01N3/04; A01N25/10; A01N43/653; A01N47/24 

(71) BASF SE 

(72) STADLER, Reinhold; VONEND, Michael; BIRNER, Erich; 

PFISTNER, Heike; HENKES, Steffen; MERK, Michael; HARMSEN, 

Sven; HADEN, Egon 

(31) 07117088.0 (32) 24 Sep 2007 (33) EP 



(57) Disclosed is a liquid composition comprising a) a water-insoluble 

sealing material in dissolved or dispersed form, which is selected 

from among water-insoluble film-forming polymers and waxes and their 

mixtures, in an amount of 1 to 40 percent by weight, based on the total 

weight of the composition; b) at least one plant protectant e.g. strobulins; 

c) at least one volatile diluent, wherein the diluent comprises at least 70 

percent by weight of water, based on the total amount of diluent; and d) 

at least one nonionic surface-active substance in an amount of from 10 

to 100 percent by weight, based on the sealing material. 

(21) 583754 (22) 17 Sep 2008 

(54) METHODS FOR REFINING HYDROCARBON FEEDSTOCKS 

(86) PCT/US2008/076716 (87) WO2009/039201 

(51) IPC2012.01:C10G11/00 

(71) Sapphire Energy, Inc.; THE UNIVERSITY OF TULSA 

(72) ARAVANIS, Alex; PYLE, Jason; PRICE, Geoffrey; CRUNKLETON, 

Daniel 

(31) 60/973,394 (32) 18 Sep 2007 (33) US 

(31) 61/085,780 (32) 1 Aug 2008 (33) US 



(57) Disclosed is a catalytic cracking process for cracking oil from a nonvascular 

photosynthetic organism comprising, extracting oil from said 

non-vascular photosynthetic organism to form a feedstock comprising 

at least one of a sesquiterpene, a diterpene, a triterpene and a 

tetraterpene; and contacting said feedstock with a catalytic composition 

comprising a large pore molecular sieve, wherein the large pore 

molecular sieve is a 12-ring zeolite. Further disclosed is oil when 

produced by said process. 

(21) 583790 (22) 10 Sep 2008 

(54) PROCESS FOR THE PREPARATION THE RAF KINASE INHIBITOR 

SORAFENIB AND INTERMEDIATES FOR USE IN THE PROCESS 

(86) PCT/GB2008/003048 (87) WO2009/034308 

(51) IPC2012.01:C07C233/65; C07C271/58; C07C275/30, 64; 

C07D213/81 

(71) Cipla Limited 

(72) RAO, Dharmaraj, Ramachandra; KANKAN, Rajendra, Narayanrao; 

GHAGARE, Maruti; CHIKHALIKAR, Sandip 

(31) 1734/MUM/2007 (32) 10 Sep 2007 (33) IN 

(31) 1733/MUM/2007 (32) 10 Sep 2007 (33) IN 



(57) A process for the preparation of the raf kinase inhibitor sorafenib 

using a compound of formula (A) wherein R’ is selected from –C(O)OA, 

-C(O)CX3, C(O)NH2, -C(O)-NHON or (a). The process comprises the 

condensation reaction of the compounds of formula (A) with 4-(4- 



aminophenoxy)-N-methylpicolinamide, or when R’ is (a) the reaction 

with 4-chloro-N-methyl-2-pyridine in the presence of a base. 

(21) 583817 (22) 2 Sep 2008 

(54) POST-HARVEST TREATMENT OF CUT FLOWERS, VEGETABLES 

AND FRUITS USING TEBUCONAZOLE 

(86) PCT/EP2008/007139 (87) WO2009/033582 

(51) IPC2012.01:A01N37/50; A01N3/02; A01P3/00; A23B7/154 

(71) Bayer CropScience AG 

(72) HAUSER-HAHN, Isolde; DAVIES, Peter Howard; WACHENDORFF- 

NEUMANN, Ulrike; KIRSCH, Klaus; EBBINGHAUS, Dirk 

(31) 07116248.1 (32) 12 Sep 2007 (33) EP 


(57) Disclosed is the use of tebuconazole and salts thereof to protect 

harvested fruit, cut-flowers or vegetables against phytopathogenic fungi 

such as Fusarium spp.; Verticillium spp.; Nigrospora spp.; Alternaria 

spp.; Phytophthora spp.; Septoria spp.; Mucor spp.; Venturia spp.; 

Glomerella spp.; Sclerotinia spp.; Ceratocystis spp.; Gloeosporium 

spp.; Phlyctaena spp.; Cylindrocarpon spp.; Stemphyllium spp.; 

Phacydiopycnis spp.; Thielaviopsis spp.; Aspergillus spp.; Nectria spp.; 

and Pezicula spp. 


(21) 583874 (22) 22 Sep 2008 

(54) CONTRACEPTIVE DRUG DELIVERY SYSTEM 

(86) PCT/EP2008/007975 (87) WO2009/036999 

(51) IPC2012.01:A61F6/06, 14; A61K9/00; A61P15/18 

(71) N.V. Organon 

(72) DE GRAAFF, Wouter; ZEEMAN, Raymond 

(31) 07018584.8 (32) 21 Sep 2007 (33) EP 



(57) A drug delivery system is disclosed, which comprises at least one 

compartment, which comprises (i) a drug-loaded thermoplastic polymer 

core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer 

and (iii) a non-medicated thermoplastic polymer skin covering the 

intermediate layer, wherein said core layer is loaded with crystals of a 

first compound which is a steroid such as progestogen, and wherein 

said intermediate layer is loaded with crystals of a second compound 

which is a steroid such as estrogen; wherein the delivery system may 

be an implant, an intrauterine system (IUS), a helical coil or a spring in a 

substantially ring-shaped form and is intended for vaginal administration 

for the purpose of contraception. 

(21) 583929 (22) 15 Apr 2005 

(54) Headgear for delivering gas under poitive pressure characterised by 

a laminated conduit which passes on either side of a patients head 

(51) IPC2012.01:A61M16/08 

(71) ResMed Ltd 

(72) Kwok, Philip Rodney; Darkin, Donald 

(31) 2004902020 (32) 15 Apr 2004 (33) AU 

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, 

Hamilton, New Zealand 

(57) Headgear for delivering a supply of gas under a positive pressure to 

a patient. The headgear includes a connector adapted to be attached 

to the supply of gas and a pair of side portions adapted to extend 

along opposite sides of the patient's head. Each of the side portions 

define a laminated conduit having a first conduit end attached to the 

connector and a second conduit end adapted to be positioned adjacent 

the patient's nose. Each conduit extends from the nose to the top of the 

patient's head, passing between the eyes and ears of the patient. 


(21) 583966 (22) 29 Aug 2008 

(54) ANTI-EPHA2 ANTIBODY 

(86) PCT/JP2008/065486 (87) WO2009/028639 

(51) IPC2012.01:A61K39/395; A61P35/00; C07K16/28, 46; C12P21/08; 

C12N15/02 

(71) DAIICHI SANKYO COMPANY, LIMITED 

(72) HASEGAWA, Jun; OHTSUKA, Toshiaki; URANO, Atsushi; 

YAMAGUCHI, Junko; AGATSUMA, Toshinori; NAKAHARA, Kaori; 

TAKIZAWA, Takeshi 

(31) 2007-224007 (32) 30 Aug 2007 (33) JP 



(57) Disclosed are antibodies against EPHA2 that have inhibitory 

activity against cell malignant transformation and tumour cell growth. 

Also disclosed are mouse hybridoma, pharmaceutical formulations, 

polynucleotides, host cells and methods of producing the antibodies. 

(21) 584019 (22) 3 Sep 2008 

(54) Method of preparing water-soluble cellulose hydrolysis products using 

ionic liquids 

(86) PCT/GB2008/050779 (87) WO2009/030949 

(51) IPC2012.01:C08B1/00; C08J3/09; C12P7/10; C08L1/02; C13K1/02; 

C08B15/02 

(71) Petroliam Nasional Berhad 

(72) FANSELOW, Markus; HOLBREY, John; SEDDON, Kenneth Richard; 

VANOYE, Laurent; ZHENG, Anna 

(31) 07253518.0 (32) 6 Sep 2007 (33) EP 



(57) Disclosed is a process for the preparation of water-soluble cellulose 

hydrolysis products, said process comprises admixing cellulose with 

an ionic liquid capable of solvating or dissolving at least some of 

the cellulose; and treating the resulting solvate or solution with an 

acid in the presence of water, said acid having a pKa in water of 

less than 2 at 25°C; said ionic liquid being a compound comprised 

solely of cations and anions and which exists in a liquid state at a 

temperature at or below 150°C, and in which the anions are selected 



from sulfate, hydrogen sulphate and nitrate, and the cation of the ionic 

liquid is preferably selected from pyridinium, pyridazinium, pyrimidinium, 

pyrazinium, imidazolium, pyrazolium, oxazolium, triazolium, thiazolium, 

piperidinium, pyrrolidinium, quinolinium or isoquinolinium; said acid 

is preferably selected from trifluoroacetic acid, p-toluene sulphonic 

acid, trifluoromethane sulfonic acid, trichloromethane sulfonic acid, 

hydrochloric acid, hydrobromic acid, hydriodic acid, tetrafluoroboric 

acid, or sulfuric acid. 

(21) 584104 (22) 28 Sep 2007 

(54) COATING COMPOSITIONS EXHIBITING CORROSION 

RESISTANCE PROPERTIES AND METHODS OF COIL COATING 

(86) PCT/US2007/079879 (87) WO2009/041977 

(51) IPC2012.01:C09D5/08; C09D139/04; C09D175/16 

(71) PPG INDUSTRIES OHIO, INC. 

(72) SPEHAR, Jean Marc; FASCELLA, Guillaume; MILLERO, Edward R 

(31) 11/862,280 (32) 27 Sep 2007 (33) US 



(57) Disclosed are coating compositions exhibiting corrosion resistance 

properties. These compositions include a non-chrome corrosion 

resisting filler and a radiation curable film-forming binder comprising an 

unsaturated monomer comprising a nitrogen-containing cyclic structure 

and one ethylenically unsaturated double bond. Also disclosed are 

methods for roll coating a metal coil. 

(21) 584135 (22) 22 Aug 2008 

(54) MPO INHIBITORS FOR THE TREATMENT OF HUNTINGTON'S 

DISEASE AND MULTIPLE SYSTEM ATROPHY 

(86) PCT/SE2008/050950 (87) WO2009/025618 

(51) IPC2012.01:A61K31/522, 519; A61P25/28 

(71) ASTRAZENECA AB 

(72) ERIKSSON, Hakan; POEWE, Werner 

(31) 60/957,525 (32) 23 Aug 2007 (33) US 

(31) 60/957,523 (32) 23 Aug 2007 (33) US 



(57) Disclosed is the use of 1-(2-isopropoxyethyl)-2-thioxo-1,2,3,5tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one 

or a pharmaceutically 

acceptable salt thereof for the manufacture of a medicament for the 

treatment of multiple system atrophy and Huntington’s disease. 

(21) 584157 (22) 25 Sep 2008 

(54) ORGANIC AMINE SALT OF 6-FLUORO-3-HYDROXY-2- 

PYRAZINECARBONITRILE AND METHOD FOR PRODUCING THE 

SAME 

(86) PCT/JP2008/067251 (87) WO2009/041473 

(51) IPC2012.01:C07D241/24, 16, 18 

(71) TOYAMA CHEMICAL CO., LTD. 

(72) TAKAMATSU, Tamotsu; YONEZAWA, Kenji 

(31) 2007-251191 (32) 27 Sep 2007 (33) JP 



(57) Disclosed is an organic amine salt of 6-fluoro-3hydroxy-2-pyrazinecarbonitrile; 

wherein the organic amine is 

dipropylamine, dibutylamine, dicyclohexylamine, dibenzylamine or Nbenzylmethylamine. 

Further disclosed is a process for producing an 

organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile, which 

comprises reacting 3,6-difluoro-2-pyrazinecarbonitrile with water in 

the presence of a base, and then forming a salt with an organic 

amine; wherein the organic amine is dipropylamine, dibutylamine, 

dicyclohexylamine, dibenzylamine or N-benzylmethylamine. 

(21) 584202 (22) 25 Sep 2008 

(54) Agricultural compositions as foliar fertilizers and methods for making 

and using the same 

(86) PCT/US2008/077752 (87) WO2009/042811 

(51) IPC2012.01:C05F11/08 

(71) Sunburst Plant Disease Clinic 

(72) YAMASHITA, Thomas T 

(31) 60/975,064 (32) 25 Sep 2007 (33) US 

(74) FB RICE, Level 23, 200 Queen Street, Melbourne, Victoria 3000, 

Australia 

(57) Disclosed is a aqueous fertilizer composition comprising: (I) a 

carbon skeleton energy component capable of providing carbon and 

energy for promoting microbial proliferation, said carbon skeleton 

energy component comprises any one or more of molasses, whey, 

corn steep liquor, grape syrup, maple syrup, corn syrup, one or more 

sugar(s), one or more sugar phosphate(s), one or sugar alcohol(s), 

one or more organic acid(s), one or more nucleotide(s) and/or 

one of more nucleotide base(s), one or more amino acid(s), and 

any combination thereof; (II) a macronutrient component capable of 

providing nutrients to a plant, said macronutrient component comprises 

one or more of (a) at least one nitrogen containing compound selected 

from the group consisting of ammonium nitrate, monoammonium 

phosphate, ammonium phosphate sulfate, ammonium sulfates, 

ammonium phosphatenitrate, diammonium phosphate, ammoniated 

single superphosphate, ammoniated triple superphosphate, nitric 

phosphates, ammonium chloride, aqua ammonia, ammonia-ammonium 

nitrate solutions, calcium ammonium nitrate, calcium nitrate, calcium 

cyanamide, sodium nitrate, urea, urea-formaldehyde, urea-ammonium 

nitrate solution, nitrate of soda potash, potassium nitrate, amino acids, 

proteins, nucleic acids and any combination thereof; (b) at least one 

phosphate containing compound selected fromthe group consisting 

of a single superphosphate, a double superphosphate, a triple 

superphosphate, phosphoric acid, ammonium phosphate, ammonium 

phosphate sulfate, ammonium phosphate nitrate, diammonium 

phosphate, ammoniated single superphosphate, ammoniated double 

superphosphate, ammoniated triple superphosphate, nitric phosphates, 

potassium pyrophosphates, sodium pyrophosphate, nucleic acid 

phosphates and any combination thereof; (c) at least one potassium 

containing compound selected from the group consisting of potassium 

chloride, potassium sulfate, potassium gluconate, sulfate of potash 

magnesia, potassium carbonate, potassium acetate, potassium 

citrate, potassium hydroxide, potassium manganate, potassium 

phosphate, potassium molybdate, potassium thiosulfate, potassium 

zinc sulfate and any combination thereof; (d) at least one calcium 

containing compound selected from the group consisting of calcium 

ammonium nitrate, calcium nitrate, calcium cyanamide, calcium acetate, 

calcium acetylsalicylate, calcium borate, calcium gluconate, calcium 

borogluconate, calcium carbonate, calcium chloride, calcium citrate, 

calcium ferrous citrate, calcium glycerophosphate, calcium lactate, 

calcium oxide, calcium pantothenate, calcium proprionate, calcium 

saccharate, calcium sulfate, calcium tartrate and any combination 

thereof; (e) at least one magnesium containing compound selected 

from the group consisting of magnesium oxide, dolomite, magnesium 

acetate, magnesium bensoate, magnesium bisulfate, magnesium 

borate, magnesium chloride, magnesium citrate, magnesium nitrate, 

magnesium phosphate, magnesium salicylate, magnesium sulfate and 

any combination thereof, and/or (f) at least one sulfate containing 



compound selected from the group consisting of ammonium sulfate, 

ammonium phosphate sulfate, calcium sulfate, potassium sulfate, 

magnesium sulfate, sulfuric acid, cobalt sulfate, copper sulfate, 

ferric sulfate, ferrous sulfate, sulfur, cysteine, methionine and any 

combination thereof; (iii) a vitamin or cofactor component comprising 

one or more of a thiamine compound, a riboflavin compound, nicotinic 

acid, a pyridoxine compound, folic acid, a biotin compound, pantothenic 

acid, coenzyme A, a cyanocobalamin compound, an inositol compound, 

a para-aminobenzoic acid (PABA), and any combination thereof; (iv) 

at least one complexing agent selected from the group consisting of 

citric acid, citric acid cycle intermediates, one or more lignosulfonate(s), 

one or more amino acid(s), one or more nucleic acid(s), 

ethylenediamin tetraacetate acid (EDTA), diethylene triamine pentacetic 

acid (DTPA), nitrolotriacetic acid (NTA), ethylenediaminediacetate 

(EDDA), ethylenediaminedi(o-hydroxyphenylacetic) acid (EDDHA), 

hydroxyethylethylene-diaminetriacetic acid (HEDTA), cyclohexane 

diamine tetraacetic acid (CDTA), propionic acid, and any combination 

thereof; (v) an exotic micronutrient component comprising a source 

of ionic species of at least any 10 different elements selected from 

the group consisting of Aluminum (Al), Antimony (Sb), Barium (Ba), 

Beryllium (Be), Bismuth (Si), Boron (B), Bromine (Br), Cadmium (Cd), 

Cerium (Ce), Cesium (Cs), Chromium (Cr), Cobalt (Co), Dysprosium 

(Dy), Erbium (Er), Europium (Eu), Fluorine (F), Gadolinium (Gd), 

Gallium (Ga), Germanium (Ge), Gold (Au), Hafnium(Hf), Holmium 

(Ho), Indium (In), Lanthanum (La), Lutetium (Lu), Lithium (Li), Mercury 

(Hg), Molybdenum (Mo), Neodymium(Nd), Nickel (Ni), Niobium (Nb), 

Platinum (Pt), Praseodymium (Pr), Rhodium (Rh), Ruthenium (Ru), 

Samarium (Sm), Scandium (Sc), Selenium (Se), Silicon (Si), Silver (Ag), 

Strontium (Sr), Sulfur (S), Tellurium (Te), Terbium (Tb), Thallium (TI), 

Thorium (Th), Thulium (Tm), Tin (Sn), Titanium (Ti), Tungsten (W), 

Vanadium (V), Ytterbium (Yb), Yttrium (Y), and Zirconium (Zr); and 

(iv) an ionophore component comprising an antibiotic and/or an amino 

butyric acid. 

(21) 584220 (22) 15 Oct 2008 

(54) HYDROCARBON GAS PROCESSING 

(86) PCT/US2008/079984 (87) WO2009/052174 

(51) IPC2012.01:C10G5/06 

(71) Ortloff Engineers, Ltd. 

(72) WILKINSON, John, D; LYNCH, Joe, T; HUDSON, Hank, M; 

CUELLAR, Kyle, T; MARTINEZ, Tony, L 

(31) 60/980,833 (32) 18 Oct 2007 (33) US 

(31) 61/025,910 (32) 4 Feb 2008 (33) US 

(31) 12/206,230 (32) 8 Sep 2008 (33) US 



(57) A process for the separation of a gas stream containing methane, C2 

components, C3 components, and heavier hydrocarbon components 

into a volatile residue gas fraction and a relatively less volatile fraction 

containing a major portion of said C2 components, C3 components, 

and heavier hydrocarbon components or said C3 components and 

heavier hydrocarbon components is disclosed, in which process: (a) 

said gas stream is cooled under pressure to provide a cooled stream; 

(b) said cooled stream is expanded to a lower pressure whereby it 

is further cooled; and(c) said further cooled stream is directed into 

a distillation column and fractionated at said lower pressure whereby 

the components of said relatively less volatile fraction are recovered; 

wherein following cooling, said cooled stream is divided into first and 

second streams; and (1) said first stream is cooled to condense 

substantially all of said first stream and is thereafter expanded to said 

lower pressure whereby said first stream is further cooled; (2) said 

expanded cooled first stream is thereafter supplied to said distillation 

column at a first mid-column feed position; (3) said second stream is 

expanded to said lower pressure and is supplied to said distillation 

column at a second mid-column feed position; (4) a vapour distillation 

stream is withdrawn from a region of said distillation column above 

said expanded second stream and is cooled sufficiently to condense 

at least a part of said vapour distillation stream, thereby forming a 

residual vapour stream and a condensed stream;(5) at least a portion 

of said condensed stream is supplied to said distillation column at a 

top feed position; (6) an overhead vapour stream is withdrawn from 

an upper region of said distillation column and is directed into heat 

exchange relation with said vapour distillation stream and heated, 

thereby to supply at least a portion of the cooling of step (4), and 

thereafter discharging at least a portion of said heated overhead vapour 

stream as said volatile residue gas fraction; and (7) the quantities 

and temperatures of said feed streams to said distillation column are 

effective to maintain the overhead temperature of said distillation column 

at a temperature whereby the major portions of the components in said 

relatively less volatile fraction are recovered. 

(21) 584253 (22) 12 Jan 2009 

(54) TRIPLE DENSITY GEL HEEL CUPS WITH A REINFORCEMENT 

COMPONENT IN THE GEL LAYER 

(86) PCT/US2009/030716 (87) WO2009/091687 

(51) IPC2012.01:A43B23/08; A43B7/32 

(71) Spenco Medical Corporation 

(72) GRANGER, David Bradley; MARTINEZ, Jacob; SULAK, Duane M 

(31) 61/021,535 (32) 16 Jan 2008 (33) US 

(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market 

Street, Sydney, New South Wales 2000, Australia 

(57) A triple density heel cup comprises a generally heel-shaped substrate 

having a length extending from a heel back wall to a front border 3. 

The front border 3 is positioned to underlie a portion of the arch area of 

the bottom of a wearer's foot when in use. The heel-shaped substrate 

comprises a structural gel layer 1 having a foot receiving surface and 

a shoe side surface. The foot receiving surface has a flat area which is 

adapted to underlie the bottom of a wearer's foot in use and an upwardly 

extending integral wall which is adapted to lie adjacent to the back and 

sides of the wearer's heel in use. The integral wall has a back apex of 

maximum height and tapers down in height from the back apex toward 

the front border 3. The shoe side surface defines a channel formed in 

the structural gel layer 1, where the channel is adapted to receive a 

reinforcement component 6. A reinforcement component 6 is secured 

to the structural gel layer 1 in the channel, where the reinforcement 

component 6 comprises a denser material than the structural gel layer 1 

and has a curvature complementary to the upwardly extending integral 

wall in the area of the back of the heel. The curvature descends toward 

the base of the heel cup and then extends along the side of the heel cup 

and forward to the front border 3. The shoe side surface further defines 

a heel cushion area. A heel cushion 7 is secured to the structural gel 

layer 1 in the heel cushion area. 



(21) 584267 (22) 26 Mar 2010 

(54) Multi-portion intra-oral dosage form with organoleptic properties 

(51) IPC2012.01:A61K9/00, 20, 24 

(71) MCNEIL AB 

(72) Hugerth, Andreas; Lindell, Katarina; Thyresson, Kristina; Nicklasson, 

Fredrik 

(31) (32) 27 Apr 2009 (33) US 

(31) 0900397-1 (32) 27 Mar 2009 (33) SE 



(57) Disclosed is a multi-portion intra-oral unitary dosage form comprising 

at least two portions, each of said two portions containing at least one 

pharmaceutically active agent or health promoting agent, wherein at 

least one of said two portions contains a pharmaceutically active agent 

selected from the group consisting of nicotine compounds, wherein said 

at least two portions each contain a different added flavour. . 


(21) 584308 (22) 1 Oct 2008 

(54) BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT 

SYSTEM FOR NUCLEIC ACIDS AND METHODS OF USE 

(86) PCT/US2008/078499 (87) WO2009/085355 

(51) IPC2012.01:C12Q1/68; C09K15/00; C12M1/00; A01N37/00; 

B01L3/00; A01N57/00 

(71) LONGHORN VACCINES & DIAGNOSTICS, LLC 

(72) FISCHER, Gerald, W.; DAUM, Luke, T. 

(31) 60/976,728 (32) 1 Oct 2007 (33) US 

(74) IP Gateway Patent and Trademark Attorneys, Suite 2, 18 Carol 

Avenue, Springwood, Brisbane, Queensland 4127, Australia 

(57) An aqueous composition for maintaining the integrity of 

polynucleotides for at least fifteen days at a temperature of 10 degrees 

Celsius to 40 degrees Celsius at a pH of 5-7. The composition 

comprises: (a) 0.5 M to 6 M of a chaotropic agent ; (b) 0.1 percent to 1 

percent (wt/vol) of a detergent; (c) 0.5 mM to 50 mM of a chelator; (d) 

0.5 mM to 30 mM of the reducing agent tris(2-caboxyethyl) phosphine 

(TCEP); (e) 0.0001 percent to 0.3 percent (wt/vol) of a surfactant; (f) A 

short-chain alkanol; and (g) A buffer. The composition can be used in 

methods to denature proteins, inactivate nucleases and kill pathogens 

while not degrading the nucleic acids in a biological sample. 

(21) 584354 (22) 15 Sep 2008 

(54) SHEAVE BLOCK HAVING REMOVABLE SIDE PLATE AND POST 

(86) PCT/US2008/076466 (87) WO2009/036469 

(51) IPC2012.01:B63H9/10; B63B21/04; B66D3/04 

(71) Harken, Inc 

(72) LANGE, Kenneth 

(31) 60/972,217 (32) 13 Sep 2007 (33) US 



(57) A block (10) with a rotating sheave (12) mounted between a pair of 

side plates (14a, 14b). Captured between the side plates is a post (18) 

about which a mounting loop may be mounted. The post is removable 

from the between the side plates to permit the loop to be attached or 

detached from the block. 

(21) 584419 (22) 6 Apr 2010 

(54) Supplementary bee food comprising a sugar and methylglyoxal, 

methylglyoxal-1,1-dimethylacetal, dihydroxyacetone and / or 2,5dihydroxydioxane-2,5-dimethanol 

(51) IPC2012.01:A01K53/00; C07H3/00; C07C47/02; C07C49/185, 17, 

175; A01K59/00; C07D319/12 

(71) Daria Heuer 

(72) Heuer, Daria 

(74) Daria Heuer, Am Krausberg 31, 41542 Dormagen, Germany 

(57) Disclosed are compositions and uses thereof as a supplementary 

bee food for increasing the MGO and/or UMF number in honey; 

said compositions comprise: a) from 0.0001% to 30% by weight 

of methylglyoxal-1,1-dimethylacetal, methylglyoxal, dihydroxyacetone 

or 2,5-dihydroxydioxane-2,5-dimethanol; and b) a sugar such as 

arabinose, 2-desoxy-D-glucose, 2-desoxy-D-ribose, fructose, fucose, 

galactose, mannose, sorbose, adonit, dulcet, erythit, inosit, mannit and/ 

or sorbit, xylit, galacturonic acid, gluconic acid-lactone, glucuronic acid 

lactone, cellubiose, lactose, lactulose, maltose, melibiose, raffinose, 

saccharose, trehalose, amylose, inulin or natural or synthetic mixture 

of these sugars or other types of honey. Further disclosed is a method 

of feeding Manuka honey collecting bees which comprises using a 

composition as defined above close to a beehive of these bees. 

(21) 584544 (22) 9 Oct 2008 

(54) Novel taxane compositions comprising lecithin and an anionic 

surfactant 

(86) PCT/FR2008/001410 (87) WO2009/083664 

(51) IPC2012.01:A61K47/24, 44; A61K9/00, 107 

(71) AVENTIS PHARMA SA 

(72) RORTAIS, Patricia; GACHON, Carine 

(31) 0707092 (32) 10 Oct 2007 (33) FR 



(57) Disclosed is an injectable emulsion containing derivatives of the 

taxane class, composed of an emulsion based on a pharmaceutically 

acceptable oil in water and on lecithin, composition in which the taxane is 

dissolved and corresponds to the general formula (I) or (II) and wherein 

the composition also contains an anionic surfactant. Also disclosed is 

a method of preparing the emulsion using a microfluidisation apparatus 

or a high-pressure homogeniser. 



(21) 584764 (22) 30 Oct 2008 

(54) Composition comprising a cellulose polymer, a sweetener, a 

plasticiser and a flavour composition 

(86) PCT/AU2008/001596 (87) WO2009/055846 

(51) IPC2012.01:A61K9/30, 36 

(71) sanofi-aventis Healthcare Pty Limited 

(72) WILLOUGHBY, David, John 

(31) 2007906008 (32) 1 Nov 2007 (33) AU 

(74) Watermark Patent and Trade Marks Attorneys, Level 2, 302 Burwood 

Road, Hawthorn, Victoria 3122, Australia 

(57) Disclosed is a tablet coating composition including a cellulose 

polymer, a plasticiser (such as polyethylene glycol), a sweetener, and 

a powdered flavour composition, the powdered flavour composition 

including a flavourant associated with a solid carrier (such as dextrin). 

(21) 584816 (22) 23 Oct 2008 

(54) CYCLOHEXYL-SUBSTITUTED SULFONAMIDES HAVING NPY Y5 

RECEPTOR ANTAGONIST ACTIVITY AND USE THEREOF 

(86) PCT/JP2008/069188 (87) WO2009/054434 

(51) IPC2012.01:C07D211/14; A61P3/04; A61K31/18, 40, 4015, 415, 

4164, 42, 423, 425, 426, 428, 44, 445, 47, 495, 50, 505, 5375, 5377, 

538, 553; C07D213/74; A61P43/00 

(71) SHIONOGI & CO., LTD 

(72) OKUNO, Takayuki; KOUYAMA, Naoki; SAKAGAMI, Masahiro 

(31) 2007-277387 (32) 25 Oct 2007 (33) JP 

(74) DAVIES COLLISON CAVE-Melbourne, 1 Nicholson Street, 

Melbourne, Victoria, Australia 

(57) Disclosed are Amine derivatives having sulfonyl group represented 

by the structural formulae depicted herein. These compounds exhibit 

NPY Y5 receptor antagonistic activity and are suitable for preparing an 

anorectic or anti-obesity composition for the treatment or prevention of 

obesity. 

(21) 584849 (22) 30 Oct 2008 

(54) NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF 

ANTICANCER TREATMENTS 

(86) PCT/FR2008/001528 (87) WO2009/092892 

(51) IPC2012.01:A61P35/00; A61K31/282, 337, 475, 555, 575; 

A61K45/06; A61P25/02 

(71) Trophos 

(72) PRUSS, Rebecca; BORDET, Thierry; ABITBOL, Jean-Louis; BERET, 

Antoine 

(31) 07 07625 (32) 30 Oct 2007 (33) FR 



(57) Disclosed is a composition comprising a cytotoxic agent, such as 

cisplatin, periwinkle alkaloids or a taxane, and a cholest-4-en-one oxime 

represented by general formula (I). The composition is used to treat 

cancer while preventing the side effects of peripheral neuropathy type 

caused by the anticancer treatment. 

(21) 584912 (22) 27 Oct 2007 

(54) NEW NON-PEPTIDE DERIVATIVES AS BRADYKININ B1 

ANTAGONISTS 

(86) PCT/HU2007/000101 (87) WO2009/053763 

(51) IPC2012.01:C07D243/08; C07D207/12; C07D295/20; C07D401/04; 

C07D211/22, 26, 44, 58, 62; A61P29/00; C07D241/06; C07D279/12; 

C07C311/21; A61K31/18 

(71) Richter Gedeon Nyrt. 

(72) VAGO, Istvan; FARKAS, Sandor; HORNOK, Katalin; BEKE, Gyula; 

BOZO, Eva; VASTAG, Monika; SZENTIRMAY, Eva; KESERU, Gyorgy; 

SCHMIDT, Eva 

(31) (32) 27 Oct 2007 (33) HU 

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, 

Victoria 3000, Australia 

(57) The disclosure relates to bradykinin B1 receptor antagonist 

phenylsulfamoyl benzamide derivatives of formula (I), wherein R1 - R5, 

Q and Z are as defined in the specification, and optical antipodes or 

racemates and/or salts and/or hydrates and/or solvates thereof, which 



are selective antagonists of bradykinin B1, to processes for producing 

these compounds, to pharmacological compositions containing them 

and to their use in therapy or prevention of painful and inflammatory 

conditions. 

(21) 585004 (22) 29 Oct 2008 

(54) ANTIBODIES WHICH BIND SELECTIVELY TO HAIR OF ANIMALS 

AND AN ANTIBODY BASED DRUG DELIVERY SYSTEM FOR 

ANIMALS 

(86) PCT/EP2008/009110 (87) WO2009/056280 

(51) IPC2012.01:C07K16/18; A61K47/48 

(71) BAYER ANIMAL HEALTH GMBH 

(72) HOFMANN, Stefan; HAMANN, Hans-Juergen; FISCHER, Rainer; 

SCHILLBERG, Stefan; VOGEL, Simon Oliver; SCHINKEL, Helga 

(31) 07021396.2 (32) 2 Nov 2007 (33) EP 


(57) Disclosed are antibodies that bind to the surface of hair of an animal 

selected from dog, cat, cattle, sheep, goat, camel, llama and horse. The 

antibodies are used in drug delivery systems and used in the treatment 

of ectoparasites. 

(21) 585091 (22) 31 Oct 2008 

(54) NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE 

DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF 

FOR THE TREATMENT OF PREMATURE EJACULATION 

(86) PCT/KR2008/006445 (87) WO2009/057974 

(51) IPC2012.01:C07D307/87; C07D405/06 

(71) DONG-A PHARMACEUTICAL CO., LTD. 

(72) LEE, Yeong Geon; CHOI, Soo-Jung; KANG, Tae-Kyung; SEO, 

Mi-Jeong; SHIN, Chang-Yong; LEE, Kyung-Seok; AHN, Gook-Jun; 

CHOI, Seul-Min; KIM, Yong-Duck; KIM, Dong-Hwan; KANG, Kyung- 

Koo; SHIM, Hyun-Joo; KIM, Dong-Sung; AHN, Byoung-Ok; YOO, Moo- 

Hi 

(31) 10-2007-0111783 (32) 2 Nov 2007 (33) KR 

(31) 10-2008-0105439 (32) 27 Oct 2008 (33) KR 


(57) Disclosed is a derivative represented by Formula 

1 or a pharmaceutically acceptable salt thereof 

e.g. 1-{3-(dimethylamino)propyl}-1-(4-methoxyphenyl)-1,3-dihydro-5isobenzofurancarbonitrile 

wherein, R1 and R2 defined in the 

specification for treating or preventing premature ejaculation. 

(21) 585103 (22) 16 Oct 2008 

(54) SUBSTITUTED LACTAMS DERIVATIVES AND THEIR USES FOR 

GLAUCOMA AND OCULLAR HYPERTENSION 

(86) PCT/US2008/080063 (87) WO2009/055289 

(51) IPC2012.01:C07D207/273; C07D413/14; A61K31/4025; A61P27/06; 

C07D409/06, 12, 14; C07D417/12 

(71) ALLERGAN, INC. 

(72) OLD, David, W.; NGO, Vinh, X. 

(31) 60/981,918 (32) 23 Oct 2007 (33) US 

(31) 60/984,838 (32) 2 Nov 2007 (33) US 



(57) Disclosed are lactam derivatives and their uses in treatment of 

glaucoma and hypertension. 

(21) 585246 (22) 10 May 2011 

(54) A piston valve where the movement of the valve has reduced friction 

due to a change in a seals compression 

(51) IPC2012.01:F16K1/00, 34, 32, 46 

(71) HANSEN DEVELOPMENTS LIMITED 

(72) PHILIP JOHN, COLLINS 



(57) A piston valve (100) that minimises friction during movement of the 

valve piston (140) is disclosed. The valve (100) has a hollow valve 

body (110) having an inlet port (111) and an outlet port (112), a piston 

chamber (130) within an interior of the body (110) and a piston (140) 

reciprocally moveable within the chamber (130). The piston (140) moves 

between a closed position where the piston (140) closes the valve (100) 

to fluid flow, and an open position. Within a groove (145) around an 

outer wall of the piston (140) a sealing element (150) is used to seal 

between the piston (140) and the chamber (130) wall when the piston is 

in the closed position. The sealing element (150) has a smaller crosssectional 

width than that of the groove (145) with allows the sealing 

element (150) to roll as the piston (140) moves between the open and 

closed positions, thus assisting in breaking the initial sticking between 

the sealing element (150)and the chamber (130) wall. The groove (145) 

or the inner wall of the chamber (130) has a varying diameter such that 

when the piston (140) is in the closed position the sealing element (150) 



is compressed between the groove (145) and the chamber and when 

the piston (140) moves from the closed towards the open position, the 

sealing element (150) moves to a position adjacent a smaller diameter 

that causes a reduction in compression of the sealing element (150). 

The sealing element (150) may be an o-ring. 

(21) 585313 (22) 21 Nov 2008 

(54) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, 

COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC 

DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, 

BACTERIAL INFECTIONS AND DERMATOSIS 

(86) PCT/SE2008/051334 (87) WO2009/067081 

(51) IPC2012.01:C07D417/10; A61P31/00; A61P35/00; A61P17/00; 

C07D401/10, 12; C07D403/10, 12; A61P27/14; A61K31/505; 

A61P11/00; C07D239/48, 49 

(71) ASTRAZENECA AB; DAINIPPON SUMITOMO PHARMA CO., LTD. 

(72) BENNETT, Nicholas, J; MCINALLY, Thomas; MOCHEL, Tobias; 

THOM, Stephen; TIDEN, Anna-Karin 

(31) 0702577-8 (32) 22 Nov 2007 (33) SE 

(31) 61/013,699 (32) 14 Dec 2007 (33) US 


(57) Disclosed are pyrimidine derivatives represented by general formula 

(I) or pharmaceutically acceptable salts thereof. An example of the 

compounds of formula (I) is Methyl 2-(3-((3-(2-Amino-4-methyl-6- 

(pentylamino)pyrimidin-5-yl)propylamino)methyl)phenyl) acetate. The 

compounds of formula (I) are used to treat asthma, COPD, allergic 

rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis B, 

hepatitis C, HIV, HPV, bacterial infections and dermatosis. 

(21) 585340 (22) 21 Apr 2005 

(54) Coated tablet composition comprising a coat for immediate release 

glucocorticoid and a core for extended release glucocorticoid for 

glucocorticoid replacement therapy 

(51) IPC2012.01:A61K9/00; A61P5/44, 42 

(71) DuoCort Pharma AB 

(72) SKRTIC, Stanko; Johnsson, Jorgen; LENNERNAS, Hans; HEDNER, 

Thomas; JOHANNSSON, Gudmundur 

(31) 04 564205 (32) 22 Apr 2004 (33) US 

(31) 0401031 (32) 22 Apr 2004 (33) SE 

(74) FB RICE, Level 23, 44 Market Street, Sydney, NSW 2000, Australia 

(57) Discloses a coated tablet composition for administration once daily 

comprising a coating and a tablet core. The coating comprises an 

immediate release part comprising one or more glucocorticoids and 

pharmaceutically acceptable release excipients or carriers adapted so 

that the one or more glucocorticoids are immediately released. The 

coating contains an amount of 20-40 % of the total hydrocortisone 

equivalents in the composition. The tablet core comprises an extended 

release part comprising one or more glucocorticoids in an amount of 

60-80% of the total hydrocortisone equivalents in the composition and 

pharmaceutically acceptable extended release excipients or carriers 

adapted so that the one or more glucocorticoids are released over an 

extended period of time of at least about 8 hours. The total daily dose 

of the glucocorticoids is in the range 1-80 mg. Further disclosed are 

various embodiments of the composition that detail the amount of total 

hydrocortisone equivalents released in a given timeframe from either the 

immediate release part or the extended release part of the composition. 

Also disclosed is the use the coated tablet composition used in the 

preparation of a medicament for the treatment of a glucocorticoid 

deficiency associated disorder. 


(21) 585493 (22) 24 Oct 2003 

(54) Low dose methods for treating disorders in which TNFalpha activity 

is detrimental 

(51) IPC2012.01:A61K39/395; C07K16/24; A61K38/19; C07K14/715 

(71) Abbott Biotechnology Ltd. 

(72) Kaymakcalan, Zehra; Kamen, Robert 

(31) 02 421262 (32) 24 Oct 2002 (33) US 



(57) Disclosed is the use of a TNFá antibody, D2E7 for treatment or 

alleviation of the symptoms of arthritis wherein the medicament is to be 

administered in a low dose of 0.01-0.1 mg per kg of the subject. 


(21) 585587 (22) 31 Oct 2007 

(54) RETINOID PRODRUG COMPOUND 

(86) PCT/JP2007/071184 (87) WO2009/057199 

(51) IPC2012.01:C07C235/84, 88; C07C237/48, 52; C07C271/30; 

C07F7/10 

(71) Research Foundation Itsuu Laboratory 

(72) MURATAKE, Hideaki; SHUDO, Koichi 

(31) (32) 31 Oct 2007 (33) JP 



(57) Disclosed is a retinoid prodrug compound represented by the 

following general formula (I) having a property of being converted into a 

retinoid after absorption in a living body, which, per se, has substantially 

no retinoid action, or has weak retinoid action, but is converted into a 

potent retinoid by an enzymatic chemical modification after absorption 

in a living body. 

(21) 585661 (22) 13 Nov 2008 

(54) PHENYLPYRAZOLE DERIVATIVES 

(86) PCT/JP2008/070712 (87) WO2009/063953 

(51) IPC2012.01:A61P3/04, 06, 10; C07D231/14; C07D413/14; 

C07D403/12, 14; C07D401/14; A61P25/08, 28; A61K31/415, 4155, 

422, 4439, 454, 5377; A61P37/08 

(71) TAISHO PHARMACEUTICAL CO. LTD. 

(72) NAKAMURA, Toshio; TATSUZUKI, Makoto; NOZAWA, Dai; TAMITA, 

Tomoko; MASUDA, Seiji; OHTA, Hiroshi; KASHIWA, Shuhei; FUJINO, 

Aya; CHAKI, Shigeyuki; SHIMAZAKI, Toshiharu 



(31) 2007-294040 (32) 13 Nov 2007 (33) JP 

(31) 2008-153736 (32) 12 Jun 2008 (33) JP 



(57) Disclosed is a phenylpyrazole derivative represented 

by formula (1) or a pharmaceutically acceptable salt 

thereof, wherein the substituents are as described within 

the specification. Examples of compounds of formula 

(1) include: 4-{[1-(4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1H-pyrazol-4yl}carbonyl)morpholine; 

and 1-(4-{3-[(2S)-2-methylpyrrolidin-1yl]propoxy}phenyl)-1H-pyrazole-4-carboxamide. 

Further disclosed is 

the use of a compound of formula (1) in the manufacture of a 

prophylactic or therapeutic agent for dementia, Alzheimer’s disease, 

attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central 

convulsion, eating disorders, obesity, diabetes, hyperlipidemia, sleep 

disorders, narcolepsy, sleep apnea syndrome, circadian rhythm 

disorder, depression or allergic rhinitis. 

(21) 585729 (22) 12 Nov 2008 

(54) HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION 

CHANNELS 

(86) PCT/US2008/083173 (87) WO2009/064752 

(51) IPC2012.01:C07D417/14; A61K31/427, 4427 

(71) Vertex Pharmaceuticals Incorporated 

(72) STAMOS, Dean; MARTINBOROUGH, Esther; NEUBERT, Timothy; 

NUMA, Mehdi Michel Djamel; WHITNEY, Tara; ZIMMERMANN, Nicole; 

HAMPTON, Tara Leanne 

(31) 60/987,490 (32) 13 Nov 2007 (33) US 



(57) Disclosed is a compound of formula (I) where the substituents are as 

disclosed in the specification and examples of compounds of formula 

(I) are (S)-4-(3-( 6,7-dichloro-3,4-dihydroisoquinolin-2(1H)-yl)-2oxopyrrolidin-1-yl)-N-(thiazol-2-yl)benzenesulfonamide 

and (S)-4-(2oxo-3-(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)yl)pyrrolidin-1yl)-N-(thiazol-2-yl)benzenesulfonamide. 

Also disclosed is a 

pharmaceutical composition comprising a compound of formula (I) and 

the use of a compound of formula (I) in the manufacture of a medicament 

for treating conditions such as arthritis, migraines, pain and epilepsy. 

(21) 585795 (22) 18 Dec 2008 

(54) CORROSION RESISTANT STEEL FOR MARINE APPLICATIONS 

(86) PCT/EP2008/067922 (87) WO2009/080714 

(51) IPC2012.01:C22C38/02, 04, 06, 22, 24, 26; C21D8/02 

(71) ARCELORMITTAL COMMERCIAL RPS S.A.R.L. 

(72) FAGOT, Anne 

(31) 07150370.0 (32) 21 Dec 2007 (33) EP 

(74) P L BERRY & ASSOCIATES, 15B Byron Street, Sydenham, 

Christchurch 8023, New Zealand 

(57) Disclosed herein is a steel composition, namely for marine 

applications, comprising by weight percent: · Carbon: 0.05 to 0.20; · 

Silicon: 0.15 to 0.55; · Manganese: 0.60 to 1.60; · Chromium: 0.75 

to 1.50; · Aluminum: 0.40 to 0.80; · Niobium and/or vanadium: 0.01 # 

[Nb] + [V] # 0.60; · Sulphur: up to 0.045; · Phosphorus: up to 0.045; 

· Molybdenum: from 0 to 0.15; · Titanium: from 0 to 0.05; wherein the 

balance is iron and incidental and/or residual impurities. 

(21) 585799 (22) 2 Dec 2008 

(54) PROCESS FOR THE MANUFACTURE OF AN INDOLINONE 

DERIVATIVE IN PARTICULAR 3-Z-[1-(4-(N-((4-METHYL- 

PIPERAZIN-1-YL)-METHYLCARBONYL)-N-METHYL-AMINO)- 

ANILINO)-1-PHENYL-METHYLENE]-6-METHOXYCARBONYL-2- 

INDOLINONE 

(86) PCT/EP2008/066580 (87) WO2009/071523 

(51) IPC2012.01:C07D209/34 

(71) Boehringer Ingelheim International GmbH 

(72) MERTEN, Joern; LINZ, Guenter; SCHNAUBELT, Juergen; 

SCHMID, Rolf; RALL, Werner; RENNER, Svenja; REICHEL, Carsten; 

SCHIFFERS, Robert 

(31) 07122122.0 (32) 3 Dec 2007 (33) EP 



(57) Disclosed herein is a process for 

the manufacture of an indolinone compound, 

namely 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl-Nmethyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2indolinone 

and its monethanesulfonate salt. 

(21) 585870 (22) 11 Dec 2008 

(54) PROCESS FOR EDIBLE OIL REFINING USING A LIPID 

ACYLTRANSFERASE 

(86) PCT/GB2008/004064 (87) WO2009/081094 

(51) IPC2012.01:C11B3/00; C12P7/64; C12N9/10, 20 

(71) DANISCO A/S 

(72) SOE, Jorn, Borch; BROWN, Anne, Victoria 

(31) 0725035.0 (32) 21 Dec 2007 (33) GB 

(31) 0809177.9 (32) 20 May 2008 (33) GB 

(31) 61/058,378 (32) 3 Jun 2008 (33) US 



(57) Disclosed is a method of water degumming an edible oil comprising 

the steps of: a) admixing approximately 0.1-5% w/w water with an 

edible oil and a lipid acyltransferase, b) agitating the admixture for 

between about 10 minutes and 180 minutes at about 45 to about 90°C, 

and c) separating the oil phase and the gum phase, wherein the lipid 

acyltransferase used has a transferase activity (TrU) per mg enzyme of 

at least 25 TrU/mg enzyme protein as determined using the following 

assay: (i) 50 mg cholesterol and 450 mg Soya phosphatidylcholine is 

dissolved in chloroform and chloroform is evaporated at 40 °C under 

vacuum; (ii) 300 mg PC:cholesterol 9:1 is dispersed at 40 °C in 10 ml 

50mM HEPEs buffer pH 7 to form a substrate; (iii) 250ìl substrate is 

added in a glass with lid at 40 °C, 25 ìl enzyme solution is added and 

incubated during agitation for 10 minutes at 40 °C; (iv) after 10 minutes, 

5 ml Hexan:Isopropanol 3:2 is added; (v) the amount of cholesterol 

ester is analysed by HPTLC using Cholesteryl stearate standard for 

calibration; and (iv) transferase activity is calculated as the amount of 

cholesterol ester formation per minute. 



(21) 585915 (22) 12 Dec 2008 

(54) AZOLYLMETHYLOXIRANES, USE THEREOF AND AGENTS 

CONTAINING THE SAME 

(86) PCT/EP2008/067394 (87) WO2009/077443 

(51) IPC2012.01:A61P31/00; A01N43/653; A61K31/4025; C07F9/40; 

C07D303/08, 12, 36; C07D407/06, 14 

(71) BASF SE 

(72) DIETZ, Jochen; GROTE, Thomas; MULLER, Bernd; LOHMANN, 

Jan Klaas; RENNER, Jens; ULMSCHNEIDER, Sarah; GLATTLI, Alice; 

VRETTOU, Marianna 

(31) 07123700.2 (32) 19 Dec 2007 (33) EP 



(57) Disclosed is a compound of formula (I) where the substituents are 

as disclosed in the description. Examples of compounds of formula 

(I) are N-(3',4',5'-trifluorobiphenyl-2-yl)-1-methyl-3-difluoromethyl-1 Hpyrazole-4-carboxamide;N-(2',4',5'-trifluorobiphenyl-2-yl)-1-methyl-3difluoromethyl-1 

H-pyrazole-4-carboxamide and N-(3',4', 5' - 

trifluorobiphenyl-2-yl)-3-chlorofluoromethyl-1-methyl-1 H-pyrazole-4carboxamide. 

Also disclosed is a composition comprising a compound 

of formula (I), a method for controlling fungus using a compound 

of formula (I) a process for preparing a compound of formula (I), a 

medicament comprising a compound of formula (I). 

(21) 585979 (22) 26 Nov 2008 

(54) PRECISION REGISTRATION FOR RADAR 

(86) PCT/US2008/084940 (87) WO2009/079187 

(51) IPC2012.01:G01S13/93, 76, 87, 91; G01S7/40; G01S5/00 

(71) Lockheed Martin Corporation 

(72) ABBETT, Michael, R; TORRES, Sergio 

(31) 60/991,588 (32) 30 Nov 2007 (33) US 

(31) 12/277,234 (32) 24 Nov 2008 (33) US 



(57) A method of registering a radar and a radar registration system are 

disclosed. The system includes a radar operable to output radar data 

including a plurality of radar based position reports associated with one 

or more targets moving within a range of the radar; a geo-referenced 

position source operable to output a plurality of geo-referenced position 

reports associated with the one or more targets; and a processor 

operable to compute both position and time bias parameters associated 

with the radar by analyzing the radar-based position reports using the 

geo-referenced position reports as a reference. The radar can include 

a first radar and the plurality of radar-based position reports include 

a first plurality of radar-based position reports associated with one 

or more targets moving within a range of the first radar. The system 

further includes a second radar operable to output radar data including 

a second plurality of radar-based position reports associated with one 

or more targets moving within a range of the second radar. The ranges 

of the first and second radars overlap and the processor is further 

operable to compute position and time bias parameters associated 

with the second radar by analyzing the second plurality of radarbased 

position reports using the first plurality of radar-based position 

reports as a reference after registration of the first plurality of radarbased 

position reports in accordance with the position and time bias 

parameters associated with the first radar. 

(21) 585980 (22) 14 Nov 2008 

(54) ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE 

TRANSPORTERS 

(86) PCT/US2008/083517 (87) WO2009/064959 

(51) IPC2012.01:C07D405/12, 14; A61K31/472, 4725; C07D401/04; 

C07D217/22; A61P11/00 


(72) HADIDA RUAH, Sara; MILLER, Mark; ZHOU, Jinglan; BEAR, Brian; 

GROOTENHUIS, Peter, D., J 

(31) 60/988,559 (32) 16 Nov 2007 (33) US 



(57) The disclosure relates to a substituted isoquinoline derivative of 

the structural formula shown herein and pharmaceutically acceptable 

salt thereof, which is useful as a modulator of ATP-Binding Cassette 

("ABC") transporter activity, including Cystic Fibrosis Transmembrane 

Conductance Regulator ("CFTR"). Said substituted isoquinoline 

compound may be suitable for treating ABC transporter mediated 

diseases selected from cystic fibrosis, asthma, smoke induced 

COPD, chronic bronchitis, rhinosinusitis, constipation, pancreatitis, 

pancreatic insufficiency, male infertility caused by congenital 

bilateral absence of the vas deferens, mild pulmonary disease, 

idiopathic pancreatitis, allergic bronchopulmonary aspergillosis, 

liver disease, hereditary emphysema, hereditary hemochromatosis, 

coagulation-fibrinolysis deficiencies, lipid processing deficiencies, 

lysosomal storage diseases, Crigler-Najjar type II, polyendocrinopathy/ 

hyperinsulemia, Diabetes mellitus, Laron dwarfism, myleoperoxidase 

deficiency, primary hypoparathyroidism, melanoma, glycanosis 

CDG type 1, congenital hyperthyroidism, osteogenesis imperfecta, 

hereditary hypofibrinogenemia, ACT deficiency, Diabetes insipidus, 

neurophyseal DI, neprogenic DI, Charcot-Marie Tooth syndrome, 

Perlizaeus-Merzbacher disease, neurodegenerative diseases several 

polyglutamine neurological disorders as well as spongiform 

encephalopathies, COPD, dry-eye disease and Sjogren’s disease. 




(21) 586019 (22) 23 Dec 2008 

(54) Mortice lock with inner and outer hubs, to move bolt when operated 

by handle, being activated by adjustable handing selector that can be 

activated to provide inner hub only or outer hub only operation 

(86) PCT/AU2008/001892 (87) WO2009/082778 

(51) IPC2012.01:E05B63/04, 08, 16; E05B13/00 

(71) ASSA ABLOY AUSTRALIA PTY LIMITED 

(72) NEWMAN, Donald, John 

(31) 2007907102 (32) 27 Dec 2007 (33) AU 

(31) 2008905647 (32) 31 Oct 2008 (33) AU 



(57) This invention relates to a mortice lock assembly (1) including a 

housing (2) and a bolt (3), movable relative to the housing by a handle 

operated actuator (6). The actuator includes an inner and outer hub (7, 

8) which may be locked by operation of a detent (12). A handing selector 

means (21) is operable from a front of the housing (2), for rendering 

either of the inner or outer hubs (7, 8) inoperable. 

(21) 586023 (22) 17 Apr 2009 

(54) METHOD FOR MANUFACTURING FERMENTED MILK 

(86) PCT/JP2009/057760 (87) WO2009/150897 

(51) IPC2012.01:A23C9/127; C12N1/00, 20 

(71) Morinaga Milk Industry Co., Ltd. 

(72) SHIMIZU, Kanetada; YONEZAWA, Sumiko 

(31) 2008-152949 (32) 11 Jun 2008 (33) JP 



(57) A method that comprises fermenting milk using both a proteolytic 

Lactococcus lactis strain having the cell wall enveloped proteinase PrtP, 

and bacteria belonging to Bifidobacterium longum. The B. longum can 

be B. longum ATCC BAA-999. 

(21) 586068 (22) 5 Dec 2008 

(54) METHOXYIMINO COMPOUNDS AND FUNGICIDE COMPOSITION 

COMPRISING SAME 

(86) PCT/KR2008/007205 (87) WO2009/072837 

(51) IPC2012.01:C07C251/32, 48 

(71) KYUNG NONG CORPORATION 

(72) KIM, Joo-Kyung; KIM, Hyung-Ho; HWANG, In-Cheon; NAM, Ho-tae 

(31) 10-2007-0125883 (32) 6 Dec 2007 (33) KR 

(31) 10-2008-0079429 (32) 13 Aug 2008 (33) KR 



(57) Disclosed herein are methoxyimino compounds of formula (I), wherein 

A is O or O-N=C(CH3); R1 is H, halogen, C1-3 alkyl, or C1-3 alkoxy; 

R2 is H or C1-3 alkoxy; R3 is H, or C1-4 alkyl substituted with one or 

more C1-4 alkyl groups or halogens; X and X' are each independently 

halogen; and W is O or NH, methods for their preparation, compositions 

comprising said compounds and uses thereof as fungicides. 

(21) 586164 (22) 18 Dec 2008 

(54) Method of degrading beta-glucan via hydrolysis in acidic solution 

(86) PCT/FI2008/050768 (87) WO2009/077659 

(51) IPC2012.01:C08B37/00; A23L1/10, 308; A23L2/52 

(71) Valtion Teknillinen Tutkimuskeskus; Glykos Finland Oy 

(72) KAUKOVIRTA-NORJA, Anu; LEHTINEN, Pekka; VIRKAJARVI, Ilkka; 

SUORTTI, Mikko; MYLLYMAKI, Olavi; HELIN, Jari; OLONEN, Anne 

(31) 20070993 (32) 19 Dec 2007 (33) FI 



(57) Disclosed is a method of degrading plant-based beta-glucan into 

a reduced molecular size in a controlled manner, characterized by 

subjecting the beta-glucan to hydrolysis in a flour like form or in the form 

of a doughy mass in a closed space under pressure in the presence of 

an acid solution at an elevated temperature followed by cooling, thus 

yielding a degraded beta-glucan product. Also disclosed is a degraded 

beta-glucan wherein the ratio of [1,4]beta-glucan to [1,3]beta-glucan is 

the same as that of native beta-glucan. The degraded beta-glucan can 

be separated from insoluble plant fibre and incorporated into foodstuffs 

such as beverages as a functional nutritional supplement. 

(21) 586209 (22) 10 Oct 2008 

(54) CORROSION CONTROL METHOD AND APPARATUS FOR 

REINFORCING STEEL IN CONCRETE STRUCTURES 

(86) PCT/US2008/079564 (87) WO2009/067304 

(51) IPC2012.01:C23F13/02; C23F11/00 

(71) FUNAHASHI MIKI 

(72) FUNAHASHI, Miki 

(31) 11/942,955 (32) 20 Nov 2007 (33) US 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 20, ANZ Centre, 324 

Queen Street, Brisbane, Queensland 4000, Australia 

(57) Disclosed is an anode for controlling corrosion of reinforcing steel 

in concrete, comprising: a mixed-metal-oxide (MMO) coated metal 

substrate; an electrically conductive adhesive layer operative to bond 

the substrate to an exposed concrete surface; and wherein the 

electrically conductive adhesive layer includes metal particles which 

reduce the contact resistance between the MMO-coated substrate and 

the concrete. Particularly the substrate is made out of titanium, tantalum, 

zirconium, niobium or alloys thereof; and the coating is composed of 

oxides of titanium, tantalum, iridium, ruthenium, palladium, or cobalt. 

(21) 586367 (22) 12 Dec 2008 



(54) Improved immunizing composition comprising an antigen from 

Streptococcus equi 

(86) PCT/SE2008/051445 (87) WO2009/075646 

(51) IPC2012.01:A61K39/09, 40; C07K14/315; C07K16/12 

(71) INTERVACC AB 

(72) GUSS, Bengt; FLOCK, Jan-Ingmar; FRYKBERG, Lars; FLOCK, 

Margareta 

(31) 61/013,495 (32) 13 Dec 2007 (33) US 

(31) 61/082,281 (32) 21 Jul 2008 (33) US 


(57) Disclosed is an isolated antigenic composition comprising at least two 

antigens, wherein each antigen comprises at least part of a protein or 

polypeptide of Streptococcus equi subsp. equi or subsp. zooepidemicus 

and said at least part of said protein or polypeptide comprises at least 

one antigenic epitope or antigenic determinant of Streptococcus equi, 

characterized in that the antigens comprise: an antigen comprising at 

least part of a protein or polypeptide which is designated EAG and has 

an amino acid sequence as shown in SEQ ID NO: 13; and an antigen 

comprising at least part of a protein or polypeptide which is designated 

IdeE and has an amino acid sequence as shown in SEQ ID NO: 10. 

(21) 586401 (22) 26 Nov 2008 

(54) A PROPULSION SYSTEM FOR A WATERCRAFT WITH SHROUD 

UNIT SURROUNDING A SURFACE PIERCING PROPELLER 

(86) PCT/IB2008/054963 (87) WO2009/069084 

(51) IPC2012.01:B63H5/16 

(71) Cape Advanced Engineering (Proprietary) Limited 

(72) TAYLOR, Andrew Bruce 

(31) 2007/10140 (32) 26 Nov 2007 (33) ZA 



(57) A propulsion system (10) for a watercraft is disclosed including 

a surface-piercing propeller (12), a drive means (24) for driving the 

propeller (12), a shroud unit (16) and a mounting means (18) for 

mounting the propeller (12) and the shroud unit (16) to the watercraft. 

The shroud unit comprises: a) An inner shroud member (31) for 

augmenting propeller thrust which is configured to surround at least the 

lower half of the propeller blade tip travel path. The inner shroud member 

(31) has a leading end disposed adjacent the blade tip travel path and 

a trailing end (30) which is located rearwardly of the propeller blade tip 

travel path and extends transversely relative to the axis of rotation of the 

propeller (12). b) And, an outer shroud member (33) which is configured 

to surround the inner shroud member (31). The outer shroud member 

has a leading end and a trailing end and is radially spaced from the 

inner shroud member (31) so as to define an air gap (34) between the 

inner (31) and outer (33) shroud members to which air can be delivered. 

The air gap (34) is open at the trailing ends (30) of the shroud members 

and closed at the leading ends. In one embodiment the outer shroud 

member (31) has a hydrodynamic lifting formation located at a lower 

external side thereof, so as to provide hydrodynamic lift as the watercraft 

travels through water. 

(21) 586406 (22) 24 Jun 2010 

(54) Low fat processed cheese slice-on-slice and block 

(51) IPC2012.01:A23C19/00, 09, 08 

(71) Kraft Foods Global Brands LLC 

(72) Reyes, Divinia; Douglas, Neil Griffith; Razavi, Kamal Seyed 

(31) USSN: 12/495,503 (32) 30 Jun 2009 (33) US 



(57) Disclosed is a low fat processed cheese product comprising a 

substantially homogeneous mixture of: from about 30 to about 54 total 

weight percent of natural skim milk cheese; additional non-powder dairy 

ingredients; and from about 2 to about 2.8 total weight percent of 

emulsifier salts, the emulsifier salts being at least a citrate salt; wherein 

the cheese product comprises: less than about 3.0 total weight percent 

fat; from about 53 to about 55 total weight percent of water; from about 

25 to about 26.7 total weight percent protein, of which from about 17 

to about 22.5 total percent weight is functional casein protein; and 

a functional casein protein/moisture ratio from about 22 to about 56 

percent. 

(21) 586452 (22) 23 Dec 2008 

(54) 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid 

gamma-lactone derivative, use thereof and medicinal products 

containing the derivative 

(86) PCT/EP2008/011162 (87) WO2009/083269 

(51) IPC2012.01:C07J53/00; A61K31/58; A61P5/28, 34, 42; C07J21/00 

(71) BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 

(72) KLAR, Ulrich; KUHNKE, Joachim; BOHLMANN, Rolf; HUBNER, 

Jan; RING, Sven; FRENZEL, Thomas; MENGES, Frederik; BORDEN, 

Steffen; PRELLE, Katja; MUHN, Hans-Peter 

(31) 10 2007 063 501.1 (32) 29 Dec 2007 (33) DE 


(57) Disclosed are 15,16-methylene-17-hydroxy-19-nor-21-carboxylic 

acid-steroid g-lactone derivatives and their solvates, hydrates, 

stereoisomers and salts, as represented by the general formula 

(I), in which Z is selected from the group comprising oxygen, 

two hydrogen atoms, NOR' and NNHSO2R'; R4 is selected from 

the group comprising hydrogen, fluorine, chlorine or bromine; R18 

is hydrogen or alkyl; and wherein the remaining substituents are 

as defined herein. Representative compounds as disclosed herein 

include 17b-hydroxy-15a,16a-methylene-19-nor-17a-pregna-4,20(Z)dien-3-one-21-carboxylic 

acid g-lactone, 17b-hydroxy-7acyclopropyl-15b,16b-methylene-19-nor-17a-pregna-4,20(Z)-dien-3one-21-carboxylic 

acid g-lactone and 17a-pregna-4,20(Z)-dien-3one-21-carboxylic 

acid g-lactone. Further disclosed is a medicinal 

product (such as an intrauterine system (IUS)) which contains at least 

one 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid glactone 

derivative as defined above and at least one suitable 



pharmaceutically harmless additive for oral contraception or for the 

treatment of pre-, peri- and postmenopausal complaints. 

(21) 586464 (22) 16 Jan 2009 

(54) CATHETERFOR TAKING SAMPLES FROM WITHIN A LENGTH OF 

A BLOOD VESSEL 

(86) PCT/GB2009/000106 (87) WO2009/090390 

(51) IPC2012.01:A61M25/00; A61B10/00; A61B5/15, 14 

(71) PlaqueTec Ltd 

(72) BLATCHER, Stephen; OWEN, Richard, Harley, Grenville; 

CORRIGAN, Joseph, Peter; NEUDECK, Thomas; SCUDAMORE, 

Andrew, Peter; HOURMAND, Yannick, Pierre, Louis 

(31) 0800981.3 (32) 18 Jan 2008 (33) GB 



(57) Disclosed is a catheter (10) and associated method for taking a 

plurality of samples from within a length of a blood vessel (2). The 

catheter includes an elongate central body (12) arranged to be inserted 

into and positioned along a central region of a blood vessel. A plurality 

of collection areas (14) are defined along the elongate central body for 

collecting samples at the central region of the blood vessel. A plurality 

of mixers (18) are provided radially outwardly of the elongate central 

body and arranged to create a flow of blood from a boundary layer at a 

wall of the blood vessel to the elongate central body. This enables the 

collection areas to collect samples from the boundary layer. 

(21) 586479 (22) 31 Dec 2007 

(54) Tunnel dressing for treating a wound with suction including a 

permeable inner layer which resists compression 

(86) PCT/US2007/026486 (87) WO2009/070152 

(51) IPC2012.01:A61F13/36; A61M1/34 

(71) Boehringer Technologies, L.P. 

(72) RADL, Christopher, L.; KLOCEK, Kevin, P.; KARPOWICZ, John, R. 



(57) Disclosed is a tunnel dressing (10) for use in treating a tunneling 

wound using negative pressure wound therapy. The tunnel dressing 

includes an elongate permeable member having a closed distal end 

(46) for entering the wound and an open proximal end (48) into 

which a removeable applicator is disposed for guiding the dressing 

into the wound. The tunnel dressing has a support structure (14) 

adapted to transport wound exudates away from the wound and to 

resist compression under suction. The tunnel dressing also has a 

wound contact surface (20) adapted to minimize tissue entanglement 

to facilitate removal. The support structure and wound contact surface 

may be formed from the same material or from two adjacent layers of 

different material. 

(21) 586589 (22) 6 Jan 2009 

(54) NOVEL INSULIN ANALOGUES HAVING AN EXTREMELY 

DELAYED TIME-ACTION PROFILE 

(86) PCT/EP2009/000018 (87) WO2009/087082 

(51) IPC2012.01:C07K14/62 

(71) Sanofi-Aventis Deutschland GmbH 

(72) HABERMANN, Paul; SEIPKE, Gerhard; KURRLE, Roland; MULLER, 

Gunter; SOMMERFELD, Mark; TENNAGELS, Norbert; TSCHANK, 

Georg; WERNER, Ulrich 

(31) 10 2008 003 566.1 (32) 9 Jan 2008 (33) DE 

(31) 61/044,662 (32) 14 Apr 2008 (33) US 

(31) 10 2008 025 007.4 (32) 24 May 2008 (33) DE 



(57) Disclosed is insulin analogs having a basal time-action profile, which 

are characterized by the addition and/or substitution of negatively and 

positively charged amino acid residues and by an amidation of the Cterminal 

carboxy group of the B chain and histidine in position 8 of the 

insulin A chain. The invention also relates to the production and use 

thereof. 

(21) 586616 (22) 22 Dec 2006 

(54) Prognosis Prediction For Colorectal Cancer 

(51) IPC2012.01:C12Q1/68; G01N33/574 

(71) Pacific Edge Biotechnology Ltd 

(72) Reeve, Anthony E; Lin, Yu-Hsin; Black, Michael A; McCall, John 

L; Nekarda, Hjalmar; Rosenberg, Robert; Friederichs, Jan; Holzmann, 

Bernhard; Pollock, Robert Craig 

(31) 544432 (32) 23 Dec 2005 (33) NZ 



(57) Provided is a method for determining the prognosis of colorectal 

cancer (CRC) in a patient, the prognosis being the likelihood of 

recurrence of the CRC, comprising the steps of: (i) determining the 

expression level of a prognostic signature comprising DLGAP4 in a CRC 

tumour sample from the patient, and (ii) establishing a prognosis by 

comparing the expression level of the prognostic signature to those of 

known recurrent and non-recurrent tumour samples. 


(21) 586642 (22) 12 Jan 2009 

(54) NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI 

-CANCER AGENTS 

(86) PCT/IN2009/000037 (87) WO2009/098715 

(51) IPC2012.01:C07D487/04; A61K31/519; A61P35/00 

(71) Natco Pharma Limited 



(72) KONAKANCHI, Durga, Prasad; PULA, Subba Rao; ANANTHANENI, 

Lakshmi; PILLI, Ramakrishna; PULLA REDDY, Muddasani; 

ADIBHATLA KALI SATYA, Bhujanga Rao; VENKAIAH CHOWDARY, 

Nannapaneni 

(31) 109/CHE/2008 (32) 11 Jan 2008 (33) IN 



(57) Disclosed are substituted pyrazolo pyrimidine compounds of 

formula I, salts thereof, and methods for their preparation. Specific 

examples of compounds of formula I include: (4-methoxy-benzyl- 

[1-(3-ethynyl-phenyl)-1H-pyrazolo [3,4-d] pyrimidine-4yl)-amine, [1- 

(3-trimethylsilanyl ethynyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4yl)- 

(3,4,5-trimethoxybenzyl)-amine, and [4-(3-morpholin-4-yl-propoxy)benzyl]-[1-(3-iodo-phenyl)-1H-pyrazolo[3,4-d]pyrimidine-4yl)-amine. 

Specifically disclosed is a synthetic method 

for N-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(3,5dimethylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine. 

Also disclosed 

is the use of a compound of formula I for treating lung cancer, 

squamous cell cancer, bladder cancer, gastric cancer, pancreatic 

cancer, breast cancer, head cancer, neck cancer, esophageal cancer, 

brain cancer, gynecological cancer, prostate cancer, kidney cancer, 

leukemia, lymphoma or thyroid cancer. 

(21) 586658 (22) 2 Feb 2009 

(54) NAVIGATION DEVICE, SYSTEM & METHOD WITH OVER THE AIR 

SEARCH MODULE 

(86) PCT/EP2009/051140 (87) WO2009/100997 

(51) IPC2012.01:G01C21/36; G08G1/0968 

(71) TomTom International B.V. 

(72) GEELEN, Pieter 

(31) 61/064,091 (32) 15 Feb 2008 (33) US 



(57) A navigation device (200) comprises an input interface (220, 240); 

a processor (210); and a display (240) controllable by the processor. 

The input interface is additionally configured to enable a user to input 

a search text and to select a reference location. The navigation device 

(200) further comprises an over the air (OTA) search module (490) for 

generating a server call message comprising the reference location and 

the search text for transmission to a remote map search server (530) and 

for receiving a search results reply message from such a remote map 

search server (530) based on the reference location and the search text, 

and the processor (210) being responsive to the OTA search module 

(490) to control said display (240) to display the search results to the 

user. A navigation system comprising the above described navigation 

device and a remote map search server (530) is also disclosed. Also 

disclosed is a navigation method for locating an unknown destination in 

a navigation device. 

(21) 586666 (22) 5 Feb 2009 

(54) ESTRADIOL-CONTAINING DRUG DELIVERY SYSTEM 

(86) PCT/EP2009/051303 (87) WO2009/101021 

(51) IPC2012.01:A61K9/00, 70; A61K31/565 


(72) FUNKE, Adrian; GENERAL, Sascha; TEREBESI, Ildiko; ZURTH, 

Christian; ALINCIC-KUNZ, Sofia; SCHAFERS, Matthias; HOLLER, 

Thomas; DIEFENBACH, Konstanze 

(31) 08002633.9 (32) 13 Feb 2008 (33) EP 

(31) 61/028,302 (32) 13 Feb 2008 (33) US 


(57) Disclosed is a unit dosage form comprising a thin water-soluble 

film matrix, wherein (a) said film matrix comprises at least one 

water-soluble matrix polymer; (b) said film matrix comprises 10-200 

micrograms of estradiol, or a therapeutically equivalent amount of 

a hydrate of estradiol or a therapeutically equivalent amount of a 

pharmaceutically acceptable ester of estradiol; and (c) said film matrix 

has a thickness of less than 300 micrometres, wherein the estradiol, 

hydrate of estradiol, or ester of estradiol is present in the unit dosage 

form in non-complexed form. Said dosage form is suitable for treating a 

physical condition selected from the group consisting of osteoporosis, 

headaches, nausea, depression, vasomotor symptoms (such as hot 

flushes, sweating attacks including night sweats, and palpitations), 

symptoms of urogenital atrophy, decrease in bone mineral density, and 

increased risk or incidence of bone fracture 

(21) 586675 (22) 8 Jan 2009 

(54) PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)- 

PIPERIDIN-3- YL]PHENYL} -2H-INDAZOLE-7-CARBOXAMIDE 

(86) PCT/GB2009/000041 (87) WO2009/087381 

(51) IPC2012.01:C07D401/10; A61K31/454; A61P35/00 

(71) MERCK SHARP & DOHME LIMITED; MERCK SHARP & DOHME 

CORP. 

(72) Foley, Jennifer, R; Wilson, Robert Darrin 

(31) 61/010,333 (32) 8 Jan 2008 (33) US 



(57) Disclosed are compounds selected from: 

(3S)-3-{4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium 4methylbenzenesulfonate;(3S)-3-{4-[7-(Aminocarbonyl)-2H-indazol-2yl]phenyl}piperidinium 

sulfate; (3S)-3-{4-[7-(Aminocarbonyl)-2Hindazol-2-yl]phenyl}piperidinium 

benzenesulfate; (3S)-3-{4-[7- 

(Aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium fumarate; (3S)-3- 

{4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium succinate; 

(3S)-3-{4-[7-(Aminocarbonyl)-2H-indazol-2-yl]phenyl}piperidinium 4methylbenzenesulfonate 

monohydrate. The compounds are used 

to treat cancer, inflammatory diseases, reperfusion injuries, 

ischemic conditions, stroke, renal failure, cardiovascular diseases, 

vascular diseases other than cardiovascular diseases, diabetes, 



neurodegenerative diseases, retroviral infection, retinal damage or skin 

senescence and UV induced skin damage. 

(21) 586699 (22) 11 Feb 2009 

(54) Dry powder inhaler with multiple medicament containing cavities in a 

rotating disc arrangement 

(86) PCT/SE2009/050143 (87) WO2009/102275 

(51) IPC2012.01:A61M15/00; B65D75/32 


(72) LASTOW, Orest 

(31) 61/027,865 (32) 12 Feb 2008 (33) US 

(31) 61/090,255 (32) 20 Aug 2008 (33) US 


(57) 1. An inhaler with a mouthpiece upstream of the medicament doses, 

comprising a circular disk base having at least one or a plurality of sealed 

cavities containing medicament, a foil portion comprising two sides, one 

side being attached to the base for sealing the medicament within the 

cavity, a separating element which is attached to the other side of the 

foil portion for separating the foil portion from the cavity, the separating 

element having a first end and an opposite second end, wherein the 

separating element is movable to an intermediate tilted position in which 

said first end is moved-away from the cavity, wherein the separating 

element is further movable from the intermediate tilted position to a 

removed position in which also said second end is moved-away from the 

cavity so that the foil portion is removed from the cavity which is thereby 

uncovered so that medicament contained therein is enabled to become 

entrained in a fluid flow. An actuator removes the separating element 

of the foil portion from the cavity by impacting upon it so it forms part 

of the air flow path. The separating element can be return to its original 

position once the medicament has been removed from the cavity. 

(21) 586744 (22) 23 Jan 2009 

(54) A portable structure, such as a water container, paddling pool, play 

pen or ball-pool which can be stored or erected 

(86) PCT/IB2009/000109 (87) WO2009/095757 

(51) IPC2012.01:E04H4/00; E04H15/40; A45C7/00; A47D13/06 

(71) PRIME HONOUR DEVELOPMENT LIMITED 

(72) YU, Teresa 

(31) 0801823.6 (32) 31 Jan 2008 (33) GB 

(31) 0805711.9 (32) 28 Mar 2008 (33) GB 

(74) PIPERS, Level 1, 5A Pacific Rise, Sylvia Park, Mt Wellington, 

Auckland, New Zealand 

(57) A portable structure (1), configurable between stored and erected 

conditions, comprises a base (4), one or more sides (5), a resilient frame 

(2) and one or more spacing members (6). The base (4) and the one 

or more sides (5) comprise a flexible material. The resilient frame (2) is 

located at the interface of the base (4) and the one or more sides (5). 

The resilient frame (2) is connected to the flexible material to provide a 

shape to the base (4) in the erected condition. The one or more spacing 

members (6) support the flexible material of the one or more sides (5) 

in a raised manner in the erected condition so as to form a container, 

bounded by the flexible material of the base (4) and the one or more 

sides (5). The resilient frame (2) and the one or more spacing members 

(6) are foldable to allow the portable structure (1) to adopt its stored 

condition, wherein folding of the resilient frame (2) and the one or more 

spacing members (6) provides energy for moving the portable structure 

(1) from the stored condition to the erected condition thereof. An opening 

(41) in the side is provided for allowing a person to enter or exit the 

portable structure. 

(21) 586756 (22) 20 Jan 2009 

(54) INDOLYL-PYRIDONE DERIVATIVES HAVING CHECKPOINT 

KINASE 1 INHIBITORY ACTIVITY 

(86) PCT/GB2009/000149 (87) WO2009/093012 

(51) IPC2012.01:C07D401/14; A61K31/4412; A61P35/00 

(71) VERNALIS (R & D) LTD 

(72) STOKES, Stephen; FOLOPPE, Nicolas; FIUMANA, Andrea; 

DRYSDALE, Martin; BEDFORD, Simon; WEBB, Paul 

(31) 0801090.2 (32) 22 Jan 2008 (33) GB 

(31) 0818695.9 (32) 11 Oct 2008 (33) GB 



(57) Disclosed are indolyl-pyridone derivatives of formula (I) having 

checkpoint kinase 1 (CHK1) inhibitory activity, wherein the variables 

are as defined in the specification. These indolyl-pyridone derivative 

compounds are suitable for the treatment of conditions responsive 

to inhibition of CHK1 protein kinase activity selected from cancer 

and autoimmune disorders such as organ transplant rejection, lupus, 

multiple sclerosis, rheumatoid arthritis and osteoarthritis. 

(21) 586825 (22) 23 Jan 2009 

(54) AQUATIC ALGAE CULTIVATION SYSTEM AS FLOATING 

STRUCTURE OPEN TO SUNLIGHT, WIND AND WAVES 

(86) PCT/US2009/000455 (87) WO2009/094196 

(51) IPC2012.01:A01G33/02, 00; C12M1/00 

(71) Stuart Bussell 

(72) BUSSELL, Stuart 



(31) 61/011,932 (32) 23 Jan 2008 (33) US 



(57) Floating ponds for the cultivation of algae are disclosed. The floating 

ponds consist of a buoyant framework, a liner, a culture, and a mooring 

system. Submersible floating ponds are disclosed with a buoyant 

framework built from tubes that may be filled or partially filled with, 

for example, air, or water, or the surrounding water, or the culture, 

and thereby the present invention provides a framework in which the 

buoyancy may be modulated. Use of submerging lines and spools are 

disclosed to control the orientation and depth of the floating pond during 

submersion. 

(21) 586864 (22) 25 Nov 2004 

(54) Vent system for a mask that has selectable vents and a blower 

controller that senses which vent is selected 

(51) IPC2012.01:G08B3/00; A61M16/00, 06; G05B13/00 


(72) DARKIN, Donald; MCAULIFFE, Patrick John 

(31) 03 524728 (32) 25 Nov 2003 (33) US 

(31) 04 538507 (32) 26 Jan 2004 (33) US 

(31) 04 550319 (32) 8 Mar 2004 (33) US 



(57) A device for treating sleep disordered breathing. The device has a 

vent system (350) constructed and arranged to utilise a selected vent 

of a plurality of vents (352, 354). A sensor (353, 355) is configured to 

detect a characteristic of the selected vent in use (354) and send a signal 

(356) to a flow generator (358) or blower controller. The signal is used 

to adjust a control algorithm of the flow generator or blower controller in 

response to the characteristic of the selected vent tailoring the operation 

of the flow generator or blower controller to the vent selected. 


(21) 586937 (22) 20 Jan 2009 

(54) BICYCLIC DERIVATIVES OF AZABICYCLIC CARBOXAMIDES, 

PREPARATION THEREOF AND THERAPEUTIC USE THEREOF 

(86) PCT/FR2009/000051 (87) WO2009/112677 

(51) IPC2012.01:A61P29/00; A61K31/4365, 437, 47; C07D401/12; 

C07D471/04; A61P3/00; A61P11/00; C07D513/04 

(71) Sanofi-Aventis 

(72) DUBOIS, Laurent; EVANNO, Yannick; GILLE, Catherine; MALANDA, 

Andre 

(31) 0800309 (32) 22 Jan 2008 (33) FR 



(57) The disclosure relates to the azabicyclic carboxamide derivative 

compounds of formula (I) in which X1, X2, X3 and X4 are, independently 

of one another, a nitrogen atom or a C-R1 group; W is an oxygen or 

sulphur atom; n is equal to 0, 1, 2 or 3; Y is an optionally substituted 

aryl or heteroaryl; A & R1 are as defined in the specification; in the form 

of a base or of an addition salt with an acid, and also in the form of a 

hydrate or of a solvate. Process for the preparation of these compounds 

and therapeutic use thereof is also disclosed. 

(21) 586959 (22) 20 Feb 2008 

(54) FOLATES, COMPOSITIONS AND USES THEREOF 

(86) PCT/EP2008/052037 (87) WO2009/103334 

(51) IPC2012.01:C07D475/04; A61K31/519 

(71) GNOSIS S.P.A. 

(72) VALOTI, Ermanno; BIANCHI, Davide; VALETTI, Marco 


(57) Disclosed is a crystalline or amorphous compound which is a 

folate or a reduced folate of D-glucosamine, D-galactosamine, folate, 

-dihydrofolate, -tetrahydrofolate, unsubstituted or substituted with a 5methyl-, 

5-formyl-, 10-formyl-, 5,10-methylene-, 5,10-methenyl- moiety, 

the compound, whenever contemplated, being in a (6R,S), (6S) or a (6R) 

configuration. Use of this crystalline or amorphous compound for the 

preparation of a medicament, a food additive or a nutritional supplement, 

for the prevention and/ or the treatment of either deficiencies or 

diseases positively affected by the administration of both folates 

and reduced folates is also disclosed, wherein the deficiencies or 

diseases is selected from neurological affection (such as subacute 

encephalitis associated with dementia and vacuolar myelopathies); 

pathopsychological, vascular and cardiovascular conditions (such 

as premature occlusive arterial disease, severe vascular disease 

in infancy and childhood, progressive arterial stenosis, intermittent 

claudication, renovascular hypertension, ischemic cerebrovascular 

disease, premature retinal artery and retinal vein occlusion, cerebral 

occlusive arterial disease, occlusive peripheral arterial disease, 

premature death due to thromboembolic disease and ischemic heart 

disease); autoimmune diseases (such as psoriasis, celiac disease, 

arthritic and inflammation conditions); megaloblastic anaemia due to 

folate deficiency, intestinal malabsorption, for reducing a female's risk 

of having a miscarriage and/ or of having a fetus with a neural tube 

defect, a cleft lip defect, and/or a cleft palate defect, for maintaining and/ 

or normalizing the homocysteine level and/or metabolism; alterations 

of the synthesis and/or the functioning and/or the changes of DNA and 

RNA and the alterations of cell synthesis; depressive illnesses. 

(21) 586983 (22) 23 Jul 2010 

(54) A Data Processing System and Method with Investment Construction, 

Appreciation Contingency and Conflict Management 

(51) IPC2012.01:G06Q40/00, 08 

(71) ARES CAPITAL MANAGEMENT PTY LTD 

(72) SKILBECK, Benjamin Everard 

(31) 2009202958 (32) 23 Jul 2009 (33) AU 

(74) Fraser Old & Sohn, Level 10, 275 Alfred Street, North Sydney, NSW 

2060, Australia 

(57) A method of using a data processing apparatus to generate a 

digitally encoded electronic signal representing the quantum required 

to settle a wholly or partially collateral dependent finance arrangement 

incorporating mitigates for collateral valuation risk and consumer 

gaming is disclosed. The method comprises the steps of: (i) inputting 

into data processing apparatus input data including a combination of: 

the amount of finance advanced; a pre-determined share of capital 

appreciation, which may be constant or a variable function of collateral 

appreciation or time; a predetermined share of capital depreciation; 



an initial value of the collateral for the purposes of commencing the 

finance arrangement; a final value of the collateral for the purposes of 

consummating the finance arrangement; and a valuation risk premium, 

the combination comprising input data sufficient to calculate or return 

output instructed of the data processing apparatus in any one of steps 

(ii) - (ix) hereof; and (ii) instructing the data processing apparatus to 

determine the amount to be repaid at the conclusion of the finance 

arrangement as the amount advanced multiplied by the addition of 

1 and the valuation risk premium, plus the pre-determined share 

of the collateral capital appreciation over the term of the finance 

arrangement, less the predetermined share of the collateral capital 

depreciation over the term of the finance arrangement; or (iii) instructing 

the data processing apparatus to determine the amount to be repaid 

at the conclusion of the finance arrangement as the amount advanced, 

plus the valuation risk premium, plus the predetermined share of the 

collateral capital appreciation over the term of the finance arrangement, 

less the predetermined share of the collateral capital depreciation 

over the term of the finance arrangement; or (iv) instructing the data 

processing apparatus to determine the amount to be repaid at the 

conclusion of the finance arrangement as the maximum of either 

the amount advanced at commencement of the finance arrangement 

multiplied by the sum of I and a valuation risk premium or the 

amount advanced at commencement of the finance arrangement plus 

a valuation risk premium amount; and the sum of the amount advanced 

at commencement of the finance arrangement plus the predetermined 

share of capital appreciation less the predetermined share of capital 

depreciation; (v) instructing the data processing apparatus to determine 

the amount to be repaid at the conclusion of the finance as the amount 

determined in accordance with (ii) or (iii) only in the event of the initial 

value and/or the final value being determined by way of a valuation 

appraisal, as opposed to a purchase price at commencement and/or 

a sale price at conclusion of the finance; or (vii) instructing the data 

processing apparatus to determine that the initial value used for the 

purposes of commencing the finance is decreased by the valuation risk 

premium, or multiplied by 1 less the valuation risk premium, before 

being used to calculate the share of collateral capital appreciation due 

to the provider of the finance; or (viii) instructing the data processing 

apparatus to determine that the amount owing under the finance 

arrangement is the amount advanced at commencement of the finance 

arrangement, plus the predetermined share of capital appreciation 

over the term of the finance arrangement, less the predetermined 

share of capital depreciation over the term of the finance arrangement, 

plus only in the event of the initial value and/or the final value 

being determined by way of a valuation appraisal, as opposed to a 

purchase price at commencement and/or a sale price at conclusion 

of the finance arrangement, a time dependent cost of finance; or 

(ix) instructing the data processing apparatus to determine that the 

amount owing under the finance arrangement is the amount advanced 

at commencement of the finance arrangement, plus the predetermined 

share of capital appreciation over the term of the finance arrangement, 

less the predetermined share of capital depreciation over the term of 

the finance arrangement, plus only in the event of the initial value and/ 

or the final value being determined by way of a valuation appraisal, 

as opposed to a purchase price at commencement and/or a sale 

price at conclusion of the finance arrangement, an additional collateral 

dependent cost of finance, which may be implemented via an increase 

in the predetermined share of the collateral appreciation over the term 

of the finance arrangement. 

(21) 586990 (22) 2 Feb 2009 

(54) CONFORMATIONALLY RESTRICTED BIPHENYL DERIVATIVES 

FOR USE AS HEPATITIS C VIRUS INHIBITORS 

(86) PCT/US2009/032830 (87) WO2009/102568 

(51) IPC2012.01:C07D403/14; A61K31/4178; A61P31/14; C07D405/14 

(71) BRISTOL-MYERS SQUIBB COMPANY 

(72) BACHAND, Carol; BELEMA, Makonen; DEON, Daniel, H.; GOOD, 

Andrew, C.; GOODRICH, Jason; JAMES, Clint, A.; LAVOIE, Rico; 

LOPEZ, Omar, D.; MARTEL, Alain; MEANWELL, Nicholas, A.; 

NGUYEN, Van, N.; ROMINE, Jeffrey, Lee; RUEDIGER, Edward, H.; 

SNYDER, Lawrence, B.; ST. LAURENT, Denis, R.; YANG, Fukang; 

LANGLEY, David, R.; WANG, Gan; HAMANN, Lawrence, G. 

(31) 61/028,266 (32) 13 Feb 2008 (33) US 



(57) Disclosed are biphenyl derivatives represented by general formula 

(I), or pharmaceutically acceptable salts thereof, wherein R2 and 

R2’ form a five to eight membered unsaturated ring. An example 

of a compound included within the scope of the compound 

of formula (I) is methyl((1S)-1-(((2S)-2-(5-(9-(2-((2S)-1-((2S)-2- 

((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1Himidazol-5-yl)-6-methyl-6,7-dihydro-5H-dibenzo[c,e]azepin-3-yl)-1Himidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate. 

The 

compounds of formula (I) are used for treating HCV infections. 

(21) 587134 (22) 23 Jan 2009 

(54) PROTOPANAXADIOL-TYPE GINSENOSIDE COMPOSITIONS 

AND USES THEREOF 

(86) PCT/US2009/000431 (87) WO2009/094177 

(51) IPC2012.01:A61K31/198, 357, 704; A61P43/00 

(71) RAPTOR THERAPEUTICS INC. 

(72) DALEY, Thomas, E; TEMPESTA, Michael 

(31) : 61/023,310 (32) 24 Jan 2008 (33) US 


(57) Provided is a ginsenoside composition suitable for administration to 

a subject consisting of a non-ginsenoside fraction and a ginsenoside 

fraction, wherein the ginsenoside fraction comprises at least 30% (w/ 

w) of the composition and consists essentially of Rb1, Rb2, Rc and 

Rd. The composition can be used to ameliorate symptoms of elevated 

acetaldehyde concentration in a subject. 

(21) 587141 (22) 23 Jan 2009 

(54) TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION 

THEREOF, AND USE AS MEDICAMENTS 

(86) PCT/EP2009/000406 (87) WO2009/097970 

(51) IPC2012.01:C07D487/04; A61K31/5025; A61P7/02 


(72) HEINELT, Uwe; WEHNER, Volkmar; HERRMANN, Matthias; 

SCHOENAFINGER, Karl; STEINHAGEN, Henning; SCHEIPER, Bodo 

(31) 08290112.5 (32) 5 Feb 2008 (33) EP 



(57) Disclosed are triazolopyridazine compounds of formula I, 

stereoisomers, tautomers, and salts thereof, and methods 

for their preparation. Specific examples of compounds of 

formula I include: 2-(6-chloro-3-imino[1,2,4]triazolo[4,3-b]pyridazin-2yl)-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone,N-[3-[2-(6-ethoxy-3imino-[1,2,4]triazolo[4,3-b]pyridazin-2-yl)acetyl]-5- 

(pentafluorosulfanyl)phenyl] acetamide, 1-(3-tert-butyl-5propoxymethylphenyl)-2-[6-(1-ethylpropoxy)-3-imino- 

[1,2,4]triazolo[4,3-b]pyridazin-2-yl]ethanone, and 1-(3-cyclohexylmethoxy-4,5-dimethoxyphenyl)-2-[6-(1-ethylpropoxy)-3-imino- 

[1,2,4]triazolo[4,3-b]pyridazin-2-yl]ethanone Also disclosed is the use 

of compounds of formula I for treating disorders associated 

with thromboses, embolisms, hypercoagulability, fibrotic changes or 

inflammatory disorders, such as myocardial infarction, angina pectoris 

and other types of acute coronary syndrome, stroke, peripheral vascular 

disorders, deep vein thrombosis, pulmonary embolism, embolic or 

thrombotic events caused by cardiac arrhythmias, cardiovascular 

events such as restenosis following revascularization and angioplasty 

and similar procedures such as stent implantations and bypass 

operations or reduction of the risk of thrombosis following surgical 

procedures such as knee and hip joint operations or procedures leading 



to contact of blood with foreign surfaces, such as for dialysis patients 

and patients with indwelling catheters or disseminated intravascular 

coagulation, sepsis and other intravascular events associated with 

inflammation, atherosclerosis, diabetes and the metabolic syndrome 

and the sequelae thereof, tumor (tumour) growth and tumor metastasis, 

inflammatory and degenerative articular disorders such as rheumatoid 

arthritis and arthrosis, impairments of the hemostatic system such 

as fibrin deposits, fibrotic changes in the lung such as chronic 

obstructive pulmonary disease, adult respiratory distress syndrome or 

fibrin deposits in the eye following eye operations or prevention and/or 

treatment of scarring. 

(21) 587142 (22) 23 Jan 2009 

(54) TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION 

THEREOF, AND USE AS MEDICAMENTS 

(86) PCT/EP2009/000407 (87) WO2009/097971 

(51) IPC2012.01:C07D487/04; A61K31/5025; A61P7/02; C07D471/04 


(72) HEINELT, Uwe; WEHNER, Volkmar; HERRMANN, Matthias; 

SCHOENAFINGER, Karl; STEINHAGEN, Henning 

(31) 08290114.1 (32) 5 Feb 2008 (33) EP 



(57) Disclosed are triazolo compounds of formula I, stereoisomers, 

tautomers and salts thereof, and methods for their preparation. 

Specific examples of compounds of formula I include: 1-{2- 

[3-acetylamino-5-(pentafluorosulfanyl)phenyl]-2-oxoethyl} -3-amino-6ethoxy-[1,2,4]triazolo[4,3-b]pyridazin-1-ium 

trifluoroacetate, 3-amino-1- 

[2-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-oxoethyl]-6-trifluoromethyl- 

[1,2,4]triazolo[4,3-a]pyridin-1-ium, 3-amino-1-[2-(3,5-di-tert-butyl-4hydroxyphenyl)-2-oxoethyl][1,2,4]triazolo[4,3-a]pyridin-1-ium,3amino-1-[2-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2oxoethyl]-6-trifluoromethyl-[1,2,4]triazolo[4,3-a]pyridin-1-ium, 

and 3amino-1-[2-(3-tert-butyl-4-methoxy-5-morpholin-4-ylphenyl)-2oxoethyl]-5-methyl-7-trifluoromethyl-[1,2,4]triazolo[4,3-a]pyridin-1-ium. 

Also disclosed is the use of compounds of formula I for treating 

disorders associated with thromboses, embolisms, hypercoagulability, 

fibrotic changes or inflammatory disorders, such as myocardial 

infarction, angina pectoris and other types of acute coronary syndrome, 

stroke, peripheral vascular disorders, deep vein thrombosis, pulmonary 

embolism, embolic or thrombotic events caused by cardiac arrhythmias, 

cardiovascular events such as restenosis following revascularization 

and angioplasty and similar procedures such as stent implantations 

and bypass operations or reduction of the risk of thrombosis following 

surgical procedures such as knee and hip joint operations or 

procedures leading to contact of blood with foreign surfaces, such 

as for dialysis patients and patients with indwelling catheters or 

disseminated intravascular coagulation, sepsis and other intravascular 

events associated with inflammation, atherosclerosis, diabetes and 

the metabolic syndrome and the sequelae thereof, tumor (tumour) 

growth and tumor metastasis, inflammatory and degenerative articular 

disorders such as rheumatoid arthritis and arthrosis, impairments of 

the hemostatic system such as fibrin deposits, fibrotic changes in the 

lung such as chronic obstructive pulmonary disease, adult respiratory 

distress syndrome or fibrin deposits in the eye following eye operations 

or prevention and/or treatment of scarring. 

(21) 587218 (22) 27 Mar 2009 

(54) Sulfoperoxycarboxylic acids, their preparation and methods of use as 

bleaching and antimicrobial agents 

(86) PCT/IB2009/051300 (87) WO2009/118714 

(51) IPC2012.01:C07C309/12, 05, 08; A23L3/3535; C07D303/16; 

C11D3/48 

(71) ECOLAB INC. 

(72) LI, Junzhong; STAUB, Richard K; MCSHERRY, David D; 

LASCOTTE, Keith G; LANGE, Steven J; EVERTS, Frank 

(31) 61/040,444 (32) 28 Mar 2008 (33) US 



(57) Disclosed is a compound according to Formula I 

e.g. 10-hydroxy-9-sulfootacdecaneperoxoic acid, 10-dihydroxy-9sulfooctadecaneperoxoic 

acid, 9-hydroxy-10-sulfooctadecaneperoxoic 

acid, and 10-sulfo-8,9-dihydroxyoctadecaneperoxoic acid wherein: R1 

is hydrogen, or a Cm alkyl group; R2 is a Cn alkyl group; X is hydrogen, 

a cationic group, or an ester forming moiety; n is 1 to 10; m is 1 to 10; and 

m+n is less than or equal to 18, or salts or esters thereof for sanitizing 

an article. 

(21) 587234 (22) 5 Aug 2010 

(54) Cyclopropene treatment of ornamental plants to improve the general 

vitality for prolongel life 

(51) IPC2012.01:A01N3/00; A01G5/06; A01N25/00; C07C13/04; 

A01P21/00; C08B37/16; A01N27/00 

(71) ROHM AND HAAS COMPANY 

(72) JAMES DALY; GARRY LEGNANI; DEIDRE MARGARET 

HOLCROFT; ANIL P. RANWALA 

(31) 61/273583 (32) 6 Aug 2009 (33) US 



(57) The disclosure relates to a method of treating ornamental plants listed 

herein to prolong the life of ornamental plants or to improve their general 

vitality, wherein the method comprises contacting said plants with a 

liquid composition comprising of one or more cyclopropene compound 

of the structural formula shown herein, wherein the concentration of 

the total of all of said one or more cyclopropene compound is 0.3 

to 300 milligrams of cyclopropene compound per liter of said liquid 

composition. 



(21) 587308 (22) 6 Feb 2009 

(54) USE OF TETRAMIC ACID DERIVATIVES FOR CONTROLLING 

ANIMAL PESTS AFTER TREATMENT OF THE TRUNK, THE 

BRANCHES, THE INFLORESCENCES OR THE BUDS 

(86) PCT/EP2009/000816 (87) WO2009/100851 

(51) IPC2012.01:A01N43/38; A01N47/06; A01P7/02, 04 

(71) BAYER CROPSCIENCE AG 

(72) FISCHER, Reiner; HUNGENBERG, Heike; ANDERSCH, Wolfram; 

VAN WAETERMEULEN, Xavier Alain Marie 

(31) 08151372.3 (32) 13 Feb 2008 (33) EP 


(57) Disclosed is the use of tetramic acid derivatives represented by 

general formula (I) or (II) for controlling thrips after bud treatment. 

(21) 587310 (22) 26 Feb 2009 

(54) ANTI-ALLERGIC AGENT COMPRISING A FERMENTATION 

PRODUCT OF A PROPIONIC ACID BACTERIUM 

(86) PCT/JP2009/000851 (87) WO2009/107380 

(51) IPC2012.01:A61K35/74, 20; A61P17/00; A61P27/14; A61P11/02, 06; 

A61P37/08 

(71) MEIJI CO., LTD. 

(72) KANO, Hiroshi; IKEGAMI, Shuji; FURUICHI, Keisuke; ITOU, Hiroyuki; 

ORII, Naoki 

(31) 2008-049714 (32) 29 Feb 2008 (33) JP 



(57) Disclosed is the use of a fermentation product of a propionic 

acid bacterium in the preparation of a medicament or food for the 

treatment of an allergic symptom, wherein the propionic acid bacterium 

is Propionibacterium freudenreichii. 


(21) 587322 (22) 6 Feb 2009 

(54) HEPATITIS C VIRUS INHIBITORS 

(86) PCT/US2009/033380 (87) WO2009/102633 

(51) IPC2012.01:A61K31/4178, 4184, 4188; C07D487/04; C07D405/14; 

C07D491/044, 052; C07D403/14; A61P31/14 


(72) BACHAND, Carol; DEON, Daniel H; GOOD, Andrew C; GOODRICH, 

Jason; JAMES, Clint A; LAVOIE, Rico; LOPEZ, Omar D; MARTEL, 

Alain; MEANWELL, Nicholas A; NGUYEN, Van N; ROMINE, Jeffrey 

Lee; RUEDIGER, Edward H; SNYDER, Lawrence B; ST. LAURENT, 

Denis R; YANG, Fukang; LANGLEY, David R; WANG, Gan; HAMANN, 

Lawrence G; Belema, Makonen 

(31) 61/028,277 (32) 13 Feb 2008 (33) US 



(57) The disclosure relates to imidazol-pyrrolidine derivative compounds of 

structure (I) and their compositions which are suitable for the treatment 

of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical 

compositions containing such compounds and methods for using these 

compounds in the treatment of HCV infection. 

(21) 587348 (22) 19 Feb 2009 

(54) The use of prostaglandins for modulating stem cell growth 

(86) PCT/JP2009/053474 (87) WO2009/104807 

(51) IPC2012.01:A61P19/08, 10; A61P7/06; A61P21/00; A61K31/5575; 

A61P43/00 

(71) SUCAMPO AG 

(72) UENO, Ryuji; KUNO, Sachiko 

(31) 61/029,713 (32) 19 Feb 2008 (33) US 


(57) Disclosed is the use of a prostaglandin compound represented by 

the formula (I) for the manufacture of a pharmaceutical composition for 

anyone of the following: (i) treating a disease or condition in which the 

tissue or organ is damaged or defective in a mammalian subject; (ii) 

replacing or managing damaged tissue after muscle or skin injury in a 

mammalian subject; and (iii) treating a neurodegenerative disorder in a 

mammalian subject, wherein said composition is to be contacted with 

the stem cells in vitro or ex vivo, and wherein the variables shown in 

formula (I) are as defined in the specification. 



(21) 587365 (22) 25 Feb 2008 

(54) WOUND-COVERING HYDROGEL MATERIAL 

(86) PCT/JP2008/053193 (87) WO2009/107189 

(51) IPC2012.01:A61L15/16, 22 

(71) TEIKOKU SEIYAKU CO., LTD. 

(72) KAMAKURA, Takashi; SATO, Aki; TAKAHASHI, Makoto; OHURA, 

Takehiko 


(57) Disclosed is a wound-covering hydrogel material which is prepared 

by spreading a hydrogel which comprises a water-soluble synthetic or 

semi-synthetic polymer, glycerol and water onto a laminated two-layer 

film which is composed of a polyurethane film and hydrophobic fibres. 

(21) 587397 (22) 19 Feb 2009 

(54) STABILIZATION OF DEHYDROGENASES USING STABLE 

CHEMICALLY MODIFIED COENZYMES 

(86) PCT/EP2009/001206 (87) WO2009/103540 

(51) IPC2012.01:C12N9/96, 06; C12Q1/32 

(71) F. HOFFMANN-LA ROCHE AG 

(72) HEINDL, Dieter; HORN, Carina; GAESSLER-DIETSCHE, Claudia; 

HOENES, Joachim 

(31) 08 003 054.7 (32) 19 Feb 2008 (33) EP 


(57) Disclosed is a method for stabilizing a coenzyme dependent 

enzyme, characterized in that the enzyme is stored in the presence 

of the coenzyme, said coenzyme being a stable coenzyme chemically 

modified by comparison to, and having a higher stability than, the 

native coenzyme. Also disclosed is a coenzyme dependent enzyme 

which is stabilized with the coenzyme, said coenzyme being a stable 

coenzyme chemically modified by comparison to, and having a higher 

stability than, the native coenzyme, characterized in that it shows on 

storage for at least 2 weeks at a temperature of at least 20 degrees C, 

where appropriate with high humidity and without a drying reagent, a 

decline in the enzymatic activity of less than 50% compared with the 

initial level, wherein the enzyme is a mutated glucose dehydrogenase 

and the mutated glucose dehydrogenase has an increased thermal or 

hydrolytic stability compared with the corresponding wild-type glucose 

dehydrogenase. 

(21) 587417 (22) 13 Feb 2009 

(54) MOBILE SYSTEM FOR IMPROVING THE PICKING AND 

PRELIMINARY PROCESSING OF APPLES, CITRUS, STONE FRUIT 

AND LIKE OBJECTS 

(86) PCT/US2009/034132 (87) WO2009/103008 

(51) IPC2012.01:A01D46/24 

(71) PICKER TECHNOLOGIES LLC 

(72) BRYAN, Vincent, E., Jr; BRYAN, Vincent, E., III; KUNZLER, 

Alex, E; ALLARD, Randy; FINAZZO, Anthony; BOMMARITO, Marc; 

CLEVERINGA, Jeffrey, A 

(31) 61/095,788 (32) 10 Sep 2008 (33) US 

(31) 61/028,351 (32) 13 Feb 2008 (33) US 



(57) A mobile fruit picking system comprising, in modular combination, a 

mobile vehicle chassis with wheels and a plurality of pneumatic tubes 

for transporting picked objects from tree height to an object decelerator 

means or water bath, a first conveyor means for transporting objects 

from the decelerator along a predetermined path of travel where a 

scanner scans the surface of the fruit with reject fruit diverted to a reject 

hopper, a second downloader conveyor receives objects from the first 

conveyor and transports the received objects to hopper then has means 

to load a storage bin or delivery point. The chassis can engage and 

reposition the storage bin. 


(21) 587426 (22) 21 Feb 2008 

(54) APPARATUS AND METHOD FOR SIMULATIVELY MEASURING 

ENVIRONMENT OF WOUND DRESSING ON SKIN INCLUDING A 

PUMP 

(86) PCT/JP2008/052983 (87) WO2009/104266 

(51) IPC2012.01:G01N15/08; G01N19/04 

(71) TEIKOKU SEIYAKU CO., LTD. 

(72) TAKAHASHI, Makoto; OHURA, Takehiko; INAMOTO, Yukiko; 

KAMAKURA, Takashi; INAMOTO, Shigeyuki 


(57) Disclosed is an apparatus for measuring the environment in a microspace 

between the human skin and a wound coating material and a 

measurement method therefor. The apparatus comprises a thermohygrostat 

chamber (14) for controlling the exterior environment, a heat 

exchanger (12), a thermostat water tank (10) and a pump (11) for 

supplying warm water, and an easily detachable container (1) located 

in the heat exchanger. The container has a water-retaining member 

(2) stored therein and the top opening thereof is covered with a vapor 

diffusion-controlling member (4). A micro-space (6) formed between 

the vapor diffusion-controlling member and a wound coating material 

(5) placed thereon corresponds to a simulationally recreated space 

between the human body and the wound coating material. A thinmodel 

thermo-hygrometer (7) is provided in this micro-space and the 

temperature and humidity are measured with the passage of time. By 

a plurality of containers, a plurality of kinds of wound coating materials 

can be measured at the same time. 



(21) 587438 (22) 17 Jun 2008 

(54) OPTIMIZED ADHESIN FRAGMENTS COMPRISING MUTATED 

AFA/DRA ADHESIONS AND CORRESPONDING NANOPARTICLES 

(86) PCT/EP2008/004867 (87) WO2009/106102 

(51) IPC2012.01:C07K14/245; G01N33/58 

(71) SIGNALOMICS GMBH 

(72) BLOCK, Christoph; MITTMANN, Karin; ARNTZ, Claudia 

(31) 08003845.8 (32) 29 Feb 2008 (33) EP 


(57) Disclosed is an adhesin comprising an amino acid sequence selected 

from the group consisting of the following sequences a. DraE group 

(SEQ ID No.3) b. DraE/AfaE-III (SEQ ID No.4) c. DraE (SEQ ID No.1) 

wherein said adhesin has one or more of the following mutations and 

may be deleted N-terminally by up to 18 amino acids: T7 (N, F, C, S, V, 

R, A, I, L, V); E17 (S, P, K, G, D, R, N, H, Q); R22 (T, A, S, N, K); D25 

(S, G, N, A, T, K, R, H, Q, M); T27 (K, R, L, V, Y, P, N, Q); V28 (W, F); 

A29 (K, R, S, E, Q, F, G, L, H, P, N, T, W); T31 (G, D, S, N); Q34 (D, 

G, S, N, L, V, T, A); D37N; A38 (S, T, L); A39 (Q, S, D, M, G, F); 141 

(V); Q47 (T, N, C, S, G, A, P); D52 (G, N, S, C, P, Q, Y, H, K, R, T); 

N84 (D, S, H); R86V; T88 (M, L); T95 (L, M, Y, F, C, W, Q, N, E, S, I, 

H); F100 (Y, V); V105 (S, A, T, R, M, V, P, N, E, Q, G, K, H); I111 (C, 

V, H, Y, T, M, F) I114 (V, L, A, C); Y115 (T, W, E, V); V116 (A, S, L); 

G118 (P, S); provided that when said adhesion contains a T88M and/or 

a N77K mutation, the adhesin comprises at least one further mutation 

selected from the above list. Also disclosed is a nanoparticle conjugated 

to the said adhesion. Further discloses is the use of the said adhesion 

or nanoparticle in the preparation of a contrast agent for medical use. 

(21) 587469 (22) 19 Feb 2009 

(54) INSERTION DEVICE WITH A MOVING PART ATTACHED TO THE 

NEEDLE THAT MOVES IN A DIFFERENT DIRECTION FROM THE 

NEEDLE 

(86) PCT/EP2009/051974 (87) WO2009/103759 

(51) IPC2012.01:A61M5/158, 142 

(71) Unomedical A/S 

(72) GYRN, Steffen; HICKMOTT, Richard, Morgan; MORTON, Alistair, 

David; JEPPESEN, Henrik 

(31) 61/030,022 (32) 20 Feb 2008 (33) US 

(31) PA 2008 00240 (32) 21 Feb 2008 (33) DK 

(31) 61/095,379 (32) 9 Sep 2008 (33) US 

(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, 

Australia 

(57) An insertion device comprising a penetrating member 50 comprising 

an insertion needle connected to transformation means 52, which 

penetrating member 50 before and during insertion is attached to a 

body holding a cannula or a sensor which body comprises retention 

means securing the body and the cannula or sensor at a surface of 

insertion after insertion has taken place, a moving part 38 comprising 

guiding means 39 which guiding means 39 restrict the movement of the 

transformation means 52 and guide the penetrating member 50 from a 

first to a second position in a first direction, i.e. the direction of insertion, 

towards the injection site, and a stationary housing 30 comprising 

guiding means 39 which guiding means 39 restrict the movement of the 

moving part 38. The guiding means 39 guide the moving part 38 in a 

second direction which is linear and different from the first direction i.e. 

the direction of insertion. 

(21) 587534 (22) 4 Mar 2004 

(54) Human or humanized anti-L-SIGN antibody that does not bind to DC- 

SIGN 

(51) IPC2012.01:A61K39/40, 42, 395; C07K16/00 

(71) Alexion Pharmaceuticals, Inc. 

(72) BOWDISH, Katherine, S.; KRETZ-ROMMEL, Anke; DAKAPPAGARI, 

Naveen 

(31) 60451816 (32) 4 Mar 2003 (33) US 

(31) 60529500 (32) 15 Dec 2003 (33) US 

(31) 60548385 (32) 28 Feb 2004 (33) US 



(57) Provided is an isolated anti-L-SIGN antibody, or an antigen-binding 

fragment thereof, that (a) does not bind to DC-SIGN or (b) selectively 

binds to L-SIGN as compared to DC-SIGN, wherein the anti-L-SIGN 

antibody is: (i) fully human, (ii) humanized, or (iii) chimeric, wherein the 

chimeric antibody comprises a non-human antibody variable domain 

and a human constant region; and wherein the antibody or antigenbinding 

fragment thereof comprises specified combinations of heavy 

and light chain CDR1, CDR2 and CDR3 sequences. The antibodies can 

be used to treat autoimmune diseases. 


(21) 587557 (22) 13 Feb 2008 

(54) IMIDAZOLYL BIPHENYL IMIDAZOLES AS HEPATITIS C VIRUS 

INHIBITORS 

(86) PCT/US2008/053779 (87) WO2009/102325 

(51) IPC2012.01:A61P31/00; C07D405/14; A61K31/41; C07D417/14; 

C07D403/14 


(72) BACHAND, Carol; BELEMA, Makonen; DEON, Daniel H.; GOOD, 

Andrew C.; GOODRICH, Jason; JAMES, Clint A.; LAVOIE, Rico; 

LOPEZ, Omar D.; MARTEL, Alain; MEANWELL, Nicholas A.; NGUYEN, 

Van N.; ROMINE, Jeffrey Lee; RUEDIGER, Edward H.; SNYDER, 

Lawrence B.; ST. LAURENT, Denis R.; YANG, Fukang; LANGLEY, 

David R.; WANG, Gan; HAMANN, Lawrence G. 



(57) Disclosed are bi-phenyl-pyrrolidine-pyrrole compounds. 

An example of the claimed compounds includes 

methyl ((1S)-2-((1R,3S,5R)-3-(4-(4'-(2-((1R,3S,5R)-2-(N- 

(methoxycarbonyl)-L-alanyl)-2-azabicyclo[3.1.0]hex-3-yl)-1H- 



imidazol-4-yl)-4-biphenylyl)-1H-imidazol-2-yl)-2azabicyclo[3.1.0]hex-2-yl)-1-methyl-2-oxoethyl)carbamate. 

The 

compounds are used to treat an HCV infection. 

(21) 587572 (22) 27 Feb 2009 

(54) PESTICIDES 

(86) PCT/US2009/035475 (87) WO2009/111309 

(51) IPC2012.01:C07D403/12; C07D413/12; C07D407/12; A01N43/40; 

C07C381/10; C07D213/14, 75; A01N47/00; A01P7/04 

(71) Dow AgroSciences LLC 

(72) BREAUX, Nneka; LOSO, Michael; JOHNSON, Timothy; BABCOCK, 

Jonathan; NUGENT, Benjamin; MARTIN, Timothy; BROWN, Annette; 

ROSS, Ronald; LO, William; OBER, Matthias 

(31) 61/067,874 (32) 3 Mar 2008 (33) US 



(57) Disclosed is a compound having the following formula 

(I) e.g. 2,2-dimethyl-N-(methyl(oxido){1-[6-(trifluoromethyl)pyridin-3yl]ethyl}-gamma4-sulfanylidene)propanamide 

wherein the substituients 

are defined in the specification. Also disclosed is a process to 

prepare said compound comprising reacting a compound e.g. 5-[1- 

(Methylsulfonimidoyl)ethyl]-2-(trifluoromethyl)pyridine. 

(21) 587580 (22) 18 Jun 2004 

(54) Factor VII or VIIa Gla domain variants 

(51) IPC2012.01:C07K14/745; C12N15/57; C12N9/64; A61K38/36 

(71) Maxygen Holdings Ltd. 

(72) Haaning, Jesper Mortensen; Andersen, Kim Vilbour; Bornaes, Claus 

(31) 03 479780 (32) 19 Jun 2003 (33) US 



(57) Provided is a conjugate comprising a Factor VII (FVIl) or Factor VIIa 

(FVlla) polypeptide variant having an amino acid sequence that differs in 

1·15 amino acid residues relative to the amino acid sequence of human 

Factor VII (hFVII) or human Factor VIla (hFVIIa) shown in SEQ ID NO:I, 

wherein a negatively charged amino acid residue has been introduced 

by substitution in position 36 in the variant sequence, conjugated to a 

biocompatible polymer. The conjugates can be used to treat diseases 

in which inducing blood clot formation is beneficial, e.g. hemorrhage, 

variceal bleeding and hemophilia. 


(21) 587586 (22) 18 Jul 2006 

(54) TREATMENT OF CANCER 

(51) IPC2012.01:A61K31/165; A01N37/18 

(71) BiPar Sciences, Inc. 

(72) Kun, Ernest Kun; Mendeleyev, Jerome; Basbaum, Carol; Lemjabbar- 

Alaoui, Hassan; Ossovskaya, Valeria S 

(31) 05 700446 (32) 18 Jul 2005 (33) US 



(57) Disclosed is the use of a compound of formula (Ia) e.g. 4-iodo-3nitrobenzamide 

or a pharmaceutically acceptable salt or solvate thereof 

in the preparation of a medicament for the treatment of bone cancer, 

wherein wherein R1, R2, R3, R4, and R5 are, independently selected 

from the group consisting of hydrogen, hydroxy, amino, nitro, iodo, 

bromo, fluro, chloro, alkyl, alkoxy, cycloalkyl, and phenyl. 


(21) 587587 (22) 11 Feb 2009 

(54) METHOD FOR RAPID HEATING OF FLUID WITH SEGMENTED 

ELECTRODES ALLOWING CONTROL OF EFFECTIVE ELECTRODE 

AREA 

(86) PCT/AU2009/000158 (87) WO2009/100486 

(51) IPC2012.01:F24H1/10; H05B1/02; F24D13/02; H05B3/03; F22B1/30 

(71) MicroHeat Technologies Pty Ltd 

(72) VAN AKEN, Robert Cornelis; ISRAELSOHN, Cedric 

(31) 2008900634 (32) 11 Feb 2008 (33) AU 


Australia 

(57) A fluid heating apparatus has a fluid flow path from an inlet to an outlet, 

with multiple heating sections positioned along the flow path (316-318). 

Each heating section is at least one pair of electrodes between which 

an electric current is passed through the fluid to resistively heat the 

fluid during its passage along the flow path. At least one of the 

heating sections has a segmented electrode made up of a plurality of 

electrically separable segments. This allows an effective active area of 

the segmented electrode to be controlled by selectively activating the 

segments. A controller measures inlet conductivity as well as variations 

in fluid conductivity with temperature and determines a required voltage 

and current to be delivered to the fluid by each heating section. The 

controller activates selected segments of the segmented electrode 

to effect delivery of desired current and voltage by the segmented 

electrode to the fluid. 

(21) 587678 (22) 10 Feb 1997 

(54) Rheumatoid Arthritis treatment by Human Antibodies that Bind 

Human TNFa 

(51) IPC2012.01:C12N15/13; A61K39/395; C07K16/24; C12N1/21 

(71) Abbott Biotechnology Ltd. 

(72) Salfeld, Jochen G; Allen, Deborah J; Kaymakcalan, Zehra; 

Labkovsky, Boris; Mankovich, John A; McGuiness, Brian T; Roberts, 



Andrew J; Sakorafas, Paul; Hoogenboom, Hendricus R J M; 

Schoenhaut, David; Vaughan, Tristan J; White, Michael; Wilton, Alison J 

(31) (32) 9 Feb 1996 (33) US 

(31) 96 31476 (32) 25 Nov 1996 (33) US 



(57) Provided is an isolated human antibody, or an antigen-binding portion 

thereof, that dissociates from human TNFá with a Kd of 1 x 10-8 M or 

less and a Koff rate constant of 1 x 10-3 s-1 or less, both determined by 

surface plasmon resonance, and neutralizes human TNFá cytotoxicity 

in a standard in vitro L929 assay with an IC50 of 1 x 10-7 M or less; 

in combination with a non-steroidal anti-inflammatory drug, which can 

be used for the treatment of rheumatoid arthritis. Further provided are 

amino acid sequences of suitable antibodies and their CDRs. 


(21) 587679 (22) 19 May 2006 

(54) Retaining wall for a sand hill 

(51) IPC2012.01:E02D17/18, 20 

(71) Elsie Spry 

(72) SPRY, William, J 

(31) 11/134945 (32) 23 May 2005 (33) US 



(57) A hill 80 of sand or similar flowable granular material is contained 

and partially supported behind the rear face 74 of a wall 70 positioned 

along the lower portion of the hill. The height of the wall is greater than 

the height of the hill adjacent the rear face. The wall includes a plurality 

of horizontal passageways 88 …104 so that the angle of repose of 

the flowable granular material permits the material to flow toward the 

front of the passageways adjacent the front face 72 of the wall without 

substantially discharging from the passageways. However, should the 

hill collapse somewhat the force exerted by the material against the rear 

face of the wall is reduced by permitting the flowable granular material 

to discharge through the passageways and out of the front face onto 

the ground 76. 


(21) 587699 (22) 30 Jan 2009 

(54) USE OF AN EXOTHERMIC MIXTURE FOR MANUFACTURING A 

BITUMINOUS MIX 

(86) PCT/EP2009/051076 (87) WO2009/095476 

(51) IPC2012.01:C08K3/00; C08K5/09, 098; C08L95/00; E01C7/24 

(71) Eurovia; Innophos, Inc. 

(72) LESUEUR, Didier; DELFOSSE, Frederic; MARTIN, Jean-Valery 

(31) 0850644 (32) 1 Feb 2008 (33) FR 



(57) Disclosed is the use of an exothermic mixture of at least i) one acid 

anhydride or acid salt and at least ii) one basic anhydride or basic salt, 

in a cold, warm or half-warm asphalt concrete based on a bituminous 

binder containing water to increase the temperature of the asphalt 

concrete. Also disclosed is the manufacture of asphalt concrete for road 

surfacing, the asphalt obtained by the process, an aggregate comprising 

the exothermic mixture. 

(21) 587704 (22) 30 Mar 2007 

(54) Use of dsRNA for inhibiting expression of Eg5 gene 

(51) IPC2012.01:C07H21/04, 02; A01N43/04; C12N15/11; A61K31/70 

(71) Alnylam Pharmaceuticals, Inc. 

(72) Bumcrot, David; Tan, Pamela; Vornlocher, Hans-peter; Geick, Anke 

(31) 06 870259 (32) 15 Dec 2006 (33) US 

(31) 06 787762 (32) 31 Mar 2006 (33) US 


Australia 

(57) A double stranded ribonucleic acid (dsRNA) that can inhibit the 

expression of a human kinesin family member 11 (Eg5). The dsRNA 

comprises an antisense strand to the sequence set forth in SEQ ID 

NO: 1266 positioned within an mRNA encoding for Eg5. The dsRNA 

can be used to inhibit a hyperproliferative disorder, in particular hepatic 

carcinoma. 


(21) 587719 (22) 25 Feb 2009 

(54) FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF 

(86) PCT/JP2009/054007 (87) WO2009/107850 

(51) IPC2012.01:A61P35/00; A61K31/4355, 4365, 437; C07D471/04; 

C07D498/04; C07D513/04 

(71) Takeda Pharmaceutical Company Limited 

(72) FUJII, Nobuhiro; OGURO, Yuya; SASAKI, Satoshi; KONDO, Shigeru 

(31) 2008-045134 (32) 26 Feb 2008 (33) JP 

(31) 2008-256755 (32) 1 Oct 2008 (33) JP 



(57) Disclosed is a fused heterocyclic compound of formula (I) 

or a salt thereof, wherein the substituents are as described 

within the specification. An example of a compound of formula 

(I) includes N-[1-(2-hydroxyethyl)piperidin-4-yl]-3-methoxy-1-methyl-4oxo-5-(2-oxo-2-phenylethyl)-4,5-dihydro-1H-pyrrolo[3,2-c]quinoline-2carboxamide. 

Further disclosed is a pharmaceutical agent comprising a 

compound of formula (I), a method of inhibiting Smo or prophylaxis or 

treatment of cancer in a non-human animal, and the use of a compound 

of formula (I) for the production of an Smo inhibitor or an agent for the 

prophylaxis or treatment of cancer. 

(21) 587724 (22) 7 Dec 2004 

(54) Hinged lid container 

(51) IPC2012.01:B65D43/16; B65D17/28; B65D55/02; B65D101:00 

(71) Alto Manufacturing Pty Limited 

(72) Janetzki, Ian; Daffurn, Paul 

(31) 2003906999 (32) 15 Dec 2003 (33) AU 

(74) Smoorenburg Pini Patent & Trade Mark Attorneys, Unit 1, 231 

Maroondah Highway, Ringwood VIC 3134, Australia 

(57) A container 1 includes a base 7 having a top opening and a lid 11 

adapted to fit over and close the top opening of the base. The lid includes 

a hinge portion 10 and is secured to the base by a frangible securement 

45, 46. The hinge portion and a lid portion 3 of the lid are located on 

opposing sides of a hinge line 38. 




(21) 587754 (22) 18 Jul 2003 

(54) TNF alpha antibody for hiradenitis suppurativa 

(51) IPC2012.01:A61K39/395; C07K16/00 

(71) ABBOTT BIOTECHNOLGY LTD 

(72) BANERJEE, SUBHASHIS; TAYLOR, LORI K; SPIEGLER, CLIVE 

E; TRACEY, DANIEL EDWARD; CHARTASH, ELLIOT KEITH; 

HOFFMAN, REBECCA S; BARCHUK, WILLIAM T; YAN, PHILIP; 

MURTAZA, ANWAR; SALFELD, JOCHEN G; FISCHKOFF, STEVEN 

(31) 60/397275 (32) 19 Jul 2002 (33) US 

(31) 60/411081 (32) 16 Sep 2002 (33) US 

(31) 60/417490 (32) 10 Oct 2002 (33) US 

(31) 60/455777 (32) 18 Mar 2003 (33) US 



(57) Provided is the use of an isolated human anti-TNFa antibody, or an 

antigen binding portion thereof, in the preparation of a medicament for 

treating Hidradenitis suppurativa (HS) in a subject, wherein the antibody 

is an isolated human antibody, or an antigen binding portion thereof, that 

dissociates from human TNFa with a Kd of 1 x 10-8 M or less and a Koff 

rate constant of 1 x 10-3 s-1 or less, both determined by surface plasmon 

resonance, and neutralizes human INFa cytotoxicity in a standard in 

vitro L929 assay with an IC50 of 1 x 10-7 M or less. 


(21) 587769 (22) 2 Mar 2009 

(54) MONITORING OF FRYING OIL QUALITY USING 

MEASUREMENTS OF OPTICAL REFLECTANCE 

(86) PCT/US2009/035649 (87) WO2009/111372 

(51) IPC2012.01:G01N33/03; G01N1/28; G01N21/00, 47 

(71) 3M INNOVATIVE PROPERTIES COMPANY 

(72) MAHMOODI, Abolghassem B; SABADE, Milind B; WEI, Ai-ping 

(31) 61/033,487 (32) 4 Mar 2008 (33) US 


(57) Disclosed are methods and devices for evaluating the quality of oils 

(e.g., cooking oil or frying oil). The methods can provide an indication 

of the free fatty acid content of the oil. The methods use an optical 

interrogation device to provide an indication of free fatty acid based 

on quantitative measurements of optical reflectance from test zones 

(10a-10d) on a sampling substrate (1) which has been in contact with 

the oil. 

(21) 587781 (22) 3 Sep 2010 

(54) Wheelie bin with main support feet and secondary feet forward of 

main feet 

(51) IPC2012.01:B65F1/14, 02, 16, 00 

(71) SULO MGB Australia Pty Ltd 

(72) VOSS, Thorsten; HUSTON, Michael; PRYOR, Jon 

(31) 2009904232 (32) 4 Sep 2009 (33) AU 



(57) A mobile garbage bin has a closed base and at least one wall 

extending upwardly from the base to define an internal cavity. The bin 

has at least two wheels mounted in the base or in the at least one 

wall adjacent to the rear portion of the base. The base has at least 

two primary feet extending downwardly from the base, and at least 

two secondary feet extending downwardly from the base and disposed 

forwardly of the primary feet, the feet being integrally formed with the 

base, and the feet and wheels being arranged such that the mobile 

garbage bin rests on the feet and the wheels. 

(21) 587782 (22) 3 Sep 2010 

(54) Wheelie bin with hollow section recessed rim for lifting 

(51) IPC2012.01:B65F1/14, 12, 00 

(71) SULO MGB Australia Pty Ltd 

(72) VOSS, Thorsten; HUSTON, Michael; PRYOR, Jon 

(31) 2009904233 (32) 4 Sep 2009 (33) AU 



(57) A rim 7, for a mobile garbage bin with a closed base and at least one 

container wall 4a defining an internal cavity, has a closed hollow section 

28 defined at a lower edge by a base surface 29 extending outwardly 

from the container wall 4a. The base surface 29 is profiled to include 

a recess 36 which is defined at least partially by a first downwardly 

projecting flange formed in the base surface and facing towards the 

container wall 4a so as to form an inner edge of an enlarged lip portion. 

(21) 587801 (22) 2 Apr 2007 

(54) Urine collection system adjustably retained by a retaining device 

(51) IPC2012.01:A61M25/00, 14; F16L3/223 

(71) TYCO HEALTHCARE GROUP LP 

(72) Tully, Stephen; Salvadori, Lawrence 

(31) 11/104543 (32) 11 Apr 2006 (33) US 



(57) A urine collection system comprises a tube 12 forming a loop where 

two sections of the tube are in an adjacent relationship to one another, 



and a retaining device 100 configured to retain, while simultaneously 

allowing for adjustment, the two sections of the tube 12 in adjacent 

relationship to one another. 


(21) 587867 (22) 9 Sep 2010 

(54) A hooked loop for receiving a safety rope that attaches to the fixing 

or support of a roof from the outside 

(51) IPC2012.01:F16P1/00; A62B35/00; A47L3/04; F16G11/00; 

E04G21/32 

(71) DARRYLL LAWRENCE HEAVEN 

(72) Heaven, Darryll Lawrence 

(74) A J PIETRAS & CO, Level 2, Gibson Sheat Centre, 1 Margaret Street, 

Lower Hutt, New Zealand 

(57) A safety system for use on a building is disclosed. The system uses 

a plurality of hooks (1) and a safety line (9). Each hook engages with 

the roof beneath roof cladding (6) and extends to a position where it can 

be accessed from in front of the cladding. In one embodiment the hooks 

clip on to the fasteners (5) holding down the cladding and are attached 

by compressing the clip to allow passage of the fastener into the clip, 

then the clip is released so that the fastener is held within a loop formed 

by the clip. In another embodiment the hooks connect ton the underlying 

structure of the roof. The safety line connects through the hooks so that 

the line runs adjacent to the lower edge of the roof. This line can be 

connected to a person to support them during a fall. 


(21) 587884 (22) 11 May 2006 

(54) Crosslaminate of biaxially oriented and stretched films which are are 

laminated selectively to help arrest tears 

(51) IPC2012.01:B29C55/18, 12; B32B3/28 

(71) Ole-Bendt Rasmussen 

(72) Rasmussen, Ole-Bendt 

(31) 2005 0509615 (32) 11 May 2005 (33) GB 

(31) 2005 0511394 (32) 3 Jun 2005 (33) GB 

(31) 2006EP 06000281 (32) 5 Jan 2006 (33) EP 



(57) A method for forming a cross-laminate web by segmental transverse 

stretching is disclosed. The web formed from two cross-oriented, semifibrillated, 

heat sealed plies of thermoplastic polymer films. The crosslaminate 

consists of linear thin (116) regions of bi-axially oriented 

material and thicker linear bosses (114) between the thinner regions. 

The method for forming the cross-laminate (1) involves segmental 

stretching of the material to form thinner regions (116) between the 

bosses using an apparatus comprising intermeshing grooved stretching 

rollers (112, 113). The mutually intermeshing grooved rollers which 

effect the segmental transverse stretching have flat crests (114) on their 

circular teeth (flat seen in cross-section) with relatively sharp edges 

(115). The segmental stretching starts on these edges and develops 

into thin continuous webs (116). The intermeshing is limited such that 

there are maintained thicker material, bosses, on the flat crests (114) 

of the circular teeth. 


(21) 587934 (22) 26 Feb 2005 

(54) Combination of reduced isoalpha acids and curcuminoids for treating 

inflammation 

(51) IPC7:A61K35/78; A61K31/12, 557 

(71) METAPROTEOMICS, LLC 

(72) Babish, John G; Tripp, Matthew L; Bland, Jeffrey S 

(31) 789817 (32) 27 Feb 2004 (33) US 



(57) Disclosed is a composition comprising (1) a 

compound selected from the group consisting of dihydroisocohumulone, 

dihydro-isoadhumulone, tetrahydro-isocohumulone, 

tetrahydroisoadhumulone, hexahydro-isohumulone, hexahydroisocohumulone 

and hexahydroisoadhumulone, and (2) a curcuminoid. 

The compound and the curcuminoid are combined in a weight ratio to 

achieve a synergistic effect with combination index (CI) value of less 

than 1. The composition can be formulated into a medicament which is 

useful for reducing inflammation. 


(21) 587951 (22) 13 Sep 2010 

(54) Phenol-containing azole compositions for the protection of industrial 

materials 

(51) IPC2012.01:C07C39/04; C07D249/08; A01N31/08, 16; A01N43/653; 

B27K3/34, 38, 50; A01P3/00 

(71) Lanxess Deutschland GmbH 

(72) Koop, Bernd; Kugler, Martin 

(31) EP09170217.5 (32) 14 Sep 2009 (33) DE 


(57) Disclosed is a composition comprising at least one azole 

and at least one phenol of formula (I). Examples of 

azoles are azaconazole, bitertanol, bromuconazole, cyproconazole, 

dic1obutrazol, difenoconazole, diniconazole, epoxyconazole, 

etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, 



furconazole, hexaconazole, imibenconazole, ipconazole, myc1obutanil, 

metconazole, penconazole, propiconazole, prothioconazole, 

simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, 

triticonazole and uniconazole. Example of phenol is 6,6' -di-tertbutyl-2,2' 

-methylenedi-p-cresol. Also disclosed is the use of the 

composition for protecting industrial materials, industrial materials 

comprising the composition and the process for protecting an industrial 

material with the composition. 

(21) 587953 (22) 26 Mar 2009 

(54) METHOD AND SYSTEM FOR STARTING A WATER JET 

PROPULSION SYSTEM BY BLOCKING AT LEAST 50% OF NOZZLE 

OUTLET. 

(86) PCT/SE2009/050318 (87) WO2009/120143 

(51) IPC2012.01:B63H11/10, 08 

(71) ROLLS-ROYCE AKTIEBOLAG 

(72) KARLSSON, Sven-Gunnar; AARTOJARVI, Reima; ANDERSSON, 

Lars 

(31) 0800687-6 (32) 27 Mar 2008 (33) SE 



(57) A method and system for starting a water jet propulsion system for 

a ship is disclosed. The propulsion system includes a stator shell (1) 

adapted to be mounted to the hull of the ship and an impeller housing 

(6) attached to the stator shell (1). The stator shell (1) has a nozzle (4) 

ending in an outlet (5) and the diameter of the outlet cross-sectional 

area (A) is at least 0.3m. The impeller housing (6) has an upstream 

inlet (7) and an impeller is rotatably mounted in the impeller housing (6) 

for receiving water from the inlet and discharging it through the nozzle 

(4). The method includes the activation of a hindering arrangement 

(8, 9) adjacent the nozzle (4) during a start-up phase. The hindering 

arrangement (8, 9) comprises an air backflow hindering arrangement (8, 

9) that blocks at least 50% of the outlet area (A) to hinder air entering 

into the impeller housing (6) via the nozzle (4). 

(21) 587997 (22) 29 Apr 2005 

(54) ADAMANTYL-ACETAMIDE DERIVATIVES AS INHIBITORS OF THE 

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 

(51) IPC2012.01:C07D213/24, 06, 72; C07D207/02 

(71) Abbott Laboratories 

(72) LINK, James T; PLIUSHCHEV, Marina A; ROHDE, Jeffrey J; 

WODKA, Dariusz; PATEL, Jyoti R; SHUAI, Qi 

(31) 10/834,459 (32) 29 Apr 2004 (33) US 

(31) 10/965,591 (32) 14 Oct 2004 (33) US 



(57) Disclosed is a substituted adamantine compound selected from 

the group consisting of: N2- [2-(4-chlorophenyl)ethyl] –N1-[(E)-5hydroxy-2-adamantyl]alaninamide; 

N2-[2-(3,4-dichlorophenyl)ethyl] 

–N1-[(E)-5-hydroxy-2-adamantyl] -N2-methylalaninamide; N2- 

[2-(4-chlorophenyl)-1-methylethyl] –N1-[(E)-5-hydroxy-2-adamantyl]- 

N2-methylalaninamide; N-[(E)-5-hydroxy-2-adamantyl]-1-{ [4- 

(trifluoromethyl)benzyl]amino}cyclopropanecarboxamide; 2-[(cis)-2,6dimethylmorpholin-4-yl] 

-N-[(E)-5-hydroxy-2-adamantyl]propanamide; 

2-azepan-1-yl-N-[(E)-5-hydroxy-2-adamantyl]propanamide; N-[(E)-5hydroxy-2-adamantyl]-2-(6,7,9,10-tetrahydro-8H-[1,3]dioxolo[4,5-g] 

[3]benzazepin-8-yl)propanamide; 2-(1,3-dihydro-2H-isoindol-2-yl)- 

N- [(E)-5-hydroxy-2-adamantyl]propanamide; 2- [3-(4chlorophenoxy)azetidin-1-yl]-N-[(E)-5-hydroxy-2adamantyl]propanamide; 

2-(5-chloro-2,3-dihydro-1H-indol- 1-yl)- 

N-[(E)-5 -hydroxy-2-adamantyl]propanamide; N-[(E)-5-hydroxy-2adamantyl] 

-2-(3-phenylazetidin-1-yl)propanamide; 2-[3-(3fluorophenoxy)pyrrolidin-1-yl]-N-[(E)-5-hydroxy-2adamantyl]propanamide; 

N-[(E)-5-hydroxy-2-adamantyl]-2-methyl-2- 

[2-(trifluoromethyl)pyrrolidin-1-yl]propanamide; N-[(Z)-5-hydroxy-2adamantyl]-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1yl}acetamide; 

N-[(E)-5-hydroxy-2-adamantyl] -2-{4-[5 - 

(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}acetamide; (2S)-N-[(E)-5hydroxy-2-adamantyl]-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1yl} 

propanamide; (2R)-N- [(E)-5 -hydroxy-2-adamantyl] 

-2- { 4- [5 -(trifluoromethyl)pyridin-2-yl]piperazin-1yl} 

propanamide; N-[(E)-5-fluoro-2-adamantyl] -2-{4- 

[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}acetamide; N-[(Z)-5fluoro-2-adamantyl]-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1yl}acetamide; 

N-[(E)-5-hydroxy-2-adamantyl] -2-[4-(5-methylpyridin-2yl)piperazin-1-yl]propanamide; 

N-[(E)-5-hydroxy-2-adamantyl] -2methyl-2-{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}propanamide;N-[(E)-5-hydroxy-2-adamantyl]-2-(4-pyridin-2-ylpiperazin-1yl)propanamide; 

2- [4-(4-fluorophenyl)piperazin-1-yl]-N-[(E)-5hydroxy-2-adamantyl]propanamide; 

N-[(E)-5-hydroxy-2-adamantyl]-2- 

[4-(4-methoxyphenyl)piperazin-1-yl]propanamide; 2-[4-(5cyanopyridin-2-yl)piperazin-1-yl]-N-[(E)-5-hydroxy-2adamantyl]propanamide;2-[4-(2-furoyl)piperazin-1-yl]-N-[(1R,3S)-5hydroxy-2-adamantyl]propanamide; 

N-[(E)-5-hydroxy-2-adamantyl] 

-2-{4-[4-(trifluoromethyl)phenyl]piperazin-1-yl}propanamide; (2S)- 

N-[(E)-5-hydroxy-2-adamantyl] -2-{4-[5-(trifluoromethyl)pyridin-2yl]piperazin-1-yl} 

propanamide; (2R)-N-[(E)-5-hydroxy-2-adamantyl] -2- 

{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide; 2-[4-(6chloropyridin-3yl)piperazin-1-yl]-N-[(E)-5-hydroxy-2adamantyl]propanamide;2-(4-benzylpiperidin-1-yl)-N-[(E)-5-hydroxy-2adamantyl]propanamide; 

2-[4-(2-fluorophenoxy)piperidin-1-yl] -N- 

[(E)-5-hydroxy-2-adamantyl]propanamide; 2-[3-(2fluorophenoxy)piperidin-1-yl]-N-[(E)-5-hydroxy-2adamantyl]propanamide; 

N- [(E)-5 -cyano-2-adamantyl] -2-methyl-2- 

{4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl}propanamide; and N- 

[(E)-5-(cyanomethyl)-2-adamantyl]-2-methyl-2-{4-[5- 

(trifluoromethyl)pyridin-2-yl]piperazin-1-yl} propanamide. Also disclosed 

is a pharmaceutical composistin comprisining a compound and the 

use of the compound for the manufacture ofa medicament for treating 

Cushing’s syndrome, non-insulin dependent type 2 diabetes, insulin 

resistance, obesity, lipid disorders, metabolic syndrome, hypertension, 

atherosclerosis, glaucoma, and osteoporosis. The compounds are 

useful as 11-beta-HSD inhibitors. 


(21) 587999 (22) 29 Mar 2005 

(54) Process for the preparation of aminopyrimidines 



(51) IPC2012.01:C07D239/46 


(72) Larsson, Ulf; Radevik, Kajsa 

(31) 04 0401001 (32) 31 Mar 2004 (33) SE 


(57) Disclosed is a process for preparing an aminopyrimidine compound of 

formula (I), wherein X is halogen, Y is ZR1, Z is O or S, R1 is C1-6 alkyl, 

C1-6 haloalkyl or C3-7 cycloalkyl, and R2 is phenyl optionally substituted 

by chloro, C1-6 alkyl, C1-6 alkoxy or (C1-6 alkyl)2N; wherein the 

process comprises conducting a one-pot hydrogenation of a compound 

of formula (III): (i) firstly at about 20 Deg. C to form a compound of 

formula (IV); (ii) and then at about 40 Deg. C;both steps (i) and (ii) 

being carried out in the presence of a suitable catalyst selected from 

platinum and a mixture of platinum and vanadium and in the presence 

of a suitable solvent selected from a C1-6 aliphatic alcohol, an ester, an 

ether, a hydrocarbon and a ketone. 


(21) 588020 (22) 11 Mar 2009 

(54) SECURITY SYSTEM INCLUDING CONTROLLER, REMOTE 

DETECTORS AND SPRAYING DEVICES 

(86) PCT/EP2009/052827 (87) WO2009/112507 

(51) IPC2012.01:G08B15/02 

(71) Selectamark Security Systems PLC 

(72) HART, Nigel; BROWN, Jason 

(31) 0804493.5 (32) 11 Mar 2008 (33) GB 



(57) A security system comprising: a controller (12); and a plurality of 

dispensing devices (16A, 16B). The controller is configured to receive 

signals from a plurality of remote detectors (14A, 14B) and transmit 

signals to the plurality of dispensing devices. The controller is adapted 

to determine which of the plurality of detectors has transmitted a signal 

and transmit a signal to a selected one or more dispensing devices to 

dispense a fluid based on that determination. Each dispensing device 

is configured to receive signals from the controller and dispense fluid 

when a signal is received. 

(21) 588025 (22) 3 Nov 2005 

(54) A process for purifying staurosporine 

(51) IPC2012.01:C07D498/22 

(71) Novartis AG 

(72) HOEHN, Pascale; KOCH, Bernd; MUTZ, Michael 

(31) 60/625,343 (32) 5 Nov 2004 (33) US 

(31) 60/642,131 (32) 7 Jan 2005 (33) US 



(57) Disclosed herein is a process for purifying staurosporine comprising: 

(a) providing a suspension of staurosporine in an alcohol solvent, 

preferably ethanol; (b) contacting the suspension with methanesulfonic 

acid; (c) further contacting the solution with triethylamine; and (d) 

isolating the product. 


(21) 588064 (22) 4 Jan 2006 

(54) Synthesis of hybrid block copolymers and uses thereof 

(51) IPC2012.01:C08F293/00; C11D17/00; C08L53/00; C08F283/06; 

C08L51/08 

(71) INTEZYNE TECHNOLOGIES, INCORPORATED 

(72) BREITENKAMP. KURT; SILL, KEVIN N 

(31) 60/641,170 (32) 4 Jan 2005 (33) US 



(57) Disclosed is a method for preparing a multi-block copolymer 

comprising two or more different poly(amino acid) blocks and one or 

more synthetic polymer blocks, wherein said method comprises the 

step of sequentially polymerizing two or more different cyclic amino 

acid monomers onto a synthetic polymer having a terminal amine salt 

wherein said polymerization is initiated by said amine salt. 


(21) 588076 (22) 23 Mar 2009 

(54) RISER END SUPPORT WITH MEANS FOR COUPLING AND 

DECOUPLING A RISER TERMINATION FOR CONNECTION TO A 

FLOATING VESSEL 

(86) PCT/AU2009/000332 (87) WO2009/124334 

(51) IPC2012.01:E21B43/01, 013; E21B17/01; F16L1/12; E21B19/00 

(71) AMOG Pty Ltd 

(72) WALES, Stuart; TURNER, Christopher 

(31) 2008901721 (32) 9 Apr 2008 (33) AU 



(57) A riser system including at least one riser (11, 11’) extending 

from infrastructure on a sea bed each riser having a riser termination 

(12). An end support (18) restrained above and relative to the sea 

bed (22) has attachment means to couple each riser termination for 

storage and decouple each riser termination for coupling to a floating 



vessel (20). An intermediate support (16, 16’) supports an intermediate 

portion of the riser to define a catenary bend (14, 14’) between the 

intermediate support (16, 16’) and the riser termination device (12, 12’). 

Also disclosed is a method of storing a riser termination (12, 12’) and a 

method of installation of the riser system. 

(21) 588080 (22) 19 Feb 2009 

(54) 2-Aza-bicyclo[2.2.1]heptane derivatives 

(86) PCT/IB2009/050689 (87) WO2009/104155 

(51) IPC2012.01:A61K31/427, 4709; C07D403/12; C07D405/12; 

C07D495/04; C07D471/04; A61P25/00; C07D417/06, 14; C07D493/04; 

C07D513/04 

(71) ACTELION PHARMACEUTICALS LTD. 

(72) AISSAOUI, Hamed; BOSS, Christoph; KOBERSTEIN, Ralf; 

SIFFERLEN, Thierry; TRACHSEL, Daniel 

(31) PCT/IB2008/050622 (32) 21 Feb 2008 (33) IB 



(57) Disclosed is a 2-aza-bicyclo[2.2.1]heptane derivative of formula (I), 

or a salt thereof, where n is 0 or 1, A and B are each optionally 

substituted aryl or heterocycle, and the other substituents are as defined 

in the specification. Also disclosed is the use of the compound for 

treating selected all types of sleep disorders, stress related syndromes, 

psychoactive substance use and abuse, cognitive dysfunctions in the 

healthy population and in psychiatric and neurologic disorders, and 

eating or drinking disorders. 

(21) 588085 (22) 18 Mar 2009 

(54) ANTIBACTERIAL WOUND DRESSING BASED ON SILVERED GEL- 

FORMING FABRIC 

(86) PCT/GB2009/000733 (87) WO2009/115804 

(51) IPC2012.01:A61L15/46, 60 

(71) CONVATEC TECHNOLOGIES INC. 

(72) KERSHAW, David; DE BOORDER, Barry; LAW, Stephen, John 

(31) 0805162.5 (32) 19 Mar 2008 (33) GB 



(57) Disclosed herein is an antibacterial wound dressing derived from 

silvered fabric comprising gel-forming fibres having silver ions linked 

thereto, the wound dressing having a weight to weight ration of silver to 

nitrate in the dressing of from 0.5 to 4, where also the wound dressing as 

disclosed is obtained by a process including the steps of forming a fabric 

comprising gel forming fibres and contacting the fabric with a solution 

containing silver nitrate by spraying the solution onto the fabric. 

(21) 588090 (22) 25 Jul 2005 

(54) Pallet for use with a fork lift having a plurality of columns with snap 

tabs to secure the columns to the deck, and a plurality of ribs extending 

between the columns 

(51) IPC2012.01:B65D19/00, 26, 32 

(71) REHRIG PACIFIC COMPANY 

(72) OGBURN, Sean T; APPS, William P; GRUBER, Robert V; 

WILKERSON, Jeffery L 

(31) 10/903661 (32) 29 Jul 2004 (33) US 



(57) A pallet for use with a fork lift is disclosed. The pallet comprises 

a deck, a plurality of columns including a centre column and at least 

one peripheral column substantially perpendicular to the deck which 

defines fork receiving regions therebetween. A plurality of snap-tabs 

secure the columns to the deck. A mid-top member is secured to the 

deck, where the mid-top member at least substantially circumscribes 

the centre column and the mid-top member partially circumscribes at 

least one peripheral column. A plurality of ribs are provided between the 

plurality of columns where the plurality of ribs extend between the deck 

and the mid-top member. 


(21) 588094 (22) 19 Aug 2005 

(54) Potting head for hollow fibre filter module 

(51) IPC2012.01:B01D63/04; B01D67/00 

(71) Siemens Water Technologies Corp 

(72) McMahon, Robert James; Cox, David John; Zha, Fufang; Phelps, 

Roger William; Johnson, Warren Thomas; Barkho, Sargon 

(31) 2004904769 (32) 20 Aug 2004 (33) AU 


Australia 

(57) A potting head for mounting porous hollow membranes 8 includes 

a preformed potting element 6 having cavities 30 for receiving curable 

potting material which in use when cured supports the membranes. 

The potting element is formed with through openings 12 for the 

communication of fluid through the element. 




(21) 588123 (22) 20 May 2004 

(54) (1S,5S)-3-(5,6-Dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane 

is an effective analgesic agent 

(51) IPC2012.01:C07D487/04; A61P29/00; A61K31/407, 4439, 397; 

C07D213/61, 74 

(71) Abbott Laboratories 

(72) Buckley, Michael J; Ji, Jianguo 

(31) 10/445,555 (32) 27 May 2003 (33) US 



(57) Disclosed is a pharmaceutical composition for treating amyotrophic 

lateral sclerosis or premenstrual syndrome which comprises a 

therapeutically effective amount of (1S,5S)-3-(5,6-dichloro-pyridin-3yl)-3,6-diazabicyclo[3.2.0]heptane 

or a pharmaceutically acceptable salt 

thereof. Further disclosed is a pharmaceutical composition comprising 

a therapeutically effective amount of (1S,5S)-3-(5,6-dichloro-3pyridinyl)-3,6-diazabicyclo[3.2.0]heptane 

or a pharmaceutically 

acceptable salt thereof, in combination with a pharmaceutically 

acceptable carrier, wherein the composition is in a solid dosage 

form or a liquid dosage form. Also disclosed is (1S,5S)-3-(5,6dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane 

(L)-tartrate and 

(1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane ptoluenesulfonate. 


(21) 588130 (22) 3 Apr 2009 

(54) A heated electric towel rail with two electrical connectors 

(51) IPC2012.01:H01R11/00; F26B3/00; F26B23/00 

(71) CDB Media Limited 

(72) SPRINGFIELD, ANDREW 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) A heated electric ladder-type towel rail, comprises a frame 1 having 

interconnected conduits for accommodating a heating element 2, the 

conduits forming a ladder construction, one or more heating elements 

2 located within the frame 1, a first electrical connector 3 for electrically 

connecting a heating element 2 to an electricity supply located at a first 

position with respect to the frame 1, and a second electrical connector 

3’ for electrically connecting a heating element 2 to an electricity supply 

located at a second position with respect to the frame 1, different to the 

first position. The heating elements 2 pass along a snaking path through 

the interconnected conduits from a first end of the heating element 2 to 

a second end of the heating element 2. 


(21) 588143 (22) 29 Jul 2005 

(54) Oxazole, imizadole and pyrrole derivatives as NF-kappaB inhibitors 

(NF-kB) 

(51) IPC2012.01:C07D473/34; C07D487/04; C07D263/48; A61P35/00; 

C07D413/12; C07D417/14, 04, 12; A61K31/4535, 454; C07D277/56; 

C07D495/04; C07D211/62; C07D513/04 

(71) 4SC Discovery GmbH 

(72) Leban, Johann; Schmitt, Harald; Wolf, Kristina; Pegoraro, Stefano; 

Wuzik, Andreas 

(31) 04 612794 (32) 27 Sep 2004 (33) US 

(31) 04 22363 (32) 20 Sep 2004 (33) EP 


(57) Disclosed are oxazole, imidazole, and pyrrole derivatives of the 

pictured formula, where R4 and R5 may join to form a ring, as may 

Z and R1 and wherein the substituents are otherwise defined in the 

specification. Also disclosed is the use of the compounds as NF-kappa 

B inhibitors, for treating diseases characterized by hyperproliferation of 

cells. 




(21) 588144 (22) 20 Apr 2009 

(54) METHOD TO DETERMINE RESPONSIVENESS TO ANTIVIRAL 

THERAPY 

(86) PCT/EP2009/054641 (87) WO2009/130176 

(51) IPC2012.01:C12Q1/68; G01N33/50, 576 

(71) Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher 

Institute for Biomedical Research; University Hospital Basel 

(72) FILIPOWICZ, Witold; HEIM, Markus; SARASIN-FILIPOWICZ, 

Magdalena; DUONG, Francois H.T.; OAKELEY, Edward 

(31) 08154878.6 (32) 21 Apr 2008 (33) EP 



(57) Disclosed is a method for determining the likelihood that a subject 

having a viral infection of the liver will be responsive to antiviral therapy 

that includes stimulation of Interferon (IFN) activity comprising analysing 

before antiviral therapy the level of expression of at least one gene 

from the following groups: i) LOC129607; RPLP0; and HERC5; (ii) 

HTATIP2; and IFI44L; (iii) IFI27; IFIT1; G1P2; IRF7; RSAD2; IFI44; 

OAS3; and IFIT2; (iv) LAMP3; HERC6; LOC286208; IFIT3; RALGPS1; 

PARP9; CCDC75; and CNP; (v) HIST1H2BG; HIST1H2BD; FLJ20035; 

PARP12; PNPT1; LGALS3BP; SAMD9; and LOC402560. The level of 

expression of the genes in the sample is compared to level of expression 

of the same genes in a control sample, wherein an increase in the level 

of expression of the genes in the sample from the subject before antiviral 

therapy relative to the level of expression of the same genes in the 

control sample indicates that the subject is not likely to be responsive 

to said antiviral therapy. 

(21) 588147 (22) 24 Mar 2009 

(54) PLANT DISEASE CONTROLLING COMPOSITION AND METHOD 

FOR CONTROLLING PLANT DISEASE 

(86) PCT/JP2009/056427 (87) WO2009/119873 

(51) IPC2012.01:A01N47/16; A01N43/653; A01P3/00 

(71) SUMITOMO CHEMICAL COMPANY, LIMITED 

(72) SOMA, Masato 

(31) 2008-077975 (32) 25 Mar 2008 (33) JP 



(57) Disclosed is a plant disease controlling composition comprising 

at least one compound (A) selected from the group consisting 

of metconazole, bromuconazole and epoxiconazole, as well 

as a compound represented by formula (I). Metconazole 

is described as (1RS,5RS;1RS,5SR)-5-(4-chlorobenzyl)-2,2dimethyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol; 

Bromuconazole 

is described as 1-(2RS,4RS:2RS,4SR)-4-bromo-2-(2,4dichlorophenyl)tetrahydrofurfuryl]-1H-1,2 

,4-triazole and Epoxiconazole 

is described as (2RS,3SR)-1-[3-(2-chlorophenyl)-2,3-epoxy-2-(4fluorophenyl)propyl]-1H-1,2,4-triazole. 

Also disclosed is a method of 

controlling plant disease using a composition as disclosed. 

(21) 588190 (22) 9 Jun 2005 

(54) Separating prion proteins with polyglycidyl methacrylate surface 

modified matrix 

(51) IPC2012.01:C12M3/06; G01N33/53, 569 

(71) PATHOGEN REMOVAL AND DIAGNOSTIC TECHNOLOGIES, INC. 

(72) Carbonell, Rubin G 

(31) 60/578061 (32) 9 Jun 2004 (33) US 

(31) 60/616118 (32) 6 Oct 2004 (33) US 

(31) 60/617669 (32) 13 Oct 2004 (33) US 



(57) A device for separating prion protein from a sample, the device 

comprising one or more porous matrices having pore sizes greater than 

10 micrometres. The one or more porous matrices are surface modified 

with polyglycidyl methacrylate (PGMA). 


(21) 588210 (22) 20 Jun 2005 

(54) A temperature control system for controlling heat transfer for a fluid 

immersed vessel 

(51) IPC2012.01:A47F3/04; F25D23/12 

(71) THE DELFIELD COMPANY 

(72) Walker, Darrel J; Smith, Wayne W 

(31) 04 874738 (32) 23 Jun 2004 (33) US 


(57) A temperature control system is disclosed for maintaining a food 

product at an acceptable temperature. The control system comprises a 

pan (20) having a thermally conductive vertical wall (30) and a thermally 

conductive bottom side (34). A first member (44) surrounds the pan 

and a channel (50, 52, and 54) is disposed between the first member 

and the pan. The channel contains a fluid (38) contacting the thermally 

conductive vertical wall (30) and the thermally conductive bottom side 

(34) of the pan. A refrigeration coil (40) is connected to a top portion 

(26) of the thermally conductive vertical wall for cooling the pan (20) 

and a second member (42) surrounds a bottom portion of the thermally 

conductive vertical wall. 


(21) 588231 (22) 27 Oct 2005 

(54) Accomodation of expansion in burner assembly of gas cooker 

(51) IPC2012.01:F24C3/08; F23D14/06 

(71) AKTIEBOLAGET ELECTROLUX 

(72) Rossi, Carlo, Antonio; Rossi, Marco 

(31) 04 906239 (32) 28 Oct 2004 (33) AU 


(57) A burner assembly for a gas cooker includes a distributor 30 and 

a first formation 46 to support the distributor in the assembly. The 

distributor and first formation include spigots 47 and recesses 48 to 

receive the spigots to allow the first formation to support the distributor. 

The recesses include a surface sized and shaped so that thermal 

expansion of the distributor results in substantially no increase in the 

contact surface area between the first formation and the distributor 

irrespective of whether the distributor is hot or cold. 




(21) 588232 (22) 27 Oct 2005 

(54) Improved cooking gas burner assembly 

(51) IPC2012.01:F24C3/08; F23D14/06 

(71) AKTIEBOLAGET ELECTROLUX 

(72) Rossi, Carlo, Antonio; Rossi, Marco 

(31) 04 906239 (32) 28 Oct 2004 (33) AU 


(57) A burner assembly includes a cap (220) and a distributor (30) on 

which the cap (220) is mounted, the distributor (30) including an internal 

and an external crown of flame ports, and at least one cross lighting 

passage (37) between the respective crowns. The cap (220) includes 

a through-going aperture (222) which is adapted to be positioned over 

said cross lighting passage (37) when said cap (220) and distributor (30) 

are assembled. 


(21) 588306 (22) 17 May 2005 

(54) Use of galactooligosaccharides and the polyfructose inulin for the 

treatment of diseases of the bowel 

(51) IPC2012.01:A23L1/29, 30, 0528; A61K31/01, 715, 702, 733 

(71) N.V. Nutricia 

(72) Speelmans, Gelske; Govers, Maria Johanna Adrianna Petronella; 

Knol, Jan; Van Tol, Eric Alexander Fransiscus 

(31) 04 4076479 (32) 17 May 2004 (33) EP 


(57) The use of galacto-oligosaccharides and polyfructose for the 

treatment or prevention of abdominal bloating, gas formation, abdominal 

pain and/or flatulence. The polyfructose is inulin with an average 

degree of polymerisation above 20. The composition can promote the 

production of short chain fatty acids in the colon and is suitable for infant 

nutrition. 


(21) 588323 (22) 16 Jul 2004 

(54) MARKERS FOR THE DETECTION OF GASTRIC CANCER 

(51) IPC2012.01:C12Q1/68 

(71) Pacific Edge Biotechnology Ltd 

(72) GUILFORD, Parry John; HOLYOAKE, Andrew John 

(31) 60/487,906 (32) 17 Jul 2003 (33) US 



(57) Provided is a method of detecting gastric cancer, comprising: 

detecting over-expression of the GTM family member serine or cysteine 

proteinase inhibitor clade B (SERPINB5) in a biological sample. The 

method can be improved by further including other specified markers. 

The overexpression can be measured by mRNA, cDNA, or protein level 

by antibody based assay. 


(21) 588340 (22) 28 May 2009 

(54) COMPOSITIONS AND METHODS FOR IMPROVING PLANTS 

(86) PCT/NZ2009/000087 (87) WO2009/148330 

(51) IPC2012.01:C12N15/29, 82; A01H5/00, 10; C07H21/04; C07K14/415 

(71) VIALACTIA BIOSCIENCES (NZ) LIMITED 

(72) PUTHIGAE, Sathish; BRYANT, Catherine, Jane; BAJAJ, Shivendra; 

TEMPLETON, Kerry, Robert 

(31) 61/058,486 (32) 3 Jun 2008 (33) US 



(57) Provided is a Lolium plant derived polynucleotide conferring 

environmental stress resistance, modulated biomass or modulated 

seed yield. Further provided are variants of the sequence and the 

use of expression vectors to make transgenic plants with improved 

characteristics. 

(21) 588477 (22) 29 Aug 2006 

(54) MULTIMEDIA COLOR MANAGEMENT SYSTEM 

(51) IPC2012.01:H04N1/46 

(71) MICROSOFT CORPORATION 

(72) VAN HOOF, Hubert; MAUZY, Charles A; STOKES, Michael D; 

VASUDEVAN, Lavanya 

(31) 11/216626 (32) 31 Aug 2005 (33) US 



(57) A method and a system for managing multimedia colour are disclosed. 

The system comprises a processor; computer storage media coupled 

to the processor; and a colour infrastructure transformation engine. The 

colour infrastructure transformation engine (125) is maintained on the 

computer storage media and executed on the processor to receive a 

first source colour content associated with a first media type and receive 

a second source colour content associated with a second media type. 

The first source colour content is associated with first media boundary 

information corresponding to the first media type. The second source 

colour content is associated with second media boundary information 

corresponding to the second media type. The colour infrastructure 

transformation engine is further executed on the processor to transform 

the first source colour content and the second source colour content 

into destination colour content in a destination colour space using 

the first media boundary information and the second media boundary 

information for rendering the first source colour content and the second 

source colour content as composited content on a destination device. 




(21) 588486 (22) 8 Oct 2010 

(54) Improvements in animal tags 

(51) IPC2012.01:A01K11/00 

(71) GOLD RYTHMN PTY LTD; KCS AUSTRALIA PTY LTD 

(72) Steinfort, John James; Schnepf, Kurt; Hendriks, William 

(31) 2009904895 (32) 8 Oct 2009 (33) AU 

(74) Patent Attorney Services, Suite 4, 26 Ellingworth Parade, Box Hill, 


(57) Disclosed is a tag for attachment to an animal. The tag includes 

a penetrating component having a pair of spaced apart penetrating 

members joined by an elongate intermediate portion. The penetrating 

members extend from respective ends of the intermediate portion. 

Each penetrating member has a stem with a first end joined 

to the intermediate portion and a second end terminating in a 

penetrating head. The penetrating head has a distal point and a 

base which forms a shoulder around the stem. The tag includes a 

complementary component, separate from the penetrating component. 

The complimentary component has a pair of apertures arranged to 

receive respective penetrating members of the penetrating component 

so as to provide positive engagement of each respective shoulder of 

the penetrating heads. Each stem has a bore open at the first end to 

receive a respective pin of an applicator to assist in piercing the skin of 

the animal and positively engage the shoulders within the apertures of 

the complementary component. A section of material of the intermediate 

portion between each bore and a respective end of the intermediate 

portion is dimensioned so that there is no overhanging part so as 

to prevent the penetrating component being dislodged by the animal 

from the complementary component after positive engagement of the 

shoulders with the complementary component. 


(21) 588511 (22) 20 May 2009 

(54) DERIVATIVES OF QUINOLINES AND QUINOXALINES AS 

PROTEIN TYROSINE KINASE INHIBITORS 

(86) PCT/EP2009/056154 (87) WO2009/141386 

(51) IPC2012.01:C07D241/44; A61P35/00; C07D215/48; C07D403/12, 

14; A61K31/4709, 498 

(71) Novartis AG 

(72) FURET, Pascal; GRAUS PORTA, Diana; GUAGNANO, Vito 

(31) 08156846.1 (32) 23 May 2008 (33) EP 



(57) Disclosed are quinoline and quinoxaline compounds represented 

by general formula (I). Examples of the compounds include: 8- 

(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5-carboxylic acid (4morpholin-4-ylphenyl)-amide8-(2,6-Dichloro-3,5-dimethoxy-phenyl)quinoxaline-5-carboxylic 

acid [4-(2-dimethylaminoethoxy)-phenyl]amide 

and 8-(2,6-Dichloro-3,5-dimethoxy-phenyl)-quinoxaline-5carboxylic 

acid (5-carbamoyl-pyridin-2-yl)-amide. The compounds are 

used to treat protein tyrosine kinase mediated diseases such as cancer. 

(21) 588539 (22) 8 Apr 2009 

(54) Method for producing microfibrillated cellulose (nanocellulose) 

involving modifying cellulose fibers with amphoteric or anionic 

carboxymethyl cellulose (CMC) 

(86) PCT/SE2009/050371 (87) WO2009/126106 

(51) IPC2012.01:D21H11/20; D21C9/00 

(71) Innventia AB 

(72) ANKERFORS, Mikael; LINDSTROM, Tom 

(31) 0800807-0 (32) 10 Apr 2008 (33) SE 



(57) Disclosed is a method for the manufacturing of nanocellulose. The 

method includes a first modification of the cellulose material, where 

the cellulose fibres are treated with an aqueous electrolyte-containing 

solution of an amphoteric cellulose derivative. The modification is 

followed by a mechanical treatment. By using this method for 

manufacturing nanocellulose, clogging of the mechanical apparatus is 

avoided. Also disclosed is nanocellulose manufactured in accordance 

with said method and uses of said cellulose. 

(21) 588547 (22) 10 Apr 2009 

(54) N-(4-Chloro-3-(pyridin-2-yl)phenyl)-4-(2-hydroxy-2methylpropylsulfonyl)-2-methylbenzamide 

(86) PCT/US2009/040165 (87) WO2009/126863 

(51) IPC2012.01:C07D403/14, 06; C07D213/06, 26, 40; A61K31/4402, 

4418; A61P35/00 

(71) Genentech, Inc.; Cruis, Inc. 

(72) GUNZNER, Janet, L; SUTHERLIN, Daniel, P; STANLEY, Mark, 

S; BAO, Liang; CASTANEDO, Georgette; LALONDE, Rebecca, L; 

WANG, Shumei; REYNOLDS, Mark, E; SAVAGE, Scott, J; MALESKY, 

Kimberly; DINA, Michael, S 

(31) 61/044,451 (32) 11 Apr 2008 (33) US 

(74) DAVIES COLLISON CAVE - Sydney, Level 14, 255 Elizabeth Street, 

Sydney, New South Wales, Australia 

(57) Disclosed is the compound N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(2hydroxy-2-methylpropylsulfonyl)-2-methylbenzamide. 

Further disclosed 

a composition which comprises the above compound, and a 

pharmaceutically acceptable carrier for the treatment of cancer in a 

mammal. 



(21) 588582 (22) 5 Jun 2009 

(54) STORAGE STABLE MELAMINE-UREA-FORMALDEHYDE RESINS 

AND APPLICATIONS THEREOF 

(86) PCT/US2009/046374 (87) WO2009/158173 

(51) IPC2012.01:C08G8/28; C08G73/02; C08G2/08; C08G12/08 

(71) MOMENTIVE SPECIALTY CHEMICALS INC. 

(72) NO, Byung, Young; MOTTER, William, K; HARMON, David, M 

(31) 12/145,871 (32) 25 Jun 2008 (33) US 



(57) Disclosed is an article of manufacture such as particleboard 

or plywood, which comprises a substrate and a melamine-ureaformaldehyde 

resin wherein: the substrate is selected from the group 

consisting of cellulosic-particles, -strands, fibers, -veneers, and mixtures 

thereof; the melamine-urea-formaldehyde resin functions to adhere the 

substrate together into the article of manufacture; and the melamineurea-formaldehyde 

resin is prepared using a method comprising a first 

cook stage, a second cook stage, and a final addition wherein: the molar 

ratio of formaldehyde to urea and melamine (F: U +M) in the first cook 

stage is from about 2.0 to about 5.0; the molar ratio of formaldehyde to 

urea and melamine (F: U + M) in the second cook stage is from about 

1.5 to 3.0; and the molar ratio of formaldehyde to urea and melamine 

(F: U + M) in the final addition is from about 0.4 to 0.7. 

(21) 588651 (22) 23 Apr 2009 

(54) METHODS FOR MANUFACTURING A POLYCLONAL PROTEIN 

(86) PCT/DK2009/050094 (87) WO2009/129814 

(51) IPC2012.01:C07K16/00 

(71) Symphogen A/S 

(72) TOLSTRUP, Anne, Bondgaard; NIELSEN, Lars, Soegaard; 

WEILGUNY, Dietmar; MULLER, Christian; WIBERG, Finn, C.; 

GRAVERSEN, Jonas, Heilskov 

(31) PA 2008 00580 (32) 23 Apr 2008 (33) DK 

(31) 61/047,389 (32) 23 Apr 2008 (33) US 



(57) Disclosed is a method for manufacturing a drug product comprising at 

least two distinct protein members of a polyclonal protein, said method 

comprising the steps of: a) providing at least two populations of cells, 

wherein each population encodes one distinct member of the polyclonal 

protein and is enclosed in a physically separate container comprising 

culture medium and cells expressing the protein, wherein the method 

comprises an upstream part comprising the steps of: i) expanding the 

at least two populations of cells in one or more steps of a seed train 

in separate containers; ii) expanding cells from the seed train in one or 

more steps of an inoculum train; iii) culturing cells from the inoculum 

train in a production phase under conditions favoring expression of 

the protein members so as to express the at least two distinct protein 

members; b) harvesting the expressed protein; c) performing at least 

one downstream purification step on the harvested protein; d) obtaining 

purified drug substance; and e) formulating purified drug substance into 

a polyclonal drug product; wherein the at least two populations of cells 

are kept separate at least during the seed train, and wherein at least part 

of the downstream purification is carried out on a mixture comprising the 

individual members of the polyclonal protein. 

(21) 588688 (22) 13 Oct 2004 

(54) Multi layer sterilization wrap with the corners of the additional panel 

attached to the edges of the first panel of sterilzation material 

(51) IPC2012.01:D04H13/00; A61B19/02; A61L2/26, 28 

(71) ALLEGIANCE CORPORATION 

(72) CANNADY, Clay; DUSKI, Michael; HOGE, Brian G.; STECKLEIN, 

Greg; WHITAKER, James F.; SCHOTZ, Debra; BLANKENSHIP, 

Barbara Anne; PUENTES, Alejandro 

(31) 10/685,545 (32) 14 Oct 2003 (33) US 

(31) 10/966,354 (32) 13 Oct 2004 (33) US 



(57) A sterilization wrap 64 for wrapping an article to be sterilized, 

comprises a first panel 60 of sterilization material, and an additional 

panel 76 of material. The additional panel 76 is attached to the first 

panel 60. The first panel 60 is multi-layered and includes at least one 

pathogen filtration layer. The additional panel 76 does not include a 

pathogen filtration layer. The first panel 60 has an outer periphery and a 

central portion, with the outer periphery including first, second, third and 

fourth edges. The additional panel 76 has first, second, third and fourth 

corners, with the first corner of the additional panel 76 bonded to the 

first edge of the first panel 60, the second corner of the additional panel 

76 bonded to the second edge of the first panel 60, and the third corner 

of the additional panel 76 bonded to the third edge of the first panel 60. 


(21) 588719 (22) 13 Oct 2004 

(54) Sterilization wrap with an additional panel of absorbent material 

attached to the panel of sterilization material 

(51) IPC2012.01:D04H13/00; A61B19/02; A61L2/26, 28 

(71) ALLEGIANCE CORPORATION 

(72) CANNADY, Clay; DUSKI, Michael; HOGE, Brian G.; STECKLEIN, 

Greg; WHITAKER, James F.; SCHOTZ, Debra; BLANKENSHIP, 

Barbara Anne; PUENTES, Alejandro 

(31) 10/685,545 (32) 14 Oct 2003 (33) US 

(31) 10/966,354 (32) 13 Oct 2004 (33) US 



(57) A sterilization wrap 30 for wrapping an article to be sterilized 

comprises at least one panel of sterilization material 32 having a central 

portion, and a panel 34attached to the central portion of the panel of 

sterilization material 32. The panel 34 attached to the central portion of 

the panel of sterilization material 32 is absorbent and is enabled to wick 

moisture away from the article after sterilization has taken place. The 

basis weight of the panel 34 attached to the central portion of the panel 

of sterilization material 32 is higher than the basis weight of the panel 

of sterilization material 32. 




(21) 588751 (22) 21 Oct 2011 

(54) Infant pacifying apparatus comprising a sound system connected to 

or housed in a hand or arm receiving portion 

(51) IPC2012.01:A61M21/00 

(71) Magic Mitten Limited 

(72) Hubble, Mark Vincent; Smith, Dean Maxwell; Rogers, Jason Paul 



(57) An infant pacifying apparatus (1000) is disclosed. The apparatus 

(1000) includes a sound system (1006), an auditory output device 

(1009) and a receiving portion (1003). The sound system (1006) 

comprises a sound generator (1007) and associated power source 

(1008) and the auditory output device (1009) is associated with the 

sound system (1006). The receiving portion (1003) is configured to be 

located on a hand or an arm. The receiving portion (1003) either houses 

or at least connects to housing for containing the auditory output device 

(1009) and/or the sound system (1006). The sound system (1006) and/ 

or auditory output device (1009) is/are configured to enable the auditory 

output device (1009) to produce a sound at a level which is audible to 

an adult cradling an infant but is not audible to any other adult within a 

1 meter radius of the user. 

(21) 588808 (22) 17 Apr 2009 

(54) MEDICATION DELIVERY DEVICE INCLUDING PISTON WITH TWO 

THREADED SECTIONS 

(86) PCT/EP2009/002806 (87) WO2009/132777 

(51) IPC2012.01:A61M5/24, 315 

(71) Sanofi-Aventis Deutschland GmbH 

(72) HARMS, Michael; RAAB, Steffen; WEBBER, Dominic, George; 

HOWARTH, James, Robert; BECKETT, Trevor, John; GRAY, Geoffrey, 

Philip; CROSS, John, David 

(31) 08008353.8 (32) 2 May 2008 (33) EP 



(57) A medication delivery device (1) comprising: a housing (3) having 

a proximal and a distal end, a medication receptacle (2) designed to 

be engaged with the housing, a piston rod (17) which is moveable in a 

distal direction for medication delivery and a drive device for rotating the 

piston rod in a first rotational direction and thereby moving the piston rod 

in the distal direction for medication delivery. The piston rod comprises 

two threaded sections (15, 16), wherein a first threaded section (15) 

is provided for threaded engagement with a reset element (11) and a 

second threaded section (16) is provided for threaded engagement with 

the drive device, the threads in the first and second threaded sections 

being oppositely disposed. In an operational state the reset element 

is prevented from rotation with respect to the housing, the piston rod 

being prevented from moving in a proximal direction, and in a resetting 

state the reset element is allowed to rotate with respect to the housing, 

the medication delivery device being resettable by rotating the piston 

rod and the reset element in a second rotational direction and thereby 

moving the piston rod in the proximal direction. 

(21) 588862 (22) 28 Apr 2009 

(54) CELLULOSIC AND LIGNOCELLULOSIC STRUCTURAL 

MATERIALS AND METHODS AND SYSTEMS FOR 

MANUFACTURING SUCH MATERIALS BY IRRADIATION 

(86) PCT/US2009/041942 (87) WO2009/140057 

(51) IPC2012.01:C12P7/10, 06, 16; C12P5/02 

(71) Xyleco, Inc. 

(72) MEDOFF, Marshall 

(31) 61/049,413 (32) 30 Apr 2008 (33) US 

(31) 61/049,404 (32) 30 Apr 2008 (33) US 

(31) 61/073,496 (32) 18 Jun 2008 (33) US 

(31) 12/417,880 (32) 3 Apr 2009 (33) US 

(31) 61/049,419 (32) 30 Apr 2008 (33) US 

(31) 61/049,415 (32) 30 Apr 2008 (33) US 



(57) Disclosed is a method comprising: quenching a biomass feedstock 

that has been irradiated with electron beam radiation to ionize the 

biomass feedstock so that the biomass feedstock has a first level of 

radicals, without dissolving the feedstock, to an extent that the quenched 

biomass feedstock has a second level of radicals lower than the first 

level, by contacting the biomass with a gas capable of reacting with 

the radicals, wherein the biomass feedstock comprises a cellulosic 

or lignocellulosic material. Also disclosed is a biomass feedstock 

processing system when used for performing the method comprising: 

an irradiating device configured to ionize a biomass feedstock so that 

the feedstock has a first level of radicals detectable with an electron spin 

resonance spectrometer; and a quenching device configured to quench 

the ionized biomass feedstock to an extent that the radicals are at a 

second level lower than the first level. 


(21) 588868 (22) 28 Apr 2009 

(54) PROCESSING BIOMASS 

(86) PCT/US2009/042000 (87) WO2009/134816 

(51) IPC2012.01:C12P7/06; C07H3/00; C12N1/20 


(72) MEDOFF, Marshall; MASTERMAN, Thomas, Craig 

(31) 61/049,407 (32) 30 Apr 2008 (33) US 

(31) 12/417,840 (32) 3 Apr 2009 (33) US 





(57) Disclosed is a method comprising: converting a low molecular weight 

sugar, said sugar being a carbohydrate or a derivative thereof in a 

mixture with a fibrous biomass, a microorganism, and water, to a 

product other than sugar, wherein the biomass comprises a cellulosic 

or lignocellulosic material and has been irradiated prior to mixing with 

the low molecular weight sugar, and wherein the converting comprises 

fermentation. 


(21) 588881 (22) 22 May 2009 

(54) INHALER FOR DISPENSING A MEDICAMENT POWDER 

(86) PCT/JP2009/059463 (87) WO2009/142306 

(51) IPC2012.01:A61M15/00; B01F7/20 

(71) OTSUKA PHARMACEUTICAL CO., LTD. 

(72) SATO, Tetsuya; NISHIBAYASHI, Toru; OGAWA, Yusuke; NAKAO, 

Takaaki; ADACHI, Shintaro 

(31) 2008-135494 (32) 23 May 2008 (33) JP 



(57) Disclosed is a powder inhaler which does not require shaking and can 

be efficiently operated. The powder inhaler is provided with a housing 

(1) equipped with an inhaling opening; a containing section provided in 

the housing and containing medicament powder (4); and a medicament 

conveying section provided in the housing. The medicament conveying 

section has at least one recess for receiving therein a predetermined 

amount of the medicament powder, and capable of taking, relative to the 

containing section, both a receiving position at which the medicament 

conveying section receives the medicament powder from the containing 

section and an inhaling position at which a user can inhale the 

medicament powder from the inhaling opening. A stirring member (7) is 

provided in the containing section for stirring the contained medicament 

powder. An operating button (3) is mounted to the housing and capable 

of moving between an initial position and a pushed-in position. When 

the operating button reciprocates between the initial position and the 

pushed-in position, the recess in the medicament conveying member 

moves from the receiving position to the inhaling position and, at the 

same time, the stirring member operates. 

(21) 588944 (22) 1 Apr 2009 

(54) INJECTOR PLUG ELECTRICAL PULSE AND VOLTAGE 

DIAGNOSTIC TESTER DETECTING POSITIVE AND NEGATIVE 

VOLTAGES 

(86) PCT/AU2009/000397 (87) WO2009/121134 

(51) IPC2012.01:G01M15/00, 04; G01M99/00 

(71) ERIC DAVID CUCKSON 

(72) CUCKSON, Eric, David 

(31) 2008901573 (32) 2 Apr 2008 (33) AU 

(31) 2008903667 (32) 17 Jul 2008 (33) AU 

(74) COLLISON & CO, 8th Floor, 117 King William Street, Adelaide, South 

Australia 5000, Australia 

(57) A diagnostic apparatus is disclosed that is adapted to indicate the 

presence or absence of both positive and negative voltages as well 

as electrical pulses when connected to the wiring of an injector plug. 

The diagnostic apparatus includes a hand held unit (12) with electronic 

circuitry (80) communicating with a first (22) and second (24) user 

viewable LEDs. The electronic circuitry (80) includes a positive electrical 

input point (82) connectable to a positive probe (16). The positive 

electrical input point (82) is connected to the anode terminal of the first 

LED (86) and the cathode terminal of the first LED is connected via 

a resistor (87) to an anode terminal of a first diode (92). The cathode 

terminal of the first diode is then connected to the negative clamp 

(20) of a power supply. The electronic circuitry (80) further includes a 

negative electrical input (84) connectable to a negative probe (14). The 

negative electrical input point (84) is connected to the cathode terminal 

of the second LED (88) and the anode terminal of the second LED is 

connected via a resistor (89) to the cathode terminal of a second diode 

(94). The anode terminal of the second diode is then connected to the 

positive clamp (18) of a power supply. When the engine is started the 

positive probe is placed upon one of the exposed wires of the injector 

plug thereby illuminating the first LED and the negative probe is placed 

upon another exposed wire at the back of the injector plug thereby 

illuminating the second LED. 

(21) 589027 (22) 26 May 2009 

(54) A process for making hydrophobic gypsum 

(86) PCT/EP2009/056349 (87) WO2009/150037 

(51) IPC2012.01:C04B20/10; C04B28/14; C04B40/00 

(71) Dow Corning Corporation 

(72) LECOMTE, Jean-Paul; SARRAZIN, Marie-Jose; GALLEZ, Laurence; 

THIBAUT, Marc 

(31) 0809526.7 (32) 27 May 2008 (33) GB 


Australia 

(57) A granulated additive for rendering gypsum material hydrophobic is 

disclosed, which comprises a particulate carrier on which is deposited 

an organosilicon component, a binder polymer and an emulsifier for the 

organosilicon component, wherein the components are agglomerated 

together in a single particle, the organosilicon component comprises 



alkoxysilyl groups and is free of organopolysiloxane having Si bonded 

hydrogen, the carrier particle is chosen amongst silicates, clay 

materials, calcium carbonates, calcium magnesium carbonate, methyl 

cellulose, carboxymethyl cellulose, polystyrene beads, sulphates, 

magnesium oxide, diatomite or calcinated diatomite and the weight ratio 

of binder versus organosilicon component is comprised between 10:100 

and 50:100. Preferably, the silicates are magnesium silicates selected 

from mica, talc, sepiolite, or silicate are calcium silicate selected from 

wollastonite, or phyllosilicates, or aluminosilicates selected from zeolite, 

metakaolin or fly ash, wherein said calcium magnesium carbonate is 

dolomite, wherein said sulphates are selected from sodium sulphate, 

calcium sulphate or magnesium sulphate; and wherein said carrier 

particle may further comprise calcinated rice, starch residues, rice hull 

ash, and/or stearates; and preferably the emulsifier and the binder is 

polyvinyl alcohol. 

(21) 589028 (22) 4 May 2009 

(54) SYSTEMIC MITIGATION OF ENVIRONMENTAL STRESS ON 

PLANTS AND THE FRUIT THEREOF 

(86) PCT/US2009/002738 (87) WO2009/137012 

(51) IPC2012.01:A01N31/02; A01N43/16; A01N25/30 

(71) Aquatrols Corporation of America 

(72) KOSTKA, Stanley, J 

(31) 12/386,395 (32) 17 Apr 2009 (33) US 

(31) 61/126,973 (32) 8 May 2008 (33) US 



(57) A method for systemically mitigating environmental stress from heat 

or radiation on a fruit plant and the pre-harvested fruit thereof is 

disclosed, wherein the method comprises the steps of:(i) preparing 

an agricultural composition wherein said composition comprises an 

active selected from the group consisting of ethylene oxide-propylene 

oxide block copolymer, C1-C4 alkyl ether of ethylene oxide-propylene 

oxide block copolymer, alkylpolyglycoside, and mixtures thereof; and (ii) 

intimately contacting root zone soil of the soil in which the fruit plant 

is growing with a bioefficaciously effective amount of said agricultural 

composition to systemically mitigate environmental stress on the plant 

and the pre-harvested fruit thereof from heat or radiation impacting 

the surface of the plant or fruit above the surface of the soil. The 

method may further comprise the additional step of: applying a climateameliorating 

product to the plant and/or pre-harvested fruit that reduces 

the amount of heat and/or radiation impacting the surface of the 

plant or fruit above the surface of the soil, wherein the most effective 

measures include evaporative cooling with water, and the use of 

sunburn protective coatings also known as particle film technology 

(PFT), bagging, reflective fabric, and shade netting. The method is 

especially bioefficacious on crops such as apples and grapes, an 

is also very useful in all crops where heat stress and/or sunburn 

may impact plant productivity and fruit quality, which include citrus 

fruits (including oranges, lemons, limes, grapefruit), solanaceous plants 

(including tomatoes and peppers), cucurbits (including cucumbers, 

squash, pumpkin, rock melon, honeydew melon, watermelon, and 

cantaloupe), stone fruits (such as peaches, cherries, nectarines, 

almonds, and plums), strawberries, raspberries, blueberries, and olives; 

and tropical crop such as avocados, bananas, mangos, and pineapple. 

(21) 589030 (22) 29 May 2009 

(54) METHOD FOR PRODUCING A CASEIN HYDROLYSATE 

(86) PCT/EP2009/056644 (87) WO2009/147105 

(51) IPC2012.01:C12N9/52; A23J3/34 

(71) NOVOZYMES A/S 

(72) LYNGLEV, Gitte, B; NIELSEN, Per Munk 

(31) 08157453.5 (32) 3 Jun 2008 (33) EP 



(57) Disclosed is a method for producing a casein hydrolysate, comprising: 

a) adding to a composition comprising from about 5% to about 25% 

casein an endopeptidase having at least 70% identity to SEQ ID NO: 1; 

and b) incubating so as to hydrolyse the casein. Also disclosed is the 

use of a casein hydrolysate produced by the method and the use of a 

casein hydrolysate in a food product. 

(21) 589185 (22) 27 May 2009 

(54) DOSING DEVICE INCLUDING TOP AND BOTTOM ROTARY DISKS 

AND A MIXING CHAMBER 

(86) PCT/EP2009/056421 (87) WO2009/144239 

(51) IPC2012.01:A47J31/40 

(71) Nestec S.A. 

(72) BERNHARDSGRUETTER, Raphael; BEAUSIRE, Cedric; 

SCORRANO, Lucio 

(31) 08157212.5 (32) 29 May 2008 (33) EP 



(57) A beverage preparation apparatus comprising: a storing powder 

soluble food ingredient container; a mixing chamber (17); and a dosing 

device for dosing a metered amount of a powdered product. The dosing 

device comprises: a fixed body (2) made of at least a disc presenting 

a single pierced aperture (5); a rotary top disk (1) disposed on the top 

of the fixed body and presenting a taking out pierced aperture; a rotary 

bottom disk (3) disposed on the bottom of the fixed body and presenting 

a discharging pierced aperture (6); and a rotary shaft (7) connecting the 

bottom disk and the top disk. In the stand-by position of the device the 

metered pierced aperture is empty and closed to the atmosphere. 

(21) 589278 (22) 1 Mar 2006 

(54) Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine 

derivatives 

(51) IPC2012.01:C07D401/04; A61K31/473; A61P11/08 

(71) Nycomed GmbH 

(72) Kautz, Ulrich; Webel, Matthias; Scheufler, Christian; Hummel, Rolf- 

Peter 

(31) 05101619.4 (32) 2 Mar 2005 (33) EP 

(31) 05108442.4 (32) 14 Sep 2005 (33) EP 



(57) Disclosed are salts of (2R,4aR,10bR)-6-(2,6-Dimethoxy-pyridin-3yl)-9-ethoxy-8-methoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-2-ol 

selected form the group consisting of fumarate; methansulfonate; 

edisilate; esilate; hydrobromide and tosylate, which are suitable for 

treating PDE4-mediated disorders such as diabetes mellitus, psoriasis 

and atopic eczema. 


(21) 589307 (22) 29 Apr 2009 

(54) COMPOSITIONS COMPRISING BACLOGEN OR TERBINAFINE 

FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS 

THROUGH A MODULATION OF ANGIOGENESIS 

(86) PCT/EP2009/055205 (87) WO2009/133141 

(51) IPC2012.01:A61K45/06; A61P25/28 

(71) Pharnext 

(72) COHEN, Daniel; CHUMAKOV, Ilya; NABIROCHKIN, Serguei; 

GUERASSIMENKO, Oxana; GRAUDENS, Esther 

(31) 61/048,583 (32) 29 Apr 2008 (33) US 

(74) Jane Pairman, 50A Dyers Pass Road, Cashmere, Christchurch, New 

Zealand 



(57) Disclosed is the use of a composition comprising baclofen or a 

salt, or sustained release formulation thereof, in the manufacture of a 

medicament for the treatment of Alzheimer’s disease. 

(21) 589323 (22) 24 Apr 2009 

(54) POLYMERIC ARTIFICIAL TEAR SYSTEM 

(86) PCT/US2009/041699 (87) WO2009/132294 

(51) IPC2012.01:A61K9/08; A61K47/02, 10, 36 

(71) Alcon Research, Ltd 

(72) KETELSON, Howard, Allen; DAVIS, James, W; MEADOWS, David, L 

(31) 61/048,175 (32) 26 Apr 2008 (33) US 



(57) The disclosure relates to artificial tear formulations and ophthalmic 

formulations suitable for drug delivery. The ophthalmic formulation 

comprises a galactomannan such as guar or hydroxypropyl guar, a 

borate source such as boric acid, and a cis-diol, said formulation 

having divalent cation concentrations of less than 5ppm and wherein 

said galactomannan is present at a concentration of 0.16 w/v% 

to 0.19 w/v% and said borate is present at a concentration of 

0.7 w/v%; wherein said cis-diol may be selected from the group 

consisting of sorbitol, mannitol, polyethylene glycols, polypropylene 

glycols, polyethyleneoxide-polybutyleneoxide block copolymers, and 

combinations thereof; and wherein said formulation may further 

comprise a demulcent selected from the group consisting of: 

glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, 

propylene glycol, polyacrylic acid, and combinations thereof. 

(21) 589351 (22) 18 Nov 2010 

(54) A retractable screen with a break system so the screen may be held 

at any point along its extent 

(51) IPC2012.01:E06B9/52, 54, 56, 58, 78, 60, 24, 40, 42, 34 

(71) Freedom Screens of Australia Pty Ltd (ACN093 847 388) 

(72) ROBERTS, Anthony Gerard 

(31) 2009905623 (32) 18 Nov 2009 (33) AU 



(57) A retractable screen (10) for extending across an architectural 

opening is disclosed. The retractable screen includes a fixed side having 

a fixed screen post (12). A displaceable handle post with an upper 

region and a lower region can move away from the fixed side towards 

a closed position, and move towards the fixed side back into an open 

position. At least one of an upper guide track and a lower guide track 

(18) engages with the upper or lower region of the handle post and 

guides the movement of the handle post between the open and closed 

positions. The retractable screen further includes a flexible sheet mesh 

(24) extending between the fixed side and the displaceable handle 

post. Since the screen is biased to rewind into the fixed screen post, a 

brake arrangement is supplied so that the movable handle post can be 

stopped and retained in any desired position between the open and the 

closed positions. The brake includes at least one brake assembly that is 

displaced into engagement with said at least one of the upper or lower 

(18) guide tracks to apply a braking action to the handle post. 

(21) 589368 (22) 11 Mar 2009 

(54) A syringe cartridge applicator with a syringe cap removal mechanism 

that operates on advance of a syringe 

(51) IPC2012.01:A61M5/24, 28, 20 

(71) Merial Limited 

(72) Holmes, Robert William Lachlan; Walker, Rodney Gordon; Ebbett, 

Todd Donald; Standing, Colin Anthony; WIlliams, Peter Robert; Ciampa, 

Giovanni; Rossingnuolo, Michael; Smith, Robert John 


Australia 

(57) A syringe cartridge holding assembly is disclosed. The assembly 

is used as a component in a syringe cartridge applicator (300). The 

assembly has a pair of opposing side walls having a cap removing 

means (302) thereon which is adapted to remove a protective cap from 

a syringe cartridge by contacting one or more protruding shoulders of 

the protective cap as the syringe cartridge is moved by the applicator 

into a dispensing position. 


(21) 589419 (22) 29 Jun 2009 

(54) Compositions comprising an ultraviolet radiation-absorbing polymer 

(51) IPC7:A61K7/42 

(71) JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 

(72) COLE, Curtis; CLEMENTE, Rudy; HILL, Gregory, A.; PALUSAK, 

Ryan; ZANINI, Diana 

(31) 61/076927 (32) 30 Jun 2008 (33) US 

(31) 12/491048 (32) 24 Jun 2009 (33) US 

(31) 12/491057 (32) 24 Jun 2009 (33) US 

(31) 12/491064 (32) 24 Jun 2009 (33) US 





(57) Disclosed is a UV-absorbing polymer, said UV-absorbing polymer 

comprising the polymerization reaction product of: a first ethylenically 

unsaturated monomer comprising a first pendant group that comprises 

a UV -absorbing moiety, and a second pendant group selected 

from the group consisting of H, or C1 to C12 alkyl; and 

a second ethylenically unsaturated monomer selected from the 

group consisting of monomethacryloxypropyl polydimethylsiloxane and 

methacryloxypropyl trimethoxysilane, wherein the number of repeat 

units of said first reacted monomer per molecule is from about 1 to 

about 6000 and the number of repeating units of said second reacted 

monomer per molecule is from about 2 to about 6300, said UVabsorbing 

polymer having a weight average molecular weight of at least 

2000 and comprising at least 5 mole per cent of said first pendant 

group. Also disclosed is the UV absorbing polymer in a blend including a 

second UV absorbing polymer wherein the blend is capable of providing 

both synergistic SPF and PFA protection over a mass per cent range 

of the first and second UV absorbing polymers of at least 40 per cent. 

Also disclosed is a method of protecting mammalian skin or hair from UV 

radiation comprising topically applying the composition to skin or hair as 

a sunscreen or sunblock. 


(21) 589433 (22) 22 Nov 2010 

(54) Low density ammonium nitrate fuel oil (ANFO) emulsion 

(51) IPC2012.01:C06B31/28 

(71) INDUSTRIAS MINCO S.A.C. 

(72) PEREZ CORDOVA, Pio Francisco; CARDENAS LOPEZ, Luis Alfredo 

(31) 001267-2009/DIN (32) 23 Nov 2009 (33) PE 



(57) A non-explosive emulsion having a density between 1.30 g/cm3 

and 1.40 g/cm3 that is selectively activated by a gas-producing agent 

resulting in an explosive emulsion having a density between 0.5 g/cm3 

and 0.90 g/cm3. The non-explosive emulsion consists essentially of 

between 84 percent and 95 percent by weight of an oxidizing solution 

and between 5 percent and 16 percent by weight of a fuel solution. 

The fuel solution includes steric acid to prevent the combination of 

the resulting nitrogen bubbles The oxidising solution consists of: 60-80 

percent by weight of ammonium nitrate, 2-16 percent by weight of 

sodium nitrate, 0.1-2 percent by weight of thiourea, 14-22 percent by 

weight of water and 2-12 percent by weight of urea. The fuel solution 

consists of: 10-30 percent by weight of an emulsifier, 10-40 percent by 

weight of oil, 10-70 percent by weight of diesel No. 2 fuel, 0.1-10 percent 

by weight of solid cacao fat and 0.1-30 percent by weight of stearic acid. 

(21) 589501 (22) 20 May 2009 

(54) SHELL AND TUBE HEAT EXCHANGER WITH SPIRAL BAFFLES 

FIXED AT MULTIPLE HELICAL ANGLES 

(86) PCT/US2009/044605 (87) WO2009/148822 

(51) IPC2012.01:F28D7/00, 02, 16; F28F9/22 

(71) Lummus Technology Inc 

(72) KARRS, Mark, S.; CHUNANGAD, Krishnan, S.; MASTER, Bashir, I. 

(31) 12/133,917 (32) 5 Jun 2008 (33) US 



(57) A shell and tube heat exchanger with a shell having a fluid inlet and a 

fluid outlet; a plurality of baffles mounted in the shell to guide the fluid into 

a helical spiral flow pattern through the shell; wherein the first helix angle 

a of the baffle next to the inlet is different than the second helix angle 

b of a baffle next the outlet. At least one tube passes through the shell 

with a second fluid flowing through to receive heat from the first fluid in 

the shell. The first helix angle can be larger or smaller than the second 

helix angle. The spiral baffles midway can have a third intermediate helix 

angle that is between the first and second helix angles. 

(21) 589505 (22) 26 May 2009 

(54) METHODS AND COMPOSITIONS FOR IMPROVING STRESS 

TOLERANCE IN PLANTS 

(86) PCT/NZ2009/000090 (87) WO2009/145645 

(51) IPC2012.01:C12N15/29, 82; A01H5/00 

(71) VIALACTIA BIOSCIENCES (NZ) LIMITED 

(72) PUTHIGAE, Sathish; BISWAS, Margaret; BRYANT, Catherine, Jane; 

BAJAJ, Shivendra; TEMPLETON, Kerry, Robert 

(31) 61/056,583 (32) 28 May 2008 (33) US 



(57) Provided is an isolated polynucleotide or a variant thereof comprising 

a sequence with at least 97% identity to it and encoding a polypeptide 

capable of modulating in a plant tolerance to at least one environmental 

stress selected from drought, cold, freezing, heat and salinity, wherein 

% identity is calculated over the whole length of the sequence. 

Further provided are corresponding expression vectors and methods of 

transforming plants for tolerance to environmental stresses and plants 

obtained by the methods. 

(21) 589511 (22) 24 Nov 2010 

(54) FIBRE-REINFORCED PLASTIC MATERIAL WITH FILLING PIECES 

BETWEEN FIBRES FOR HIGHEST POSSIBLE PACKING DENSITY 

WHILE AVOIDING FRETTING 

(51) IPC2012.01:B29C70/02, 10; B29B15/08 

(71) SIEMENS AKTIENGESELLSCHAFT 

(72) GROVE-NIELSEN, Erik; WINTHER-JENSEN, Martin 

(31) EP09014906 (32) 1 Dec 2009 (33) EP 



(57) Fibre-reinforced plastic materials have matrix material 3 and fibres 

1 which are embedded in the matrix material 3. Fibre spacers 4 are 

embedded between the fibres 1 to avoid direct fibre-to-fibre contacts. 

(21) 589545 (22) 1 Jun 2009 



(54) DECORATIVE COMPOSITION COMPRISING GREATER THAN 

50% FILLER, A POLYMERIC RESIN AND A COALESCENT ESTER 

ALCOHOL SOVENT 

(86) PCT/US2009/045780 (87) WO2009/148986 

(51) IPC2012.01:C09D1/00; C09D7/12; C09D175/04; C09D201/00; 

C07C69/003, 30 

(71) United States Gypsum Company 

(72) BURY, Rafael; LI, Donghong 

(31) 12/132,204 (32) 3 Jun 2008 (33) US 

(74) CreateIP, 20 Bealey Avenue, Merivale, Christchurch, New Zealand 

(57) Disclosed is a decorative composition which comprises: a) a 

first filler selected from the group consisting of calcium carbonate, 

limestone, gypsum, nepheline syenites, titanium dioxides, lithophones, 

wollastonites, bismuth oxychlorides, talc, clays and mixtures thereof in 

an amount of at least 50% by weight; b) a polymeric resin selected from 

the group consisting of an acrylic latex emulsion, a vinyl/acrylic latex 

emulsion, a styrene/acrylic latex emulsion, a polyurethane and mixtures 

thereof; c) an ester alcohol solvent (such as texanol - 2,2,4-trimethyl-1,3pentanediol 

monoisobutyrate) for film-formation of said polymeric resin; 

and d) water in amounts of about 10% to about 50% by weight, wherein 

said decorative composition is free of hydraulic components selected 

from one or more cementatious materials. 

(21) 589574 (22) 26 May 2009 

(54) SALTS AND POLYMORPHS OF A TETRACYCLINE COMPOUND 

(86) PCT/US2009/045143 (87) WO2009/143509 

(51) IPC2012.01:A01N37/18 

(71) Paratek Pharmaceuticals, Inc. 

(72) CVETOVICH, Raymond; WARCHOL, Tadeusz 

(31) 61/128,712 (32) 23 May 2008 (33) US 



(57) Disclosed is a tosylate salt of an aminoalkyl tetracycline 

compound (4S,4AS,5AR,12AS)-4-7-Bis(dimethylamino)-9 {[(2,2dimethylpropyl)amino]methyl}-3,10,12,12A-tetrahydroxy-1,11dioxo-1,4,4A,5,5A,6,11,12A-octahydrotetracene-2-carboxamide 

(9- 

(2,2-dimethyl-propyl-aminomethyl)-minocycline) and a crystalline form 

of said tosylate salt. A polymorph of the crystalline form of this compound 

having an X-ray powder diffraction pattern with preaks at approximately 

8.06, 13.02 and 18.83 2 degrees theta, is also disclosed. Also disclosed 

is a method for preparing the above mentioned crystalline tosylate salt. 


(21) 589585 (22) 3 Jun 2009 

(54) STACKABLE TWIN SEPARABLE EGG PACKAGING UNIT WITH 

HINGED LID 

(86) PCT/NL2009/050306 (87) WO2009/148310 

(51) IPC2012.01:B65D85/32; D21J3/10 

(71) HUHTAMAKI NEDERLAND B.V. 

(72) Dijkstra, Wijbe; Kloosterman, Hendrik Freerk; Niemarkt, Christian 

(31) 08157501.1 (32) 3 Jun 2008 (33) EP 



(57) A pair set of mutually connected packaging units or cartons for eggs 

or similar fragile articles such as kiwifruit, made of moulded paper 

pulp and each packaging unit comprising: a bottom part comprising 

compartments that match the contours of the articles contained within 

said unit; a cover lid comprising a top surface and substantially planar 

or flat front- and rear surfaces and side end surfaces, said cover part 

being a rectangular shape with rounded comers hinged to the bottom 

part, with bridges containing a compressed higher density band of 3-10 

mm width and with a thickness of 30-70% compared to the rest of the 

bridge, connecting the pair of packaging units either on the lid or the 

bottom part or both parts. The packaging unit is made in a pre-mould 

from pulp and squeezed to form the shape. A raised or elevated ridge or 

region extends to a height of 0.3-0.6 mm above the mould wall to form 

the compressed bridge. 

(21) 589593 (22) 26 May 2009 

(54) C-ring-substituted pregn-4-ene-21,17-carbolactones,and 

pharmaceutical products comprising the same 

(86) PCT/EP2009/003716 (87) WO2009/146811 

(51) IPC2012.01:C07J53/00; A61K31/58, 585; A61P5/28, 34, 42 


(72) RING, Sven; BOHLMANN, Rolf; KUHNKE, Joachim; ZORN, Ludwig; 

BORDEN, Steffen; PRELLE, Katja 

(31) 10 2008 026 793.7 (32) 2 Jun 2008 (33) DE 


(57) Disclosed are pregn-4-ene-21,17-carbolactones of the general 

formula I, in which R6,7 is an a or b-methylene 

group and R9 is hydrogen and R11 is bromine, chlorine 

or fluorine; or R9 and R11 together are a bond. 

Representative compounds include 6b,7b;15b,16b-dimethylene-3oxo-17-pregna-4,9(11)-diene-21,17b-carbolactone,11bchloro-6b,7b;15b,16b-dimethylene-3-oxo-17-pregn-4-ene-21,17bcarbolactone,6b,7b;15b,16b-dimethylene-11b-fluoro-3-oxo-17pregn-4-ene-21,17b-carbolactone 

and 6a,7a;15b,16bdimethylene-11b-fluoro-3-oxo-17-pregn-4-ene-21,17b-carbolactone. 

Further disclosed is 11a-hydroxy-15b,16b-methyleneandrost-4ene-3,17-dione 

as a starting compound for preparing the compounds 

of the general formula I as defined above. Also disclosed are 

pharmaceutical products which comprise at least one compound as 

defined above, and a pharmaceutically acceptable carrier. 

(21) 589649 (22) 14 Oct 2005 

(54) ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE 

SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR 

TREATING DISORDERS THAT RESPOND TO MODULATION OF 

THE DOPAMINE D3 RECEPTOR 

(51) IPC2012.01:A61P25/16; C07D215/38; C07C211/19; C07D311/04; 

A61K31/47, 13, 35 

(71) Abbott GmbH & Co. KG 



(72) Drescher, Karla; Haupt, Andreas; Unger, Liliane; Turner, Sean, C.; 

Braje, Wilfried; Grandel, Roland; Henry, Christophe 

(31) 618776 (32) 14 Oct 2004 (33) US 

(31) 711942 (32) 26 Aug 2005 (33) US 



(57) Disclosed are aromatic sulfonyl compounds of formula I, 

being either arylsulfonylmethyl or arylsulfonamide compounds, and 

methods for their preparation. The compounds are dopamine 

D3 receptor ligands. Specific examples of compounds of 

formula I are: 4-Isopropyl-N-((R)-6-propylamino-5,6,7,8-tetrahydronaphthalen-2-yl)-benzenesulfonamide,(R)-N-[5-(4-Isopropylbenzenesulfonylamino)-1,2,3,4-tetrahydro-naphthalen-2-yl]propionamide,N-((S)-6-Allylamino-5,6,7,8-tetrahydro-naphthalen-2yl)-4-isopropylbenzenesulfonamide, 

hydrochloride, and N-[3-(4- 

Trifluoromethoxy-benzenesulfonylamino)-5,6,7,8-tetrahydroquinolin-7-yl]-propionamide. 

Also disclosed is the use of compounds of 

formula I for treating central nervous system diseases such as addiction. 


(21) 589682 (22) 2 Dec 2010 

(54) Apparatus for generating electric power using wind energy where 

each wind collecting blade has a movable auxilliary plate contained 

therein 

(51) IPC2012.01:F03D1/04, 06; F03D11/02 

(71) FUNG GIN DA ENERGY SCIENCE AND TECHNOLOGY CO. LTD. 

(72) Chung, Chun-Neng 

(31) 098141529 (32) 4 Dec 2009 (33) TW 



(57) An apparatus for generating electric power from wind energy is 

disclosed. The apparatus comprises: a base; a blade device; at least 

one blade unit; a generator; and a wind collecting unit mounted on 

the base. The blade device includes an upright rod extending vertically 

along a pivot axis and has a lower end disposed pivotally in the base. At 

least one blade unit has a plurality of upright blades connected directly 

and fixedly to the upright rod such that the blade device is rotatable 

relative to the base about the pivot axis so as to convert wind energy 

into a mechanical rotary power output. Each of the blades of the blade 

unit have opposite first and second side surfaces, and a plurality of first 

wind-collecting ribs extend vertically from the first side surface, spaced 

apart from each other such that a wind-collecting space is defined 

between any two adjacent ones of the first wind-collecting ribs. The wind 

collecting ribs have a thickness that increases gradually toward the first 

side surface where the first side surface of each of the blades of the 

blade unit face the second side surface of an adjacent one of the blades. 

The generator is disposed in the base and coupled to the lower end 

of the upright rod of the blade device to convert the mechanical rotary 

power output into electric power. The wind-collecting unit is mounted on 

the base and includes a plurality of upright plates angularly equidistant 

and disposed around the blade device where any two adjacent ones of 

the upright plates define an inwardly converging wind-guiding channel 

therebetween. The upright plates of the wind-collecting unit are non-flat 

so that wind is guided by the upright plates of the wind-collecting unit 

to blow onto the first side surfaces of the blades of the blade unit of the 

blade device via the wind-guiding channels in the wind-collecting unit. 

(21) 589711 (22) 15 Jul 2009 

(54) Au-Ga-In brazing filler metal 

(86) PCT/JP2009/062793 (87) WO2010/010833 

(51) IPC2012.01:B23K35/30; C22C5/02; H01L23/02 

(71) TANAKA KIKINZOKU KOGYO K.K. 

(72) TANIGUCHI, Hiroyasu; SHIMADA, Tomohiro; MIYAZAKI, Kenichi 

(31) 2008-191192 (32) 24 Jul 2008 (33) JP 



(57) Disclosed is a brazing material comprising a gold-gallium-indium (Au- 

Ga-In) alloy, where the weight concentrations of each metal falls within 

a region of a polygon with a point A (Au: 90%, Ga: 10%, In: 0%), a point 

B (Au: 70%, Ga: 30%, In: 0%), a point C (Au: 60%, Ga: 0%, In: 40%) 

and a point D (Au: 80%, Ga: 0%, In: 20%) as vertexes (excluding lines 

on which In and Ga become 0%), in a Au-Ga-In ternary phase diagram, 

as shown within the shaded area of Fig 1 and that the brazing material 

contains a non-zero amount of each metal. 

(21) 589747 (22) 19 May 2009 

(54) Fluid container with a magnetic coupling device at the bottom 

(86) PCT/US2009/044534 (87) WO2009/143164 

(51) IPC2012.01:B65B3/04 

(71) Grinon Industries 

(72) SPRINGER, Josh 

(31) 61/054,686 (32) 20 May 2008 (33) US 

(31) 61/154,726 (32) 23 Feb 2009 (33) US 



(57) A fluid container 102, 300, comprising a rim defining an open top 

of the container 102, 300, an opening 302 in a bottom surface of the 



container 102, 300, and a coupling device connected to the bottom 

surface of the container 102, 300 around the opening 302. The coupling 

device includes a first component 306 in contact with the bottom surface 

of the container 102, 300 around the opening 302, and a second 

component 304 in contact with the first component 306 in a fluid – 

tight closed configuration. Both the first and second components include 

a magnetic material. A top surface of the second component 304 is 

viewable from a top of the container 102, 300 and includes a personal 

or commercial message. The coupling device is biased in the fluidtight 

closed configuration by the magnetic attraction between the first 

component 306 and the second component 304. 


(21) 589751 (22) 7 Dec 2010 

(54) A cap that adjusts for different head sizes without deformation or 

puckering 

(51) IPC2012.01:A42B1/00, 22, 04, 06; A42C1/00; A42C5/02 

(71) Yupoong, Inc. 

(72) Cho, Byoung-Woo 

(31) 10-2010-0055625 (32) 11 Jun 2010 (33) KR 

(74) Golja Haines & Friend, Suite 1, 43 Oxford Close, West Leederville, 

WA 6007, Australia 

(57) A cap (100) with a head receiving portion stretchable along at least 

one direction is disclosed. A sweat absorbing member (105) is disposed 

along a lower edge of the head receiving portion, to absorb sweat from 

the forehead and is stretchable along the head circumferential direction 

of the head receiving portion. The sweat absorbing member comprises 

a non-stretchable added portion at a location that corresponds to the 

forehead of a wearer. The head receiving portion includes at its lower 

edge a first stitch having an upper line and two lower lines. The upper 

line is formed of a non-stretchable yarn and formed of stitches arranged 

in one line with predetermined intervals between them. The first and 

second lower lines are connected to each other and the upper line in 

a loop shape. 

(21) 589774 (22) 12 May 2009 

(54) CARBONIZATION METHOD AND DEVICE 

(86) PCT/FR2009/050867 (87) WO2009/147346 

(51) IPC2012.01:C10B53/02; C01B31/08; C10B49/02 

(71) Carbonex Societe a responsabilite limitee 

(72) SOLER-MY, Pierre; LOISEAU, Arnaud; SOLER-MY, Philippe 

(31) 08 53093 (32) 13 May 2008 (33) FR 



(57) A process for manufacturing charcoal or/and activated carbon from 

a wood load, characterized in that: - said load is placed in at least one 

basket in a sealed device between a first upstream chamber and a 

second downstream chamber; - via at least one heating means external 

to said load, first non-oxidizing hot fuel gases are generated that do 

not comprise oxygen in gaseous form O2, - these first hot fuel gases 

are introduced into a mixing chamber; - in this mixing chamber said 

first hot fuel gases are mixed with second dilution gases, in order to 

form a mixture of non-oxidizing incoming gases that do not comprise 

oxygen in gaseous form O2; - said mixture of incoming gases is sent 

upstream into said load in order to generate therein a pyrolysis front; - an 

overpressure is created between the upstream end and the downstream 

end of said load in order to force said pyrolysis front to pass through 

it in a single direction from the upstream end to the downstream end; 

and - downstream of said load third exiting gases are recovered, at least 

a first portion of which is transported, directly into the mixing chamber 

by a transportation means, in the form of a flow of said second dilution 

gases in order to be mixed with said first hot fuel gases, and a second 

portion of which complementary to the first portion is discharged in the 

form of a flow of fourth service gases by a transportation means to an 

outlet orifice. 

(21) 589785 (22) 4 Jun 2008 

(54) INLINE PNEUMATIC VENTURI EVACUATION PUMP WITH TIMING 

CONTROL UNIT FOR MOVING SOLID AND LIQUID MIXTURES 

(86) PCT/AU2008/000800 (87) WO2009/146479 

(51) IPC2012.01:F04F1/02; B65G53/10, 14, 28, 50; B65G65/40; 

F04F5/20, 24 

(71) Tyco Flow Services AG 

(72) KROHN, Mark 



(57) A pneumatic evacuation pump including an inlet assembly having 

a pneumatically operated inlet knife-gate valve interposed between 

an inlet accepting material from a material supply and a charging 

port and selectively operable purge air injection port angled to the 

axis of the charging port to directly inject air downstream, located on 

the charging port side of the inlet valve; a chamber using standard 

pipe sections of selectable length and substantially constant cross 

section and having a charge end opening to said charging port and 

a discharge end; and a delivery assembly having a passage opening 

to said discharge end and extending to a delivery outlet, a delivery 

valve interposed in said passage between said discharge end and said 

delivery outlet, a selectively operable, venturi vacuum source opening to 

said passage between said discharge valve and said discharge end, and 

selectively operable exhaust air injection means located downstream 

of said discharge valve and utilizing exhaust air from said venturi; a 

compressed air supply supplying said venturi and said purge air injection 

means; and control means acting to coordinate a cycle of operation 

of said venture vacuum source, said purge air injection means, said 

exhaust air injection means and said inlet and delivery valves. Pipe 



joints are sealed using pipe collar clamps. The control means is 

selected from a timed-cycle or condition-responsive software loaded in 

a programmable logic controller operating the pneumatic valves. 

(21) 589820 (22) 28 Apr 2006 

(54) ANTI-IL6 ANTIBODIES, COMPOSITIONS, METHODS AND USES 

(51) IPC2012.01:C07H21/04; A61K39/395; C07K16/24 

(71) CENTOCOR, INC.; APPLIED MOLECULAR EVOLUTION, INC. 

(72) CHEN, Yan; GARDENER, Debra; KNIGHT, David M; LARK, Michael 

W; LIANG, Bailin; SHEALY, David J; SONG, Xiao-Yu R; STOJANOVIC- 

SUSULIC, Vedrana; SWEET, Raymond W; TAM, Susan; WU, Sheng- 

Jiun; YANG, Jing; MARQUIS, David Matthew; SMITH, Eric Michael; 

VASSEROT, Alain Philippe 

(31) 60/676,498 (32) 29 Apr 2005 (33) US 

(31) 60/677,319 (32) 3 May 2005 (33) US 



(57) Provided is an isolated nucleic acid molecule encoding an IL-6 

antibody, comprising a specified nucleotide sequence or corresponding 

specified nucleotide motifs for the light and heavy chain three CDRs. 

Further provided are corresponding expression vectors, host cells with 

the vectors and methods of producing the antibody. 


(21) 589851 (22) 15 Jul 2009 

(54) Cooling and grinding lignocellulosic biomass material for enzymatic 

fermentation to ethanol 

(86) PCT/US2009/050705 (87) WO2010/009240 

(51) IPC2012.01:C10L5/00, 44; C12P7/10 


(72) MEDOFF, Marshall 

(31) 61/081,709 (32) 17 Jul 2008 (33) US 



(57) A method comprising: processing an embrittled material to make 

a product that is chemically different from the embrittled material, the 

embrittled material having been produced by treating a biomass material 

to embrittle the biomass material, wherein treating comprises irradiating 

the biomass material with electron beam irradiation, wherein treating 

also comprises cooling the biomass material, simultaneous grinding 

or comminuting while cooling the biomass may also be performed 

in a freeze grinding or freeze milling device, and wherein cooling is 

performed prior to irradiating; thereby reducing the recalcitrance of the 

material. The biomass material comprises a lignocellulosic material, 

and the method further comprises separating lignin from cellulose. Said 

processing of the material can further comprise contacting the material 

with an enzyme and/or a microorganism, or the material comprises 

cellulose and the method comprises utilizing an enzyme to saccharify 

the cellulose, the saccharified material can then be converted to a 

product, e.g., fermented to ethanol. 


(21) 589909 (22) 25 Jun 2009 

(54) Piperidinyl derivative as a modulator of chemokine receptor activity 

(86) PCT/US2009/048564 (87) WO2009/158452 

(51) IPC2012.01:C07D211/52; A61K31/451; A61P19/02 


(72) SANTELLA, Joseph, B 

(31) : 61/075,394 (32) 25 Jun 2008 (33) US 

(31) 12/490,477 (32) 24 Jun 2009 (33) US 



(57) Disclosed are compounds of formula (I), pharmaceutically 

acceptable salt forms thereof, and methods for their preparation. The 

compounds of formula (I) are used in the modulation of chemokine 

(chemotactic cytokines) or chemokine receptor activity such as 

CCR-1 or CCR-1 receptor activity. They can be used for treating a 

disorder selected from osteoarthritis, aneurysm, fever, cardiovascular 

effects, Crohn’s disease, congestive heart failure, autoimmune 

diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic 

pulmonary fibrosis, transplant arteriosclerosis, physically- or chemicallyinduced 

brain trauma, neuropathic pain, inflammatory bowel disease, 

alveolitis, ulcerative colitis, systemic lupus erythematosus, nephrotoxic 

serum nephritis, glomerulonephritis, asthma, multiple sclerosis, 

arthrosclerosis, rheumatoid arthritis, restenosis, organ transplantation, 

multiple myeloma, colorectal cancer, hepatocellular cancer and other 

cancers. 

(21) 589914 (22) 13 Dec 2010 

(54) An antenna isolation circuit and a meter including the antenna 

isolation circuit 

(51) IPC2012.01:H01Q1/52; G01R11/48; G08B1/08 

(71) ELSTER SOLUTIONS, LLC 

(72) Ellsworth, Thomas B 

(31) 12/689316 (32) 19 Jan 2010 (33) US 



(57) An antenna isolation circuit and a meter device having an antenna 

isolation circuit is disclosed. The antenna isolation circuit comprises: 

a multilayer planar structure comprising at least two conductive layers 

separated from one another by a dielectric material; (b) a first radio 

frequency port electrically connected to the multilayer planar structure 

where the first radio frequency port is electrically connected to an 

antenna; (c) a second radio frequency port electrically connected to the 

multilayer planar structure where the second radio frequency port is 

electrically connected to a radio circuit receiving power from a power 

source; and (d) a distributed circuit element electrically connected to the 

first radio frequency port and to the second radio frequency port and 

comprising at least some of the conductive layers of the multilayer planar 

structure. The distributed circuit element electrically isolates the antenna 

from the power source when the antenna is electrically connected to the 

first radio frequency port and the radio circuit is electrically connected 

to the second radio frequency port. 

(21) 589922 (22) 10 Apr 2006 



(54) Dietary supplement comprising dietary fibre, glucomannan and 

xanthan gum and methods of use 

(51) IPC2012.01:A23L1/308; A61K31/723, 736; A61P3/00 

(71) InovoBiologic, Inc. 

(72) GAHLER, Roland J.; LYON, Michael; LEE, Nicole 

(31) USSN: 60/670,944 (32) 12 Apr 2005 (33) US 



(57) Provided is a food product comprising from about 2% to about 10% 

(w/w) of a dietary fibre composition comprising from about 48% to about 

90% 5 (w/w) glucomannan, from about 5% to about 20% (w/w) xanthan 

gum, and from about 5% to about 30% (w/w) alginate, wherein the 

dietary fibre composition is not granulated. 


(21) 589923 (22) 10 Apr 2006 

(54) Dietary supplement comprising glucomannan, xanthan and alginate 

(51) IPC2012.01:A23L1/308; A61K31/723, 736; A61P3/00 

(71) InovoBiologic, Inc. 

(72) GAHLER, Roland J.; LYON, Michael; LEE, Nicole 

(31) USSN: 60/670,944 (32) 12 Apr 2005 (33) US 



(57) Provided is method for preparing a dietary fibre composition 

comprising the step of combining from about 48% to about 90% (w/w) 

glucomannan, from about 5% to about 20% (w/w) xanthan gum, and 

from about 5% to about 30% (w/w) alginate, wherein the dietary fibre 

composition is not granulated. Water can be added from about 30% to 

about 60% (w/w) water to the combination. 


(21) 589954 (22) 27 Oct 2006 

(54) Blower motor with flexible support sleeve having integral downwardly 

projecting support element(s) on bottom wall 

(51) IPC2012.01:A61M16/00; F04B17/00; A61M1/00 


(72) Kenyon, Barton John 

(31) 06 841202 (32) 31 Aug 2006 (33) US 

(31) 06 775333 (32) 22 Feb 2006 (33) US 

(31) 05 730875 (32) 28 Oct 2005 (33) US 



(57) A substantially cup-shaped flexible sleeve is configured to partially 

enclose a blower motor assembly. The sleeve has a peripheral side wall 

and a bottom wall, and the outer surface of the bottom wall is formed 

with at least one downwardly projecting resilient support element. 


(21) 590092 (22) 30 Jun 2009 

(54) CORROSION RESISTANT INTRUDER SCREEN WITH SEALING 

MEMBERS ON BOTH SIDES OF THE MESH 

(86) PCT/AU2009/000844 (87) WO2010/000023 

(51) IPC2012.01:E06B5/11; E06B7/16; E06B9/52 

(71) IPH International Pty Ltd 

(72) BRABECK, Steven; BOUMA, Peter 

(31) 2008903317 (32) 30 Jun 2008 (33) AU 

(74) FISHER ADAMS KELLY, Level 29, 12 Creek Street, Brisbane, 

Queensland 4000, Australia 

(57) A corrosion resistant intruder screen which comprises a frame 

comprising elongate frame members 3 each having a first holding 

channel 50 formed therein and a clamping portion 6 spaced from the 

first holding channel 50, a mesh 4 covering an opening enclosed by 

the frame, separately formed clamping members 7 each co-acting with 

respective fastening means 8 to thereby clamp the mesh 4 between the 

clamping members 7 and the clamping portions with leveraged clamping 

action, covers which are each configured to be clipped to a frame 

member and which have a second holding channel formed therein, and 

a sealing assembly comprising first sealing members 51 supported by 

the first holding channels and positioned against one side of the mesh 

4, and second sealing members 61 supported by the second holding 

channels and positioned against another side of the mesh 4. 

(21) 590094 (22) 21 Dec 2010 

(54) Attachment to two syringes, where the attachment has a mechanism 

to control the flow of material from the syringes 

(51) IPC2012.01:A61M5/19; B67D3/00 

(71) Bayer New Zealand Limited 

(72) Millar, Jared Peter 



(57) A method of delivering a substance from dispensing devices 18, 19 

via an attachment 1, comprises at least one dispensing nozzle 3, a 

first input port 4 and a second input port 5, where each input port is 

configured to engage with a dispensing device containing a substance 

to be delivered, a first passage 11 linking the first input port 4 to the 

dispensing nozzle 3, a second passage 12 linking the second input port 

5 to the dispensing nozzle 3, where the passages intersect prior to the 

dispensing nozzle 3 to form a common passageway 13, and where the 

attachment 1 includes an user actuated mechanism 7 positioned at the 

intersection of the passages and configured with a passageway 14 to 

allow the substances to be delivered via the first or second passage of 

the dispensing nozzle 3. The method includes the steps of connecting 

a first dispensing device 18 to the first input port 4, and operating the 

user actuated mechanism 7 so that its passageway 14 aligns with the 

first passage 11 and the common passageway 13 to link the first input 

port 4 to the dispensing nozzle 3 and then delivering the contents of the 

first dispensing device 18. 



(21) 590148 (22) 29 Dec 2005 

(54) PIPERAZINYL AND PIPERIDINYL UREAS AS MODULATORS OF 

FATTY ACID AMIDE HYDROLASE 

(51) IPC2012.01:C07D241/42; C07D295/20; C07D215/12; C07C275/28; 

C07D405/12; C07D317/58; C07D401/12; C07D417/12; C07D239/42; 

A61P25/04, 22, 28 

(71) JANSSEN PHARMACEUTICA N.V. 

(72) Apodaca, Richard; Breitenbucher, J. Guy; Pattabiraman, Kanaka; 

Seierstad, Mark; Xiao, Wei 

(31) 60/640,869 (32) 30 Dec 2004 (33) US 



(57) Disclosed are piperazinyl and piperidinyl urea compounds of formula 

(I) and their pharmaceutically acceptable salts, wherein the substituents 

are as described within the specification. An examples of a compound 

of formula (I) is 4-(3,4-dibromo-benzyl)-piperazine-1-carboxylic acid 

pyridine-4-ylamide. Further disclosed is a pharmaceutical composition 

comprising an effective amount of a compound of formula (I) and a 

pharmaceutically acceptable excipient, and the use of a compound of 

formula (I) in the preparation of a medicament for treating a disease, 

disorder, or medical condition mediated by FAAH activity. 


(21) 590170 (22) 29 Jun 2009 

(54) PROCESS FOR THE PREPARATION OF SUBSTITUTED 

PYRIMIDINE DERIVATIVES 

(86) PCT/US2009/049027 (87) WO2010/002774 

(51) IPC2012.01:A61K31/497 

(71) JANSSEN PHARMACEUTICA N.V. 

(72) CESCO-CANCIAN, Sergio; CHEN, Hongfeng; GRIMM, Jeffrey, S; 

MANI, Neelakandha, S; MAPES, Christopher, M; PALMER, David, C; 

PIPPEL, Daniel, J; SORGI, Kirk, L; XIAO, Tong 

(31) 61/076,752 (32) 30 Jun 2008 (33) US 



(57) Disclosed herein is a process for the preparation of a compound 

of formula (I), in particular a compound of formula (I-S), wherein the 

substituents are as defined within the specification, wherein the process 

comprises reacting a compound of formula (V) with a compound of 

formula (VI) in a first organic solvent and in the presence of a coupling 

agent system to yield the corresponding compound of formula (VII), deprotecting 

the compound of formula (VII), to yield the corresponding 

compound of formula (VIII); and followed by reacting the compound 

of formula (VIII) with a compound of formula (IX) in a second organic 

solvent to yield the corresponding compound of formula (I). 

(21) 590201 (22) 17 Jul 2009 

(54) Locking arrangement with secondary locking with overriding feature 

to act on shoulder of locking bar 

(86) PCT/AU2009/000909 (87) WO2010/006371 

(51) IPC2012.01:E05B47/00, 06 

(71) DAVID STUCKEY INVESTMENTS PTY LTD 

(72) STUCKEY, David, Martin 

(31) 2008903698 (32) 18 Jul 2008 (33) AU 

(31) 2009900673 (32) 17 Feb 2009 (33) AU 

(31) 2009902827 (32) 19 Jun 2009 (33) AU 

(74) HOULIHAN2, Level 1, 70 Doncaster Road, Balwyn North, Victoria 


(57) A locking arrangement comprising: (a) a handle assembly; (b) 

a primary locking mechanism comprising: (i) a locking bar movable 

between an extended latching position and a retracted release position, 

whereby when the locking bar is in the retracted release position 

the handle assembly is movable between a locked condition and an 

unlocked condition; and (ii) an actuator means which acts upon the 

locking bar to move the locking bar between the extended latching 

position and the retracted release position; (c) a secondary locking 

mechanism which acts independently upon the locking bar to move the 

locking bar between the extended latching position and the retracted 

release position; and (d) at least one biased catch means to releasably 

retain the locking bar in either the extended latching position or the 

retracted release position. 

(21) 590206 (22) 23 Dec 2010 

(54) Wood treatment and treated wood using a silicone emulsion, boron 

compound and a metal salt 

(51) IPC2012.01:B27K3/15, 52; C09D183/04; A01N59/14; B27K5/00; 

A01N25/10, 24; B05D7/08; A01P7/00; A01P3/00 

(71) Nissin Chemical Industry Co., Ltd. 

(72) Wakamatsu, Masaki; Yamamoto, Akira 



(31) 2009-296743 (32) 28 Dec 2009 (33) JP 

(74) DAVIES COLLISON CAVE-Melbourne, 1 Nicholson Street, 

Melbourne, Victoria, Australia 

(57) Disclosed is a wood comprising in its surface a cured product of a 

film-forming silicone emulsion composition [I], (F) a boron compound, 

and (G) a di- or trivalent metal salt, wherein the silicone emulsion 

composition [I] is a composition comprising the following components 

(A) to (E) dispersed and emulsified in water, (A) 100 parts by weight of 

an organopolysiloxane containing at least two silicon-bonded hydroxyl 

groups on the molecule, (B) 0.5 to 20 parts by weight of the reaction 

product of an amino-containing organoxysilane and an acid anhydride, 

(C) 0 to 20 parts by weight of an epoxy-containing organoxysilane and/or 

partial hydrolyzate thereof, (D) 0 to 50 parts by weight of colloidal silica 

and/or poly silsesquioxane, and (E) 0 to 10 parts by weight of a curing 

catalyst, and wherein the boron compound (F) is present in an amount 

of 10 to 1,500 parts by weight and the di- or trivalent metal salt (G) is 

present in an amount of 10 to 300 parts by weight per 100 parts by weight 

of the cured product of film-forming silicone emulsion composition [I], all 

calculated as solids. Also disclosed is a method of treating wood using 

the silicone emulsion composition [I], (F) a boron compound, and (G) a 

di- or trivalent metal salt. Examples of the metal salts are zinc acetate, 

zinc chloride, calcium acetate and calcium chloride. 

(21) 590240 (22) 24 Dec 2010 

(54) An interlocking connection means comprising a curved finger joint 

(51) IPC2012.01:B27F1/00 

(71) Duncan Glover 

(72) Glover, Duncan 

(74) Duncan Glover, 251 Mayfair Avenue, Hastings, New Zealand 

(57) Inter-fitting first and second parts 2, 3, typically forming a container, 

have fingers and recesses of complementary shape so as to able to 

be locked together. The most outward part of each flared finger is the 

same width or is marginally wider than the entrance to the corresponding 

recess. However, a curve of the outer corner of the finger enables the 

finger to slide against and enter the recess. 

(21) 590345 (22) 3 Jul 2009 

(54) CONCENTRATE FOR PREPARING A DISINFECTANT AND 

METHODS FOR ITS PREPARATION AND USE 

(86) PCT/CH2009/000234 (87) WO2010/003263 

(51) IPC2012.01:A01N59/16, 00; A01N25/02, 22; A01P1/00 

(71) SANOSIL AG 

(72) GOMORI, Janos 

(31) 08104720.1 (32) 11 Jul 2008 (33) EP 


(57) Disclosed is a storage-stable aqueous concentrate for the preparation 

of a disinfectant, the concentrate comprising: hydrogen peroxide, 

colloidal silver, a stabilizer comprising at least one biopolymer and 

phosphoric acid to adjust the pH value of the concentrate to less than or 

equal to 3, characterized in that the concentrate comprises at least one 

sodium salt selected from the group consisting of sodium nitrate, sodium 

sulfate and combinations thereof the concentrate being essentially free 

of any synthetic organic complexing agents. The composition can be 

used to treat drinking water. 

(21) 590358 (22) 23 Jul 2009 

(54) A POLYPEPTIDE COMPLEX COMPRISING NON-PEPTIDYL 

POLYMER HAVING THREE FUNCTIONAL ENDS 

(86) PCT/KR2009/004114 (87) WO2010/011096 

(51) IPC2012.01:C07K19/00 

(71) Hanmi Holdings Co. Ltd. 

(72) SONG, Dae Hae; SHIN, Jae Hee; LEE, Mi Ji; HONG, Sung Hee; 

KWON, Se Chang; LEE, Gwan Sun 

(31) 10-2008-0071766 (32) 23 Jul 2008 (33) KR 



(57) Disclosed is a protein complex, comprising a physiologically active 

polypeptide, an immunoglobulin Fc domain and a non-peptidyl polymer 

having three functional ends, with the linkage of both the physiologically 

active polypeptide and the immunoglobulin Fc domain of the nonpeptidyl 

polymer via respective covalent bonds. 

(21) 590426 (22) 9 Jul 2009 

(54) SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, 

PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF 

(86) PCT/FR2009/051362 (87) WO2010/004215 

(51) IPC2012.01:A61K31/502; C07D237/28, 36; A61P35/00; 

C07D405/04; A61P25/00; C07D409/04 

(71) SANOFI-AVENTIS 

(72) BARBAGALLO, Elodie; RINALDI-CARMONA, Murielle; ROUX, 

Pascale; VERNHET, Claude 

(31) 08/03974 (32) 11 Jul 2008 (33) FR 



(57) Disclosed are substituted benzyl-cinnolin-one derivative represented 

by general formula (I), in the form of the base or of an addition 

salt with an acid. A process for preparing the compounds of 

formula (I) are also disclosed. Also disclosed is the use of the 

compounds of formula (I) in the preparation of a medicament for 

treating any pathology in which CB2 cannabinoid receptors are 

involved such as, pain, inflammatory diseases, autoimmune diseases, 

allergic diseases, infectious diseases, neurodegenerative diseases, 

cardiovascular diseases, cancers, gastrointestinal diseases, obesity, 

type II diabetes, insulin resistance and adipose tissue inflammation. 

(21) 590583 (22) 18 Jan 2011 

(54) A method of generating a three dimensional model of an object using 

mesoscopic geometery modulation 

(51) IPC2012.01:G06T17/10, 05; G06T15/04 

(71) DISNEY ENTERPRISES, INC.; ETH ZURICH (EIDGENOESSISCHE 

TECHNISCHE HOCHSCHULE ZURICH) 

(72) BEELER, Thabo Dominik; BICKEL, Bernd; GROSS, Markus; 

SUMNER, Robert; BEARDSLEY, Paul 

(31) 61/310,667 (32) 4 Mar 2010 (33) US 

(31) 12/897,518 (32) 4 Oct 2010 (33) US 

(31) 12/689,170 (32) 18 Jan 2010 (33) US 





(57) A computer-implemented method for mesoscopic geometry 

modulation is disclosed. The method comprises the steps of: (a) 

determining a first set of mesoscopic details associated with an object 

by applying a filter to an image of an object, wherein mesoscopic details 

included in the first set of mesoscopic details are detectable in the image 

of the object and are not detectable when generating a coarse geometry 

reconstruction of the object; and (b) generating a three-dimensional 

model for the object by modulating the coarse geometry with the first 

set of mesoscopic details. The coarse geometry is performed by stereo 

reconstruction based on two images of the object, where the object may 

be a human head, and the mesoscopic details may comprise spots, 

freckles, moles, pores, fine wrinkles, or facial hair. 


(21) 590614 (22) 22 Jul 2009 

(54) Method of spooling a b-metallic pipeline with a plurality of pipe 

sections which are filled with a fluid 

(86) PCT/GB2009/050899 (87) WO2010/010390 

(51) IPC2012.01:F16L1/20; F16L25/00 

(71) TECHNIP FRANCE 

(72) HOWARD, Brett; HOSS, Jean Louis 

(31) 0813545.1 (32) 24 Jul 2008 (33) GB 



(57) Disclosed is a method of spooling onto a reel a marine pipeline 

comprising a plurality of bi-metallic pipe sections (10, 66). A first pipe 

section is filled with a fluid (12), the fluid is pressurised, and then the first 

pipe section is spooled onto the reel. A second pipe section is likewise 

filled with a fluid (78) which is pressurised. The first pipe section with the 

second pipe section are then joined, at least one of the first and second 

pipe sections maintaining the pressurised fluid therein. The second pipe 

section is then spooled onto the reel. 

(21) 590617 (22) 14 Aug 2009 

(54) cMET INHIBITORS 

(86) PCT/US2009/053913 (87) WO2010/019899 

(51) IPC2012.01:C07D519/00; C07D487/04; A61P35/00; C07D471/04; 

A61K31/437 

(71) Takeda Pharmaceutical Company Limited 

(72) BRESSI, Jerome, C; CHU, Shaosong; ERICKSON, Philip; 

KOMANDLA, Mallareddy; KWOK, Lily; LAWSON, John, D; STAFFORD, 

Jeffrey, A; WALLACE, Michael, B; ZHANG, Zhiyuan; DAS, Sanjib 

(31) 61/088,959 (32) 14 Aug 2008 (33) US 

(31) 61/117,910 (32) 25 Nov 2008 (33) US 

(31) 61/161,007 (32) 17 Mar 2009 (33) US 



(57) Disclosed are imidazo pyridazinyl c-MET inhibitor 

compounds of formula I, salts thereof, and methods 

for their preparation. Specific examples of compounds of 

formula I include N-(6-([1,2,4]triazolo[4,3-a]pyridin-3-ylthio)imidazo[1,2b 

]pyridazin-2-yl)cyclopropanecarboxamide; Cyclopropanecarboxylic 

acid [6-(6-bromo-benzotriazol-1-ylmethyl)-imidazo[1,2-b]pyridazin-2yl]-amide;N-(6-(6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridin-3ylthio)imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide; 

N-(6-(6- 

(6-methoxypyridin-2-yl)-[1,2,4]triazolo[4,3-a]pyridin-3ylthio)imidazo[1,2-b]pyridazin-2-yl)cyclopropanecarboxamide; 

Also 

disclosed are methods for inhibiting cMET using the compounds of 

formula I 

(21) 591050 (22) 20 Jul 2009 

(54) A container to disinfect a sponge wherein the sponge an be soaked 

and then squeezed out 

(86) PCT/AU2009/000922 (87) WO2010/009497 

(51) IPC2012.01:A61L2/18, 04, 12, 26; B08B3/08 

(71) Staffarena Corporation Pty Ltd 

(72) PLEWRIGHT, Glen; DIXON, Michael 

(31) 2008203290 (32) 23 Jul 2008 (33) AU 

(74) WRAYS, Ground Floor, 56 Ord Street, West Perth, WA 6005, 

Australia 

(57) A steriliser unit (10) for sterilising an absorbent body (30), such as 

a sponge is disclosed. The steriliser unit firstly comprises a container 

(12) for holding a disinfectant, the container providing a soak position 

(22) and a discharge position (26). The steriliser unit also includes a 

discharge unit (14) for cooperation with the container, the discharge 

unit defines a compression compartment (28) in which the absorbent 

body can be held. The discharge unit is further movable between a 

release position in which the absorbent body can be located within 

the compression compartment and a compression position in which 

the discharge unit will apply a compressive force on the absorbent 

body inside the compression compartment. In use the compression 

compartment can be located within the soak position of the container 

when the discharge unit is located in its release position, thereby 

allowing the absorbent body to absorb an amount of disinfectant. The 

discharge unit can also be moved to its compression position when the 

compression compartment is located in the discharge position of the 

container, such that the absorbent body is compressed to squeeze out 

the disinfectant which it had absorbed when it was located inside the 

soak position of the container. This feature allows the user to place the 

steriliser unit into a microwave, for example, to heat the disinfectant 

while the sponge is in the disinfectant, and then squeeze out the hot 

disinfectant without risk of harm from the hot liquid. 

(21) 591237 (22) 21 Jul 2009 

(54) A DEVICE FOR THE UTILISATION OF WAVE ENERGY USING 

DARRIEUS AND WELLS ROTORS 

(86) PCT/NL2009/000152 (87) WO2010/011133 

(51) IPC2012.01:F03B13/18; F03B17/06 

(71) Ecofys Investments B.V. 

(72) SCHEIJGROND, Peter, Cornelis 

(31) 1035727 (32) 21 Jul 2008 (33) NL 



(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, 

Australia 

(57) The disclosure relates to a device for the utilisation of wave energy, 

with an increased efficiency. Thereto, the device according to the 

invention comprises - a Darrieus rotor having at least two Darrieus rotor 

blades, wherein the Darrieus rotor has a solidity sD, and - a Wells rotor 

having at least two Wells rotor blades, wherein the Wells rotor has a 

solidity sW, wherein - the Darrieus rotor and the Wells rotor are rotatable 

about a common axis of rotation A, and - sW is larger than or equal to 

sD. The disclosure also relates to a method for harnessing wave energy. 

(21) 591920 (22) 6 Oct 2009 

(54) COMPOSITIONS AND METHODS FOR INHIBITING THE 

AGGLOMERATION OF HYDRATES 

(86) PCT/US2009/059649 (87) WO2010/042482 

(51) IPC2012.01:C07D241/04; C10L3/06 

(71) NALCO COMPANY 

(72) ACOSTA, Erick J. 

(31) 12/245,849 (32) 6 Oct 2008 (33) US 



(57) Disclosed herein is a composition for inhibiting the formation of 

hydrate agglomerates in a fluid comprising water, gas, and optionally 

liquid hydrocarbon, the composition comprising an organic solvent; and 

a compound of the given formula and optionally salts thereof, wherein 

the substituents are as defined within the specification. Also disclosed 

is a method of inhibiting the formation of hydrate agglomerates in a fluid 

comprising water, gas, and optionally liquid hydrocarbon comprising 

adding to the aqueous medium an effective anti-agglomerant amount of 

the composition as defined above. 

(21) 591948 (22) 5 Oct 2009 

(54) HYDROPHILIC SILICONE MONOMERS, PROCESS FOR THEIR 

PREPARATION AND THIN FILMS CONTAINING THE SAME 

(86) PCT/IN2009/000550 (87) WO2010/038242 

(51) IPC2012.01:A61Q19/00; C08G61/12; C01B33/152, 00; C07F7/21 

(71) Momentive Performance Materials Inc. 

(72) GUYER, Kendall, Louis; LEWIS, Kenrick, Martin; UMAPATHY, 

Senthilkumar; SAXENA, Anubhav; WANG, Yi-Feng 

(31) 61/195,086 (32) 3 Oct 2008 (33) US 

(74) PETER MAXWELL & ASSOCIATES, Level 6, 60 Pitt Street, Sydney, 

NSW 2000, Australia 

(57) Disclosed is a mono-functional silicone-containing monomer o the 

formula R3Si-O – [Si(R)(Z)O]a – [Si(R1)(R2)O]b –SiR3 or formula II 

wherein the substituents are as described within the specification. 

Further disclosed is a polymer comprising the reaction product of at 

least one monomer of formula II, a copolymer comprising the reaction 

product of least two monomers of formula II wherein at least one of said 

monomers has a different structure to at least one other monomer, and 

a copolymer comprising the reaction product of at least one monomer 

of formula II and at least one additional monomer. Also disclosed is a 

process for producing a silicone-containing monomer. Also disclosed is 

a silicone-hydrogel film comprising a polymer comprising the reaction 

product of at least one monomer of formula II, and a contact lens 

comprising said silicone-hydrogel film. 

(21) 592109 (22) 16 Oct 2009 

(54) METHOD OF CONTROLLING GAS HYDRATES IN FLUID 

SYSTEMS 

(86) PCT/US2009/060941 (87) WO2010/045520 

(51) IPC2012.01:C10L3/00 

(71) NALCO COMPANY 

(72) CARLISE, Joseph R; LINDEMAN, Olga E S; REED, Peter E; 

CONRAD, Peter G; VER VERS, Leonard M 

(31) 12/253,529 (32) 17 Oct 2008 (33) US 



(57) Disclosed is a method of inhibiting hydrates in a fluid comprising 

water, gas comprising treating the fluid with an effective hydrateinhibiting 

amount of an inhibitor composition comprising: a. a polymer 

prepared by polymerizing one or more N-alkyl (alkyl)acrylamide 

monomers using a free radical polymerization initiator, wherein the 

polymerization initiator comprises t-butyl peroxyoctanoate; and b. a 

solvent comprising one or more glycol ether solvents of formula CH3- 

(CH2)m-(O-CH2- CH2)n-OH where m is an integer of 0-1, and n is 

an integer greater than or equal to 1. A hydrate inhibitor composition 

comprising the above mentioned composition is also disclosed. 

(21) 592113 (22) 14 Oct 2009 

(54) HIGHLY CONCENTRATED DRUG PARTICLES, FORMULATIONS, 

SUSPENSIONS AND USES THEREOF 

(86) PCT/US2009/005629 (87) WO2010/044867 

(51) IPC2012.01:A61K9/00, 16; A61K38/26; A61K47/12, 14, 18, 26, 32 

(71) Intarcia Therapeutics, Inc. 

(72) ALESSI, Thomas R; MERCER, Ryan D; ROHLOFF, Catherine M; 

YANG, Bing 

(31) 61/204,714 (32) 9 Jan 2009 (33) US 

(31) 61/196,277 (32) 15 Oct 2008 (33) US 



(57) Disclosed is a pharmaceutical suspension formulation comprising, 

a particle formulation comprising, about 25 wt percent to about 80 

wt percent drug, wherein the drug is a protein, and about 75 wt 

percent to about 20 wt percent of one or more additional component, 

wherein the one or more additional component comprises antioxidant 

e.g. methionine, carbohydrate e.g. sucrose, and buffer e.g. citrate, and 

the ratio of drug:antioxidant:carbohydrate:buffer is between about 2-20: 

1-5: 1-5: 1-10; and a non-aqueous, single-phase suspension vehicle 

comprising one or more polymer and one or more solvent. 

(21) 592462 (22) 10 Sep 2009 

(54) HIGH LIGHT-TRANSMISSION SHEET MATERIAL 

(86) PCT/JP2009/066207 (87) WO2010/047198 

(51) IPC2012.01:B32B27/18, 12 

(71) HIRAOKA & CO., LTD. 

(72) SUZUKI, Hiroshi; MATUSHITA, Youko 

(31) 2008-274298 (32) 24 Oct 2008 (33) JP 





(57) Disclosed is a high light-transmission sheet material which comprises 

a base fabric formed from a fibrous material, a front surface IR reflecting 

resin layer formed on a front surface of the base fabric, and a back 

surface thermoplastic resin layer formed on a back surface of the base 

fabric and which overall has a visible light transmission of 40 to 80 

percent, wherein at least the front surface IR reflecting resin layer 

contains interference mica particles in a content of 0.5 to 5 percent by 

mass based on a total composition mass of the front surface IR reflecting 

resin layer, and either one or both of the front surface IR reflecting resin 

layer and the back surface thermoplastic resin layer includes at least one 

type of particles selected from ultrafine titanium oxide particles having a 

particle size of 0.01 to 0.5 micrometre and ultrafine zinc oxide particles 

having a particle size of 0.01 to 0.5 micrometre in a content of 0.3 to 3% 

by mass, based on the total composition mass of each of the layers. 

(21) 592591 (22) 3 Nov 2009 

(54) BINDING PROTEINS COMPRISING ANKYRIN REPEAST 

DOMAINS THAT INHIBIT THE VEGF-A RECEPTOR INTERACTION 

(86) PCT/EP2009/064483 (87) WO2010/060748 

(51) IPC2012.01:C07K14/47; A61P27/02; A61P35/00; A61K38/16 

(71) Molecular Partners AG 

(72) BINZ, Hans Kaspar; FORRER, Patrik; STUMPP, Michael Tobias 

(31) 08168166.0 (32) 3 Nov 2008 (33) EP 



(57) A recombinant binding protein that comprises an ankyrin repeat 

domain that binds to VEGF-Axxx with a Kd below 10-7 M and inhibits 

VEGF-Axxx binding to VEGFR-2. The binding protein can be used for 

inhibiting angiogenesis in cancer and in eye disorders such as agerelated 

macular degeneration. 

(21) 593062 (22) 19 Feb 2007 

(54) Process for production of 3-[5-[4-cyclopentyloxy)-2hydroxybenzoyl]-2-[(3-hydroxy-1,2-benzisoxazol-6yl)methoxy]phenyl]propionate 

ester and intermediate for the process 

(51) IPC2012.01:C07D311/14, 00, 02, 06; C07C59/90; C07B61/00; 

C07C67/303; C07C69/76, 007, 003 

(71) Toyama Chemical Co., Ltd. 

(72) Yonezawa, Kenji; Takamatsu, Tamotsu; Aoki, Naokatu; Hashimoto, 

Tomohiro; Takebayashi, Masahiro; Suzuki, Yoshiaki; Oonishi, Yuji 

(31) 2006-043777 (32) 21 Feb 2006 (33) JP 

(31) 2006-121582 (32) 26 Apr 2006 (33) JP 

(31) 2006-121601 (32) 26 Apr 2006 (33) JP 



(57) Disclosed is a method for preparing benzophenone derivatives of 

formula 20 by subjection a compound of formula 16 to a dealkylation 

reaction to give a compound of formula 17 which is further subjected to 

an alkylation reaction to give a compound of formula 18 which is further 

subjected to a ring-opening reaction to give a compound of formula 19 

which is reduced to give a compound of formula 20. The variables are as 

disclosed in the description. Further disclosed is a compound of formula 

36 where the variables are as disclosed in the description. 


(21) 593074 (22) 21 Dec 2006 

(54) sulfonamide-pyrrolidone derivatives as Modulators of Ion Channels 

(51) IPC2012.01:C07D471/10; C07D405/12; C07D401/12; C07D239/42; 

C07D491/10; C07D417/14, 12; A61P25/04; A61K31/506 


(72) Wilson, Dean; Fanning, Lev T. D.; Sheth, Urvi; Martinborough, 

Esther; Termin, Andreas; Zimmermann, Nicole; Knoll, Tara; Whitney, 

Tara; Kawatkar, Aarti; Lehsten, Danielle; Stamos, Dean; Zhou, Jinglan; 

Arumugam, Vijayalaksmi; Gutierrez, Corey; Neubert, Timothy 

(31) 60/752,926 (32) 21 Dec 2005 (33) US 

(31) 60/791,181 (32) 11 Apr 2006 (33) US 

(31) 60/799,797 (32) 12 May 2006 (33) US 

(31) 60/839,444 (32) 23 Aug 2006 (33) US 

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, 

Australia 

(57) Disclosed are sulphonamide, pyrrolidone derivatives represented by 

general formula (N-1), wherein P is a leaving group. 


(21) 593162 (22) 20 Jul 2006 

(54) DATABASE FRAGMENT CLONING AND MANAGEMENT 

(51) IPC2012.01:G06F7/00; G06F11/20, 14; G06F17/30 

(71) MICROSOFT CORPORATION 

(72) GERBER, Robert H; RAMAN, Balan S; HAMILTON, James R; 

LUDEMAN, John F; KRISHNA, Murali M; SMITH, Samuel H; ASHWIN, 

Shrinivas 

(31) 11/207482 (32) 19 Aug 2005 (33) US 



(57) A device-executable method for monitoring and updating cloned 

fragments comprises the steps of monitoring cloned fragments 

associated with a database object with the cloned fragment including 

primary and secondary cloned fragments; determining that at least 

one of the cloned fragments has become unavailable; incrementing an 

update identifier associated with the database object; transactionally 

persisting the update identifier; identifying a DML statement associated 

with the database object with the DML statement including an update 

to the database object; associating the persisted update identifier with 

the DML statement; implementing the update on the primary cloned 



fragments that are affected by the DML statement; storing the update 

identifier associated with the DML statement in each row in the primary 

cloned fragments that is affected by the update; propagating the update 

and the update identifier to the secondary cloned fragments associated 

with the affected primary cloned fragments and storing the update 

identifier on the secondary cloned fragments. 


(21) 593188 (22) 3 Dec 2009 

(54) Intramammary teat sealant comprising one or more plant oils and 

bismuth subnitrate 

(86) PCT/US2009/066594 (87) WO2010/065747 

(51) IPC2012.01:A01N65/22, 00, 24; A01N59/16; A01P1/00 

(71) Merial Limited 

(72) RAZZAK, Majid; HOLMES, Robert; JOHNSON, Alan; GOSWAMI, 

Jitendra; AWASTHI, Atul 

(31) 61/119,763 (32) 4 Dec 2008 (33) US 


Australia 

(57) Disclosed is a teat sealant formulation comprising one or more plant 

oil(s) having anti-infective properties and bismuth subnitrate, wherein 

the formulation is a gel or a paste. 

(21) 593617 (22) 29 Oct 2001 

(54) Nucleic acids and proteins from streptococcus groups A & B 

(51) IPC2012.01:C07K14/195 

(71) Novartis Vaccines and Diagnostics, Inc.; J. Craig Venter Institute, Inc. 

(72) Telford, John; Masignani, Vega; Grandi, Guido; Fraser, Clare; 

Tettelin, Herve; Scarselli, Maria 

(31) 01 0105640.7 (32) 7 Mar 2001 (33) GB 

(31) 00 0028727.6 (32) 24 Nov 2000 (33) GB 

(31) 00 0026333.5 (32) 27 Oct 2000 (33) GB 


Australia 

(57) Disclosed are nuclieic acid sequences and proteins derived from 

Streptococcus groups A and B. Specifically S. pyrogenes or S. 

agalactiae. Further disclosed are methods and kits for identifying and 

extracting the disclosed sequences and proteins. 


(21) 593651 (22) 28 Feb 2012 

(54) An insulated drop-down electric fence for passage of large irrigators 

(51) IPC2012.01:A01K3/00; E04H17/14 

(71) HFO Holdings Limited 

(72) Hobbs, Brett Lester 



(57) Disclosed is an electric fence which includes electric fencing material 

supported between a series of spaced posts. The fencing material 

includes a drop-down section and a sprung section. The drop-down 

section includes means for electrically insulating the drop-down section 

and means for securing the drop-down section to a ground anchor so 

as to inhibit lateral movement of the drop-down section. 

(21) 593701 (22) 23 Jun 2011 

(54) A system for HVDC power transmission having one or more single 

wire earth returns 

(51) IPC2012.01:H02J5/00; H02J3/36; H02M5/40 

(71) Renergyx Pty Limited 

(72) Harrison, Craig 

(31) 2010902854 (32) 28 Jun 2010 (33) AU 


Australia 

(57) A system for HVDC power transmission is disclosed. The system 

comprises: an AC power source (101); a primary isolation transformer 

(104) and a rectifier (105) forming an AC/DC transformer; one or more 

SWER (Single Wire Earth Return) transmission lines (107) extending 

from the AC/DC transformer to one or more DC/AC transformers, where 

one or more inverters (108) and secondary isolation transformers (109) 

form DC/AC transformers. One or more local AC distribution systems 

(111) are each connected to an AC output of a DC/AC transformer. The 

SWER transmission lines (107) are operated at a DC voltage of 1.41 

times the nominal AC voltage. 

(21) 593738 (22) 11 Dec 2007 

(54) A BARRIER COMPRISING A KICKBOARD WITH RIGID ELONGATE 

BASE AND A RESILIENT MEMBER 

(51) IPC2012.01:E04H17/16; E04G21/32; E04G7/28; E04G1/00 

(71) Workright Edge Protection Systems Pty Ltd 

(72) Pandazopoulos, Andrew; Blundell, Roland; Whelan, Brian 

(31) 2007900228 (32) 19 Jan 2007 (33) AU 

(31) 2007201540 (32) 19 Jan 2007 (33) AU 



(57) A barrier assembly employed on construction sites that can be used 

as temporary fencing and rail systems for floor slab edge installation 

during the construction of multi storey buildings is disclosed. The barrier 

assembly (10) has an upright frame (15) that supports a barrier (20) 

consisting of a pair of barrier members (22, 23) that slide relative to each 

other so that they are adjustable in length. These barrier members are 

supported by a stirrup (19) as well as the frame (15). 




(21) 593962 (22) 28 Dec 2009 

(54) BARLEY WITH REDUCED LIPOXYGENASE ACTIVITY AND 

BEVERAGE PREPARED THEREFROM 

(86) PCT/DK2009/050355 (87) WO2010/075860 

(51) IPC2012.01:C12C7/00; C12C1/18; A01H5/10; C12N15/01; 

C12C12/00 

(71) Carlsberg Breweries A/S; Heineken Supply Chain B.V. 

(72) SKADHAUGE, Birgitte; LOK, Finn; BREDDAM, Klaus; OLSEN, Ole; 

BECH, Lene Molskov; Knudsen, Soren 

(31) PA 2008 01851 (32) 30 Dec 2008 (33) DK 


Australia 

(57) Disclosed is a beverage prepared from a barley plant, or a part 

thereof, wherein said beverage comprises less than 50% T2N potential 

compared to the T2N potential of a beverage prepared in the same 

manner from barley cv. Power. Said barley plant, or part thereof, 

comprises a lox-1 gene that encodes a mutated form of LOX-1, lacking 

some or all of amino acids 520-862 of LOX-1 resulting in a total 

loss of functional lipoxygenase (LOX)-1 enzyme, and said barley plant 

comprises a lox-2 gene that encodes a mutated form of LOX-2 lacking 

some or all of amino acids 515-717 of LOX-2 resulting in a total loss of 

functional LOX-2 enzyme. 

(21) 594073 (22) 28 Feb 2012 

(54) A vertically mounted rotor with a follower skid or wheel connected to 

a three point linkage to make channels 

(51) IPC2012.01:A01B13/00; A01B63/10, 111, 24; E02F5/02; A01B15/20; 

E02B13/00; A01B35/18; A01B79/00; A01B33/14 

(71) Peter Sutherland 

(72) Sutherland, Peter 



(57) A drain forming and/ or clearing apparatus is disclosed. The apparatus 

has a body (1) adapted to be attachable (6, 8) to a three point linkage 

of a suitable vehicle, the vehicle having a power take off ("PTO") and a 

hydraulic system. The body can be raised and lowered by the hydraulic 

system of the vehicle. A rotor assembly (2) is carried by and extends 

below the body and is rotated in use about a substantially vertical axis. 

The rotor is used to create and/or clear a ground channel when rotating 

and being advanced at least in part below ground level. The rotor is 

powered from a vehicle PTO connectable drive (9), or a vehicle hydraulic 

system connectable drive, carried by the body. At the other end of the 

body from the three point linkage is a ground following assembly (3). The 

follower assembly extends below the body so as to follow in a channel 

formed or cleared by the rotor. This helps to smooth out the channel 

made by the rotor. The rotor has a hub (11) connected to a plurality of 

blades (13), paddles or vanes outstanding from the hub and with a cant 

or rake to uplift soil when rotated in one rotational direction. Each blade 

assembly defines a leading edge with a member that is replaceable. Ties 

connect and support each blade assembly, each such tie connecting 

from the outside training edge of one blade to the next. One or more prerippers 

(17) may be attached to the body near the three point linkage to 

loosen the soil prior to the channel being cleared by the rotor. 


(21) 594651 (22) 14 Oct 2008 

(54) LED street lamp with associated reflectors 

(51) IPC2012.01:F21V11/02; F21V7/04, 10; F21V13/10; F21S8/08 

(71) LSI Industries, Inc. 

(72) Boyer, John D.; Vanden Eynden, James G. 

(31) 60/980,562 (32) 17 Oct 2007 (33) US 

(31) 12/166,536 (32) 2 Jul 2008 (33) US 



(57) A lighting apparatus particularly suitable for street or road lighting 

has a housing including a base 21, a plurality of LEDs 52 forming a 

column oriented in opposite directions along an axis designated as the T 

axis which is directed across the roadway and parallel to the surface of 

the roadway, and reflectors 70 adjacent some of the LEDs. A reflective 

surface 70 of the reflector faces the adjacent LED, and each reflective 

surface defines a plane oriented at an angle ä of from 0 to -20 degrees 

from perpendicular to the base for reflecting light emitted in the –T 

direction toward the +T direction. 


(21) 595253 (22) 1 Nov 2010 

(54) Anti-slip stocking sole with grip members on the bottom surface 

comprising rough tread 

(51) IPC2012.01:A61F13/08 

(71) DP Healthcare Solutions Pty Ltd 

(72) Burmeister, Dianne 


Australia 

(57) Disclosed is a compression stocking with a foot portion for covering 

at least portion of a wearer's foot. The foot portion includes a toe region 

and a heel region and a sole extending between the toe region and heel 

region, the sole having a bottom surface for contacting a floor. Anti-slip 

means are provided at the bottom surface of the sole, the anti-slip means 

comprising a tread that overlays at least a portion of the bottom surface, 

the tread having a rougher surface than the surrounding surfaces of the 

foot portion. 




(21) 595357 (22) 29 Jan 2008 

(54) A device to detect the presence or absence of events in a sample 

using prime numbers 

(51) IPC2012.01:G06F17/11; C12Q1/00; G01N33/00 

(71) Scientific Institute of Public Health (IPH) 

(72) VAN DEN BULCKE, Marc Henri Germain; LIEVENS, Antoon 

Piet Nelly Raoul; LEUNDA, Amaya; MBONGOLO MBELLA, 

Etondoh Guillaume; BARBAU-PIEDNOIR, Elodie; SNEYERS, Myriam 

Jacqueline Sylviane 

(31) 07447008.9 (32) 29 Jan 2007 (33) EP 

(31) 07108343.0 (32) 16 May 2007 (33) EP 



(57) A computing device programmed to carry out steps to conclude 

the presence or absence of one or more events in a sample, wherein 

each event is characterised by one or more traits, and wherein the 

presence or absence of the one or more traits in the sample has been 

detected is disclosed. The steps comprise: (a) assigning a unique prime 

number value to each trait, (b) representing each event as a product of 

the prime number values assigned to traits characteristic of the event, 

(c) representing the sample as a product of the prime number values 

assigned to traits detected as present in the sample, and (d) dividing 

the product representing the sample as defined in (c) by the product 

representing an event as defined in (b), whereby: - if the value obtained 

by the division equals 1, then the event or material thereof is potentially 

present in the sample; - if the value obtained by the division is an integer 

greater than 1, then the event or material thereof is potentially present 

in the sample; - if the value obtained by the division is not an integer, 

then the event or material thereof is absent from the sample. 


(21) 595873 (22) 1 Nov 2010 

(54) Anti-slip stocking sole with grip members on the bottom surface 

comprising beading 

(51) IPC2012.01:A61F13/08 

(71) DP Healthcare Solutions Pty Ltd 

(72) Burmeister, Dianne 


Australia 

(57) Disclosed is a compression stocking comprising a foot portion for 

covering at least portion of a wearer's foot. The foot portion includes a 

toe region (13) and a heel region (14) and a sole (15) extending between 

the toe region and heel region, the sole having a bottom surface (20) 

for contacting a floor. The foot portion has anti-slip means comprising 

beading (22) forming one or more grip members (21) disposed on the 

bottom surface of the sole. 


(21) 595895 (22) 20 Oct 2011 

(54) Determining the distance of a vehicle from a radio beacon by 

analysing the gradient of its doppler-shifted transmission frequency 

(51) IPC2012.01:G01P15/16; G01S11/10; G07B15/06 

(71) KAPSCH TRAFFICCOM AG 

(72) NAGY, Oliver 

(31) 10450189.5 (32) 7 Dec 2010 (33) EP 


(57) Disclosed is a radio installation for a road toll system (1) which 

determines the distance (a1, a2) of a passing vehicle (12). The vehicle 

has an on-board unit (11) which emits a signal (10) with a known curve 

of its frequency over time. The radio installation (1) contains a receiver 

(8) configured to receive the signal (10) of a passing vehicle (12) and 

a memory connected to the receiver (8). The memory is configured to 

record the curve of the frequency of the received signal (10) over time in 

relation to the known frequency curve over time. A detector is provided 

to detect a change in the recorded frequency curve. The system also 

includes an evaluation device which is connected to the memory and 

detector and is configured to look for two far regions in the frequency 

curve. These far regions lie before and after the detected change in time 

and show a frequency change below a threshold value. A scaling device 

is connected to the memory and the evaluation device and is configured 

to scale the recorded frequency curve so that the far regions assume 

predetermined values. A differentiator then determines the gradient of 

the scaled frequency curve at an inflection point and determines the 

distance (a1, a2) between the passing vehicle (12) and the installation 

from this gradient. 

(21) 596440 (22) 15 Nov 2011 

(54) Method for capturing images of vehicles 

(51) IPC2012.01:G08G1/017, 052, 054 

(71) KAPSCH TRAFFICCOM AG 

(72) ABL, Alexander; TIJINK, Jasja; NAGY, Oliver 

(31) 10 450 197.8 (32) 27 Dec 2010 (33) EP 


(57) A method for capturing images (PIC1) of vehicles (1) passing through 

a section (2) between an entry (3) and an exit (4) at excessive speeds 

comprises generating a random access identifier (RID) for a vehicle (1) 

at the entry (3); capturing an image (PIC1) of the vehicle (1) at the entry 

(3) and storing the entry image (PIC1) and the access identifier (RID) in 

a first memory (8) which can only be accessed via this access identifier 



(RID); recording the entry time (TS1) and at least one identifier (LPN1 ) 

of the vehicle at the entry (3), forming an encrypted or hashed value (h) 

of this entry identifier (LPN1) and storing the entry time (TS1), the value 

(h (LPN1)) and the access identifier (RID) as a data set (16) in a second 

memory (9); recording the exit time (TS2) and at least one identifier 

(LPN2) of the vehicle (1) at the exit (4), forming an encrypted or hashed 

value (h) of this exit identifier (LPN2) and ascertaining the data set (16) 

with the same encrypted or hashed value (h) from the second memory 

(9) and if the exit time (TS2) lies within a preset time span (tmax ) from 

the entry time (TS1) of this data set (16), using the access identifier 

(RID) from this data set (16) for accessing the first memory (8), in order 

to retrieve the associated stored entry image (PIC1) of the vehicle (1). 

(21) 596917 (22) 6 Dec 2011 

(54) Door handle mounting structure with an an adaptor plate which can 

be exchanged to accomodate different preformed door lock apertures 

(51) IPC2012.01:E05B9/08, 00 

(71) Classic Hardware Suppliers Pty Ltd 

(72) Yu, James 

(31) 2010905423 (32) 10 Dec 2010 (33) AU 



(57) Disclosed is a door handle mounting structure for a door handle which 

includes a mounting plate having a defined first outer perimeter and a 

plurality of retainer openings. Each retainer opening is configured for 

cooperation with a threaded fastener which, in use, passes through a 

transverse door opening to engage with a cooperating mounting plate 

on an opposite side of the door. The mounting structure also includes an 

adaptor plate member which cooperates with the mounting plate. The 

adapter plate member has a spaced outer edge portion which defines 

a second outer perimeter positioned radially outwards of the first outer 

perimeter. 

(21) 596952 (22) 22 Dec 2008 

(54) APPARATUS WHICH AUTOMATICALLY ENERGISES A LOWER 

PACKER OF A TELESCOPING JOINT OF A DRILLING APPARATUS 

IF UPPER PACKER PRESSURE IS LOST 

(51) IPC2012.01:E21B47/00; E21B17/00, 01, 07 

(71) TRANSOCEAN SEDCO FOREX VENTURES LIMITED 

(72) RODGER, Bradley Ray 

(31) 61/015,494 (32) 20 Dec 2007 (33) US 



(57) Disclosed is a riser slip joint circuit. The circuit has an upper packer 

and a lower packer, and first, second and third conduits with associated 

first, second, and third pressures. The second conduit is connected to 

the first conduit and the upper packer. The circuit also has a differential 

pressure valve connected to the first, second, and third conduits, and 

the differential pressure valve allows the third pressure to energize the 

lower packer when the second pressure is operationally lower than the 

first pressure. 


(21) 597084 (22) 14 Dec 2009 

(54) TAG GENERATION FOR VIDEO COMMUNICATION SESSIONS 

(51) IPC2012.01:H04N7/15; H04N21/258, 422, 4415, 4788 

(71) BANK OF AMERICA CORPORATION 

(72) Newman, Kurt D; Ghosh, Debashis; O'Hagan, Michael James; Joa, 

David; Bendel, Timothy J 

(31) 12/347838 (32) 31 Dec 2008 (33) US 



(57) A method of tagging an individual in a video conference comprises 

generating a tag associated with an identified individual in a video 

conference; displaying on a video conferencing screen the tag 

associated with the identified individual; and changing the tag when an 

event occurs with regard to the identified individual. The displayed tag 

changes colour when the identified individual is talking. An apparatus 

for tagging an individual in a video conference comprises at least one 

processor and a memory having stored therein computer-executable 

instructions that, when executed by the at least one processor, cause 

the apparatus to perform the method tagging an individual in a video 

conference. 




(21) 597878 (22) 30 Jan 2012 

(54) J- shaped waste fishing line holder with resilient cushion pad in one 

leg of J to hold wound line against other leg 

(51) IPC2012.01:A01K91/00; A01K97/00, 06; A01K89/00 

(71) Wayne Tracy Smith 

(72) Smith, Wayne Tracy 

(74) Wayne T Smith, 18 Aberdeen Road, Castor Bay, North Shore City, 


(57) A fishing line holder for securing lines or cords has a generally J 

shaped body. A deformable resilient cushioned material is affixed to the 

short leg of the J so as to create a retention means in an area between 

the material and the long leg so that the lines are compressed and 

retained. The long leg of the J projecting beyond a gap opening of the 

device is formed as an elongate finger used to coil line before being 

inserted into the gap and providing a guide for the line. 

(21) 597949 (22) 15 Oct 2007 

(54) Antidepressant, neuroprotectant, amyloid beta deposition inhibitor 

or age retardant containing heterocyclic compound having specific 

structure 

(51) IPC2012.01:A61K31/429, 437, 438, 519; C07D487/04, 20; 

C07D471/10, 04; C07D513/04; A61P25/00, 24, 28 

(71) Zenyaku Kogyo Kabushikikaisha 

(72) Yamaguchi, Yoshimasa; Yui, Ryogo; Matsuno, Toshiyuki; Saitoh, 

Kenichi; Miyashita, Hitoshi; Nagata, Takeshi 

(31) 2006280768 (32) 13 Oct 2006 (33) JP 


Australia 

(57) Disclosed is the use of a heterocyclic compound of formula (I), 

wherein the substituents are as described within the specification, 

in the manufacture of a medicament for treatment by inhibiting 

amyloid beta deposition, amyloidosis, cerebral amyloid angiopathy, 

cataract, glaucoma, the progression of glaucoma age-related 

macular degeneration, rheumatism, osteoporosis, metabolic syndrome, 

wrinkles, and hair loss. 


(21) 598147 (22) 30 Jan 2009 

(54) MESOIONIC PESTICIDES 

(51) IPC2012.01:C07D401/06; C07D487/04; C07D417/06; C07D239/54; 

C07D471/04; A01N43/54; C07D498/04; C07D513/04 

(71) E. I. DU PONT DE NEMOURS AND COMPANY 

(72) TONG, My-hanh, Thi; COATS, Reed, Aaron; ZHANG, Wenming; 

MCCANN, Stephen, Frederick; CHAN, Dominic, Ming-tak; HOLYOKE, 

Caleb William 

(31) 61/063,789 (32) 6 Feb 2008 (33) US 

(31) 61/043,428 (32) 9 Apr 2008 (33) US 

(74) HOULIHAN2, Level 1, 70 Doncaster Road, Balwyn North, Victoria 


(57) Disclosed are pyrimidinium compounds as represented by the general 

formula (I), wherein: X is O; Y is O; R1 is phenyl, naphthalenyl 

or a heteroaromatic mono or bicyclic ring system, which may be 

further substituted; R2 is alkyl, haloalkyl or CR5R6CH2OR21; R3 

and R4 are alkyl or haloalkyl, or R3 and R4 may be taken together 

to form an optionally substituted heterocyclic or heteroaryl ring 

system, such as a pyridine or thiazole ring system; and wherein 

the remaining substituents are as defined herein. Representative 

compounds include 3-(2,4-difluorophenyl)-2-hydroxy-4-oxo-1-(2,2,2trifluoroethyl)-4H-pyrido[1,2-a]pyrimidinium 

inner salt; 3-(4fluorophenyl)-2-hydroxy-4-oxo-1-(2,2,2-trifluoroethyl)-4H-pyrido[1,2a]pyrimidinium 

inner salt; and 2-hydroxy-4-oxo-3-phenyl-1-(2,2,2trifluoroethyl)-4H-pyrido[1,2-a]pyrimidinium 

inner salt. Further disclosed 

is a composition which comprises a parasiticidally effective amount of 

compound as defined above, and at least one carrier for protecting an 

animal from an invertebrate parasitic pest. Also disclosed is a seed 

which has been treated with a compound as defined above.

Patent abridgements Part 2 [2.7 MB PDF] - Intellectual Property ...

Create successful ePaper yourself

Delete template?

Save as template?